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Summary 
P2Y12 antagonists are commonly prescribed in coronary artery disease (CAD) patients 
undergoing coronary intervention, however non-P2Y12 mediated effects have also been 
observed. The thienopyridine-Clopidogrel, for example, forms S-nitrosothiols (RSNO) at low 
pH, in the presence of nitrite in-vitro but it is unclear whether this occurs substantially in-vivo.  
It is unknown whether the newer class of non-thienopyridine antiplatelets(ticagrelor) has 
similar properties. Dietary sources of inorganic nitrate (NO3-) are also known to provide 
alternative pathways for NO production.  
This thesis investigates the effect of dietary nitrate supplement with or without clopidogrel 
therapy on NO metabolites and platelet inhibition in CAD patients and explores the potential 
role of ticagrelor in RSNO biosynthesis. 
In vitro studies demonstrate dietary NO3- (in the form of SIS®-Go+ and Beet-It®) gets 
converted to nitrite via bacterial nitrate reductase and thereby readily formed S-nitrosothiols 
in the simulated acidic gastric medium with and without clopidogrel.  
In CAD patients, dietary NO3- (SIS® Go+) along with or without clopidogrel therapy results in 
a significant rise in plasma nitrate, nitrite and RSNO levels. NO3- + clopidogrel therapy caused 
significantly more inhibition of TRAP mediated platelet activation with patients receiving 
clopidogrel with little change in the ADP mediated platelet inhibition, suggesting a non-ADP 
mediated effect due to RSNO. Concomitant PPI therapy has no effect.  
Importantly, Ticagrelor has the ability to form RSNO in vitro and in-vivo. RSNO increased 
significantly in patients following a loading dose of Ticagrelor. However, elevated RSNO are 
not sustained in patients receiving a maintenance dose of Ticagrelor. 
In conclusion, dietary NO3- therapy significantly augments RSNO level with or without 
clopidogrel in CAD. Ticagrelor exhibits RSNO formation in-vitro and in CAD patients. 
Augmented RSNO may explain the P2Y12 independent effects seen with these agents and 
represents a novel therapeutic approach in future management of CAD.  
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1 General Background 
1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a leading non-communicable disease (NCD) and a major 
cause of death across the globe. CVD includes coronary artery disease (CAD), 
cerebrovascular accidents (CVA), peripheral vascular disease (PVD), congenital heart 
disease, cardiomyopathies, heart failure, and aortic disease. 
In 2013, approximately 54 million deaths occurred worldwide, of which 17.3 million (32%) 
deaths were attributable to CVD (1). By 2030 CVD deaths are expected to rise to more than 
23.6 million (2).  In the United Kingdom, CVD was the biggest killer in 2010 responsible for 
approximately one in three of all deaths in that year. Nearly half of these arise from coronary 
artery disease, making it the most common singular cause of death.  The British Heart 
Foundation have estimated the annual cost of CVD to the United Kingdom’s economy is 
approximately £19 billion annually (3). 
CAD and CVA are a leading cause of premature deaths across the globe. Approximately 30-
50% of all CVD cases are due to coronary artery disease. Approximately 70,000 deaths in the 
UK each year are due to CAD and most deaths are due to acute myocardial infarction. The 
lifetime risk of developing CAD at the age of 55 is 67.1% in men and 66.4% in women (4). In 
recent years, there has been an overall decline in incidence across Europe including the UK,  
but in contrast the incidence and prevalence of CAD and CVA deaths have doubled in 
developing countries and approximately  80% of  CVD deaths occur at younger ages (<60yr) 
(2). The burden of CAD is rising with an ageing population and increasing prevalence of type 
2 diabetes and obesity. 
Stable CAD is characterised by episodes of reversible myocardial demand/supply mismatch, 
leading to ischaemia or hypoxia. These episodes are often reproducible and are inducible by 
exercise, stress or sometimes spontaneously.  Stable CAD is a stable subtype in the 
continuum of CAD. It is associated with an estimated annual mortality rates of 1.2-2.4% per 
annum (5) and an annual incidence of 0.6-1.4% cardiac death and 0.6 to 2.7% of non-fatal 
myocardial infarction (6) (7).   
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Angina is often the most common clinical manifestation in patients with ischemic heart 
disease.  Stable angina pectoris or stable angina is defined as discomfort in the chest, jaw, 
shoulder, back or arm, occurring at certain levels of exertion and is relieved with rest or nitro-
glycerine (itself an organic or pharmacological “NO” donor, typically called “Nitrates”). A 
diagnosis of stable angina is made based on a classical history of angina pectoris, with 
associated one or more risk factors for atherosclerotic CAD.  
Lifestyle modification such as smoking cessation, increase in physical activity, healthy diet, 
dietary sodium reduction, avoidance of excess alcohol, and weight management, along with 
therapeutic management of diabetes and hypertension, have significant clinical beneficial 
effects on cardiovascular morbidity and mortality(8-11).  
There has been a significant decline in the rate of deaths due to CVD in UK over the last four 
decades, but this remains relatively high compared to other European countries (12). This 
decline is attributed to advances in medical and surgical treatments with modification of 
cardiovascular risk factors. An estimated 58% mortality decline was attributed to reduction of 
major cardiovascular risk factors and the remaining 42% of mortality decline was due to 
individualised patients care where secondary prevention plays a significant role (12).  
Antiplatelet therapy forms a core component of medical therapy in patients with CAD 
especially in acute coronary syndromes and in CAD patients undergoing percutaneous 
coronary interventional (PCI) procedures. PCI procedures are now more commonly 
undertaken for patients with CAD compared to a decade earlier. Despite this, adverse cardiac 
events can still occur in this group of patients. 
Continuing research in this field is vital, to facilitate a better understanding of the 
pathophysiology involved in CVD. This would pave a way for the development of more 
effective treatment and prevention strategies.  
 
1.2 Vascular endothelium and its functions 
The cardiovascular system comprises the heart and the blood vessels forming the coronary, 
cerebral and peripheral circulation. Atherosclerotic plaque formation within the lumen of the 
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blood vessels is the principal pathological process of development of CVD. These plaques 
cause a disruption to the flow of blood to the vital organs leading to their dysfunction or death. 
A review of the vascular structure and their function is essential in the understanding of CVD. 
The blood vessels are grossly divided into arteries and veins. Arteries carry oxygenated blood 
to all organs of the body.  Anatomically, the vascular wall comprises three layers- the tunica 
intima, tunica media and the tunica adventitia. 
The tunica adventitia is the outermost layer of the vessel, which is comprised of connective 
tissue and contains a network of smaller vessels (vasa vasorum) and nerves.  
The tunica media is the mid-layer of the artery, which is the thickest and has concentric layers 
of smooth muscle in the fibrous matrix.  
The tunica intima is the inner most layer made up of a single layer of simple squamous ECs.  
A thin layer of sub endothelial connective tissue called the internal elastic lamina supports this 
layer.  
An intact endothelial layer is vital for cardiovascular health. It is a dynamic organ which 
responds to various physical and humoral conditions. The endothelium is less than 0.2µm 
thick, comprising of 1 to 6x1013 endothelial cells  with a total surface area of 4000-7000 m2 
and approximate weight of 1 kg in an average-sized human (13). It acts as a physical barrier 
with a feature to act as a semipermeable layer regulating the movement of molecules. In 
addition to this it has a major role in the regulation of vascular tone, haemostasis, smooth 
muscle proliferation, cellular adhesion, and inflammation. These functions are co-ordinated by 
the synthesis and release of various neurotransmitters, vasoactive factors and hormones, 
which influences cellular function throughout the body (Figure 1.1) (14, 15). 
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Figure 1.1: Vascular endothelium is a dynamic, multifunction organ, which secretes a spectrum of mediators 
influencing cardiovascular physiology. This diagram summarises the mediators with their effects. Adapted from 
Sumpio et al(16). (NO: Nitric Oxide, PGI2 : Prostacyclin, tPA : Tissue Plasminogen Activator, PGE2 : 
Prostaglandin E2, EDHF :Endothelium Derived Hyperpolarising Factor TXA2 : Thromboxane A2,  ACE : 
Angiotensin Converting Enzyme, EDCF : Endothelium Derived Contracting Factor, vWF: Von Willebrand Factor,  
PAF : Platelet Activating Factor, PAI : Plasminogen Activator Inhibitor, LDL: Low Density Lipoprotein, PDGF : 
Platelet Derived Growth Factor, EDGF : Epidermal Derived Growth Factor, FGF : Fibroblast Derived Growth 
Factor, IGF : Insulin Like Growth Factor, TGF-b : Transforming Growth Factor Beta, GM-CSF : Granulocyte-
Macrophage Colony-Stimulating Factor, G-CSF : Granulocyte-Colony Stimulating Factor, IL : Interleukin, LT : 
Leukotriene, MCP : Monocyte Chemoattractant Protein, MHC : Major Histocompatibility Complex, CAM : Cell 
Adhesion Molecule, TX : Thromboxane) 
 
1.2.1 Haemostasis 
The intimal surface of healthy endothelial cells has both procoagulant and anticoagulant 
features. Under normal physiological conditions there is a critical balance between thrombotic 
and antithrombotic properties. It is the major site for anticoagulant reactions involving thrombin 
(17).  The predominant antithrombotic factors are protein C, protein S proteoglycans, 
thrombomodulin, annexin V & II, ectonucleotidase, tissue plasminogen activator (tPA), tissue 
factor pathway inhibitor, NO and PGI2. Platelet activation factor (PAF) and von Willebrand 
factor (vWF) is the predominant prothrombotic factor present on the endothelium surface.  
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Prostacyclin (PGI2) and nitric oxide (NO) are important factors in the prevention of platelet 
adhesion and aggregation, through the increase in cAMP and cGMP in platelets (18). The 
ectonucleotidase on the liminal surface hydrolyses ATP and ADP into AMP and adenosine, 
thereby minimising the extent of platelet aggregation. 
Tissue plasminogen activator (tPA) is a powerful thrombolytic agent secreted by endothelial 
cells in response to vasopressin, norepinephrine, and thrombin, which allows conversion of 
plasminogen to plasmin which breaks the fibrin network in the thrombus (19).  Protein C in 
complex with protein S inactivates factor VIIIa and Va cofactors which are essential for 
coagulation. Thrombomodulin prevents thrombin from interaction with fibrinogen. Platelet 
activation factors,  thrombin, ADP and ATP activate the release of prostacyclin from 
endothelium thus limiting the extent of plug formation (20).   
Endothelial cells are activated in the event of a vessel wall injury or exposure to thrombin, 
histamines and cytokines (TNF-α, IL-1, IL-6). Activated endothelial cells synthesize PAF and 
vWF. PAF is a potent platelet activator which promotes platelet adhesion to endothelial cells 
(21).  Whereas vWF is primarily stored in Weibel-Palade bodies within endothelial cells. It is 
mobilized rapidly upon stimulation, which binds platelets to exposed extracellular matrix as a 
result of vessel injury (22).  
1.2.2 Vascular tone 
Endothelial cells regulate vascular smooth muscle contraction and vascular tone, thereby 
regulating blood flow and blood pressure within the vasculature. This effect is mediated 
through the release of endothelial derived relaxing factors such as NO, PGI2, endothelium 
derived hyperpolarising factor (EDHF), and vasoconstrictor molecules like thromboxane 
(TXA2), superoxide (O2-) and endothelin-1(ET-1). NO is the predominant vasodilator released 
from endothelial cells and it has several additional beneficial effects such as inhibition of 
platelet aggregation, smooth muscle proliferation, inhibition of leukocyte adhesion and anti-
atherosclerotic effects (23-25). These effects are discussed in detail in section 1.5. 
PGI2 is formed from arachidonic acid by the enzyme cyclooxygenase (COX). Cyclooxygenase-
1 (COX1) is the main isoform involved in the production of PGI2 which is primarily expressed 
in endothelial cells.  PGI2 acts on IP receptors on smooth muscle cells, causing an increase 
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in intracellular levels of cyclic adenosine monophosphate (AMP) through stimulation of 
adenylate cyclase, affecting vascular smooth muscle relaxation. PGI2 and NO work 
synergistically to facilitate vascular smooth muscle relaxation. NO inhibits phosphodiesterase 
enzyme that degrades cyclic AMP hence prolonging the cyclic AMP mediated effect of PGI2 
in smooth muscle cells. PGI2 enhances NO release from endothelial cells (26). Upon entering 
the blood stream PGI2 inhibits platelet aggregation (27, 28). 
Potassium ions, hydrogen peroxide, and epoxyeicosatrienoic acids have all been proposed 
as the endothelial derived hyperpolarising factor (EDHF), which causes a relaxation of the 
vascular smooth muscle by hyperpolarization (29). EDHF is thought to take precedence where 
NO activity is limited, and as such is predominantly active in smaller vessels/arterioles lacking 
smooth muscle. 
Endothelin is an extremely potent vasoconstriction factor. There are 3 isoforms of endothelin 
-ET1, ET2 and ET3. ET1 and ET2 are more potent agonists than ET3. ET1 is synthesised by 
the vascular endothelial cells and is the most abundant isoform.  ET1 synthesis is enhanced 
in the presence of hypoxia, Ischaemia, thrombin, vasopressin, catecholamine, interleukin-1 
and transforming growth factor 1 (30-32). ET1 acts on endothelin receptor A and B (ETA and 
ETB) located mainly on the smooth muscle and endothelial cells, thereby regulating vascular 
tone and provoking proinflammatory and mitogenic reactions, ET1 play an essential role in 
various cardiovascular diseases such as systemic hypertension, pulmonary hypertension and 
atherosclerosis(33). ET2 has a key role in ovarian physiology, it can also mimic the actions of 
ET1 by acting on ETA and ETB(34). ET3 is important for development of neural crest-derived 
cell lineages, such as melanocytes and enteric neurons(35). 
Superoxides, causes vasoconstriction by scavenging the NO, sensitising the vascular smooth 
muscle for calcium ion and direct oxidative disruption of normal signalling mechanisms in the 
endothelium and vascular smooth muscle cells. Superoxide radicals are formed in response 
to a rise in blood pressure and endothelial agonists (36).  Superoxide, is an anion, produced 
by the one-electron reduction of molecular oxygen, and is formed in all living organisms that 
come in contact with air. Its level is regulated in vivo primarily by superoxide reductase and 
superoxide dismutase (as well as other cellular antioxidants). Superoxide can act as a 
signalling agent, a toxic molecule or a harmless intermediate, depending upon its biological 
context (37) (38).  
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1.2.3 Endothelial activation and endothelial dysfunction 
Endothelial cells are dynamic, with the ability to adapt their phenotype according to the nature 
of the local milieu (39). Alteration of the normal endothelial function constitutes endothelial 
activation and can lead to endothelial dysfunction. 
 Endothelial activation 
The participation of endothelial cells in the acute inflammatory response induced by infection 
or injury has been long appreciated. The classical signs of inflammation such as rubor, dolor, 
pallor and tumor are due to the endothelial mediated effects on microvascular tone, 
permeability and leukocyte adhesion. These acute responses are collectively termed as 
endothelial activation type 1 (40).  
Endothelial activation can be considered a proinflammatory, pro-coagulative and proliferative 
state. Bacterial endotoxins, interlekin-1, tumor necrosis factor (TNF) and interferon-gamma 
stimulates a more sustained endothelial activation referred to as type 2 activation.  Endothelial 
activation causes a loss of vascular integrity, change in phenotype from antithrombotic to 
prothrombotic with expression of leukocyte adhesion molecules, upregulation of HLA 
molecules and cytokine production. The hall mark of this form of response is the activation of 
pleiotropic transcription factors such as nuclear factor-kappa-B (NF-κB). Once activated, 
NFκB is transported into the nucleus where it binds promoter genes which are upregulated in 
endothelial activation, resulting in the expression of various effector proteins with 
pathophysiological consequences (41, 42). The effector proteins include inducible endothelial-
leukocyte adhesion molecules such as VCAM-1 and ELAM-1 (E-selectin), chemokines such 
as interleukin-8 and procoagulant molecules such and tissue factor. VCAM-1 and chemokines 
such as IL-8, IL-1, and MCP-1 are important links between endothelial activation and vascular 
atherogenesis (39, 43). Endothelial activation promotes all stages of atherogenesis (44).  
The presence of infection, inflammation and cardiovascular risk factors increases the activity 
of NADPH oxidases causing an increase in ROS in the tissues. ROS molecules target NF-κB 
and phosphates leading to endothelial cell activation. ROS mediated endothelial activation is 
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a host defense response in infections or inflammation and a pathophysiological response in 
the presence of cardiovascular risk factors.  
 Endothelial dysfunction 
Endothelial dysfunction is characterized by impaired vasodilation, increased pro-thrombotic 
and a pro-inflammatory state. This is typically the result of diminished production and/or 
availability of vasodilators, predominantly NO, with or without an imbalance in the relative 
production of other endothelium derived relaxing and constricting factors (45).  
Endothelial dysfunction is associated with traditional cardiovascular risk factors such as 
smoking, ageing, hypercholesterolemia(46, 47), hyperglycemia, hypertension, along with 
other risk factors like chemotherapy(anthracyclines) (48) and radiation (49).   
These risk factors have a well-established association with alteration in endothelial function 
resulting in a chronic inflammatory process leading to a loss of antithrombotic factors and an 
increase in vasoconstrictor and prothrombotic effects associated with increased 
cardiovascular events (Figure 1.2) (47, 50, 51).   
More recently, endothelial dysfunction has also been associated with obesity (52), chronic 
systemic infection (53), chemotherapy (48), radiation (49) and post heart transplantation. 
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Figure 1.2: Diagrammatic representation of various factors affecting the ECs causing endothelial dysfunction and 
its consequences. Adopted from (54) 
 
These cardiovascular risk factors and pro-inflammatory conditions cause an increase in the 
activity of NADPH oxidases, leading to increased reactive oxygen species (ROS) production. 
ROS at low concentrations function as signalling molecules of fundamental cell activities like 
growth and cell adaptations. At higher concentration where there may be an imbalance 
between ROS generation and antioxidant defences, when ROS can cause vascular oxidative 
stress and cell injury. Vascular oxidative stress causes an alteration in the function of 
endothelial nitric oxide synthase (eNOS). There is upregulation of eNOS and NADPH oxidase 
expression. The combination of both enzymatic products (NO and superoxide, respectively) 
increases the amount of peroxynitrite (ONOO-). Peroxynitrite in turn causes eNOS uncoupling 
by oxidising the eNOS co-factors (BH4 and zinc) causing eNOS to produce further superoxide 
instead of NO. Prolonged impairment of NO production and chronic ROS production leads to 
further endothelial dysfunction (38) (37). 
eNOS is the main source of NO in the vasculature (55)  It has been reported that 70% of 
resting plasma nitrite is derived from eNOS activity in humans and other mammals (56). An 
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imbalance in the production and consumption of NO is critical in endothelial dysfunction (is 
discussed in section 1.5.3). 
Endothelial dysfunction is an independent predictor for the occurrence of cardiac events. It 
plays a crucial role in the pathogenesis of acute coronary syndromes. It precipitates the plaque 
destabilisation process through a complex interplay of cellular plaque components and 
proinflammatory mediators (51). Impaired NO production enhances the endothelial expression 
of several adhesion molecules and inflammatory mediators that increases plaque vulnerability 
(25, 57, 58). Endothelial dysfunction is also referred to as a barometer of vascular health, a 
unified overall effect of risk factors and intrinsic defence mechanisms. 
 Assessment of endothelial dysfunction 
Endothelial dependent vasodilatory function is commonly evaluated in the coronary and 
peripheral circulations.  
The potential detection of endothelial dysfunction as an early marker of atherosclerosis makes 
these assessments an extremely useful tool for early stratification of patients at risk of 
cardiovascular events.  
In recent years numerous invasive and non-invasive methods of measuring endothelial 
function were studied and validated. An invasive quantitative coronary angiographic method 
of evaluation of the changes in diameter of coronary arteries in response to intracoronary 
infusion of acetylcholine remains the “gold standard” to assess the endothelium-dependent 
vasodilation (59).   However, the invasive nature of these methods limits its widespread clinical 
application.  
Non-invasive evaluation of brachial-artery flow mediated dilation using ultrasound is a 
technique that has been widely used and is a clinically applicable method for the study of NO 
dependent endothelial function. This technique examines the change in forearm blood flow in 
response to direct administration of agonists in the brachial artery. The arterial compliance 
and wave form morphology provide a marker of vascular well-being (60). 
Circulating biomarkers such as NO metabolites, inflammatory cytokines, and adhesion 
molecules can be measured as surrogate indicators of endothelial function. These techniques 
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are often difficult and expensive to measure, with a risk of erroneous interpretation and many 
confounding factors. 
1.2.3.3.1 Endothelial dysfunction and cardiovascular risk factor modification 
The cardiovascular risk factors modification approach, such as weight reduction, smoking 
cessation, cholesterol lowering, antihypertensive therapy, ACE inhibitor therapy, 
supplementation with folic acid and physical exercise have all been shown to improve 
endothelial function (61, 62). Obesity is a major risk factor for endothelial dysfunction and 
atherosclerosis, with recent evidence suggesting that obesity is associated with accelerated 
coronary atherosclerosis and premature aging, in adolescent and young adults. Control of 
obesity is important in the prevention of endothelial dysfunction, atherosclerosis and its 
sequelae (63-65)  
Smoking is a well-known health hazard, both active and passive smoking led to endothelial 
dysfunction, hypertension, and increased ROS generation and decreased NO bioavailability, 
thereby contributing significantly towards CV morbidity and mortality. The full effect of smoking 
on CV health is not fully understood, and there exists a smoking paradox which is nicely shown 
in a recent study that shows patients who continued to smoke following PCI had fewer repeat 
coronary interventions(66) (67).  
 
1.2.4 Atherosclerosis 
Atherosclerosis is the most common pathological process causing arterial thickening and 
luminal narrowing leading to ischaemia of the organ supplied by that vessel. This is commonly 
associated with endothelial dysfunction.  
Atherosclerosis is the pathological basis of almost all of CAD resulting in myocardial ischaemia 
and infarction. The earliest lesions of atherosclerosis develop in a distinctive, non-random 
pattern at branch points and at regions of altered blood flow supporting the role of 
haemodynamic forces. It begins in childhood, with silent progression over the years appearing 
as fatty streaks, which are not clinically significant but serve as a precursor of formation of 
more complex plaques, containing a necrotic lipid rich core with smooth muscle accumulation.  
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These atherosclerotic plaques cause a luminal narrowing resulting in tissue ischaemia 
producing typical symptoms such as angina or claudication. Clinical events such as MI/CVA 
are initiated when a plaque ruptures exposing its vasoactive core which culminates in a 
downstream thrombotic occlusion (Figure 1.3). 
 
Figure 1.3: Diagrammatic representation of the timeline for progression of atherosclerosis over time in the 
vasculature, RBC represent red blood cells 
Atherosclerosis is regarded as a systemic inflammatory disease. Lipid lowering therapy with 
statins has been shown to inhibit progression of coronary plaques, by reducing the size and 
alteration of cellular and chemical composition  (68). Lipid lowering therapy in combination 
with antiplatelet therapy remains the mainstay therapeutic approach to effecting a significant 
reduction of cardiovascular events in patients with atherosclerotic CAD (69, 70).  
 
1.3 Role of platelets in coronary artery disease 
Platelets are anucleate disc shaped circulating cells which play a crucial role in vascular 
haemostasis, repair of injured vascular endothelium and prevent blood loss after vascular 
injury. These cells are derived from bone marrow megakaryocytes, and they carry parent RNA 
for expression of protein required in haemostasis. They contain numerous granules and a 
wide range of surface receptors. 
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Platelets usually circulate in an inactive state. They are activated when there is an injury to 
endothelium or alteration in blood flow in the vasculature.  An intact endothelium secretes NO, 
prostacyclin and ADPase, which inhibits platelet activation and shape change. 
The major platelet functions include  
a) Adherence 
b) Activation and secretion 
c) Aggregation 
d) Binding with coagulation factors 
1.3.1 Platelet activation and thrombosis 
A break in the endothelial cell integrity exposes the connective tissue matrix which lies 
underneath the endothelial layer. Platelets adhere to the exposed collagen fibrils and von 
Willebrand factor, and in the presence of other mediators like ADP, thromboxane and 
adrenaline, platelets get activated. A change in shape occurs at this stage which increases 
the expression of glycoprotein IIb-IIIa receptors promoting a cross linking with other activated 
platelets via fibrinogen. Activated platelets release ADP and thromboxane A2 causing further 
recruitment of circulating platelet activation, platelet aggregation and thrombus formation 
(Figure 1.4) (71). 
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Figure 1.4: Diagrammatic representation of the process of platelet activation and its role in haemostasis and 
vessel repair, RBC : red blood cells, ADP: Adenine diphosphate, GP:  glycoprotein 
Platelets play an integral role in thrombus formation.  Atherosclerotic-thrombotic occlusions of 
the arteries is the most common cause for coronary and cerebrovascular events.  
Platelets are known to contribute to the pathogenesis of atherosclerosis. Activated platelets 
enhance smooth muscle proliferation via the release of vasoactive substances (72, 73). The 
phagocytized platelet can act as a source of lipids, promoting atherosclerotic plaque and 
thrombi formation.(74, 75) 
Platelets contain numerous intracellular granules and a wide range of receptors on their 
surface, which play a critical role in the adhesion-activation-aggregation-coagulation cascade. 
Platelet surface P-selectin is considered as a gold standard marker of platelet activation. 
However, Michelson et al, demonstrated that circulating monocyte-platelet aggregates are a 
more sensitive marker of in vivo platelet activation than P-selectin (76).  
There is an increase in degranulated platelets with greater monocyte platelet aggregation in 
patients with stable coronary artery disease (CAD) (77, 78), suggesting a central role in the 
pathogenesis of stable CAD. 
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Collagen, thrombin, ADP, epinephrine, and thromboxane A2 are well recognised platelet 
agonists. Most agonists stimulate the cell receptors present on the platelet membrane (Figure 
1.5). These receptors interact with the G proteins at their cytosolic surface. These G proteins 
contain a GTP binding alpha subunit and Beta-gamma heterodimers. In its inactive state GDP 
is bound to the G protein. The stimulated receptor displaces GDP with GTP, causing G protein 
activation with increase in intracellular calcium, thereby stimulating the platelets.  
 
Figure 1.5: Diagrammatic depiction of the known receptors, with their respective agonists and blocking agents 
involved in platelet participation in haemostasis and thrombotic process. Adapted from (79).   
 
1.4 Antiplatelet medications 
Antiplatelet medications are designed to alter platelet function, primarily targeting activation or 
propagation of the aggregation cascade. They form an integral therapeutic component in 
management of CAD and cerebrovascular disease.  
Antiplatelet drugs that are currently prescribed can be broadly classified into the following 
three groups based on their mechanism of action. 
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a) Cyclooxygenase inhibitors: Aspirin 
b) GP IIb/IIIa Inhibitors: Abciximab, tirofiban. 
c) P2Y12 receptor blockers: Thienopyridine (ticlopidine, clopidogrel and prasugrel) and 
non-thienopyridine (ticagrelor and cangrelor).  
1.4.1 Aspirin and GPIIB/IIIA receptor blockers 
Aspirin was the first drug to be used widely as an effective antiplatelet agent. It binds to COX1 
and inhibits thromboxane A2 (TxA2) mediated platelet activation. Platelets then lack the ability 
to synthesise TxA2 for rest of their life span (approximately 7 to 10 days). Lack of synthesis of 
TxA2 also impairs platelet stimulation by other agonists like ADP and thrombin. Aspirin blocks 
platelet aggregation more than adhesion.  
Numerous randomised trials and meta-analysis have confirmed statistically significant and 
clinically noticeable benefits of use of aspirin in CAD (80-83). Aspirin is an essential 
component of antiplatelet therapy in patients undergoing PCI (84, 85) and coronary artery 
bypass grafting (CABG) (86, 87). 
Aspirin therapy has noticeable adverse effects, the more common adverse effect is bleeding, 
specifically gastro-intestinal bleeding (88, 89) and less frequently, haemorrhagic stroke. (90) 
Despite being on aspirin therapy, patients do suffer from recurrent cardiovascular events.  
Although Aspirin blocks one of the many mechanisms of platelet activation, there are many 
other pathways through which platelets get activated leading to thrombotic events (Figure 1.5).  
An ongoing search for a more comprehensive, potent and efficient antiplatelet drug has been 
pursued in the last 3 decades. Despite these, aspirin remains the first line of antiplatelet 
therapy due its low cost and relative proven safety and efficacy. The newer antiplatelet drugs 
are used as an added therapy along with aspirin to enhance platelet inhibition in patients at 
high risk of CV recurrent events or used as substitutes in patient’s intolerant or high risk for 
aspirin therapy.  
GPIIB/IIIA drugs such as abciximab, tirofiban, eptifibatide inhibit the final common pathway of 
platelet aggregation, preventing the cross binding of platelets to fibrinogen. These drugs cause 
a potent and effective platelet inhibition, with increased risk of bleeding. Current medications 
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are available in intravenous form and are being used in ACS patients undergoing PCI (91-93). 
These drugs are used as an additional antiplatelet agent along with aspirin and P2Y12 receptor 
blockers (94). 
 
1.4.2 P2Y12 receptor Blockers 
P2Y12 is a G protein coupled purinergic receptor found mainly on the platelet surface. It is a 
chemoreceptor for adenosine diphosphate (ADP) (95). ADP acts as a potent, broad-spectrum, 
physiological agonist which activates P2Y1, P2Y12 and P2X1.  
P2Y12 receptor activation by ADP forms an important step in platelet activation and thrombus 
formation. P2Y12 receptors also potentiate platelet activation by other agonist like collagen, 
and thromboxane A2 (96).  
P2Y12 receptors has been studied extensively and numerous agents aimed at blocking this 
receptor have been developed successfully and are used in clinical settings (Figure 1.6). 
P2Y12 receptor blocking agents have shown a significant reduction in thrombotic vascular 
events in patients with ACS and in those undergoing PCI. Currently available P2Y12 receptor 
blocking drugs are classified as thienopyridines or non-thienopyridines, based on their 
chemical structure. 
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:  
Figure 1.6: Adapted diagram depicting the process of P2Y12 receptor mediated activation of platelets and 
currently available P2Y12 receptor blocking drugs, with their metabolic process (97). 
 
 Thienopyridines 
Thienopyridines (Ticlopidine, Clopidogrel and Prasugrel) act by binding to the cysteine residue 
of the P2Y12 receptor irreversibly and modifies the receptor configuration, thereby preventing 
ADP induced activation of the receptor.   
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Ticlopidine was the first drug used in this class in the 1970’s. It is a prodrug, requiring 
metabolism by cytochrome p450 enzymes to form an active compound(98). This drug has 
demonstrated a clear effectiveness in reducing thrombotic events in patients with CVD(99) 
and was used in combination with aspirin, especially in patients undergoing PCI (100). Its use 
has been limited due to rare but severe side effects causing neutropenia (> 1%) and 
thrombotic thrombocytopenic purpura (0.2%) with a 50% fatality.  Clopidogrel was developed 
to overcome these adverse effects. Clopidogrel is synthesised by an addition of a substituted 
ester linkage to the Ticlopidine base molecule.  
1.4.2.1.1 Clopidogrel 
Clopidogrel is the most commonly prescribed antiplatelet drug across the globe and has 
become the cornerstone therapy for secondary prevention of ischaemic cardiovascular events 
in patients with CAD (101-104) . Clopidogrel is an inactive compound and forms active 
metabolites in the liver via two-step metabolism (Figure 1.7).  
Upon absorption 85% of the drug forms a carboxylic acid derivative of clopidogrel which is a 
major but inactive metabolite. About 15% of absorbed clopidogrel gets transformed to a thiol 
metabolite via a host of CYP enzymes in the liver, which is an active metabolite (Figure 1.7). 
The active metabolite irreversibly inhibits platelet aggregation by selectively inhibiting the 
binding of ADP to the platelet P2Y12 receptors; thereby interfering with subsequent ADP 
mediated activation of glycoprotein IIb-IIIa signalling for the lifetime of the platelet. 
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Figure 1.7: Clopidogrel molecular structure and metabolism 
The clopidogrel active metabolite peaks at approximately 90 minutes post ingestion, achieving 
a maximum antiplatelet effect within 2 hours. The peak active metabolite concentration can 
be further increased by administering “loading” clopidogrel doses up to 600 mg and has 
become routinely used in clinical practice to ensure greater rapidity of action and improved 
clinical efficacy.(105) Following this a regular dose of 75 mg once daily to maintain steady 
state platelet inhibition is typically administered.   
Clopidogrel is used as an additional antiplatelet agent along with aspirin in high risk conditions 
such as ACS(102) and PCI (97).  Clopidogrel has morbidity and mortality benefit in the 
prevention of ischemic complications in patients with ACS (101, 103, 104) and/or after PCI 
(103). 
Drug eluting stents are used in the majority of PCI procedures performed currently. Stent 
thrombosis (ST) is a serious but uncommon complication of coronary artery stenting. Dual 
antiplatelet therapy with aspirin and platelet P2Y12 receptor blocker (clopidogrel) significantly 
reduces the risk of stent thrombosis and Ischemic events(106).  
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The benefits of pre-treatment with clopidogrel in patients undergoing elective PCI is well 
established. In the CREDO trial, 2100 patients were randomised to 300mg of clopidogrel or 
placebo. A significant reduction was observed in the combined end point of MI, stroke and 
death in patients loaded with 300mg of clopidogrel. The benefit was maximum when given at 
least 24 hours prior to PCI (105). The limitation of very early initiation of clopidogrel therapy 
(>15hrs) was overcome by giving an additional 300mg of Clopidogrel to the dose used in the 
CREDO trial. 
The ARMYDA-2 trial compared 600mg of clopidogrel vs 300mg of clopidogrel, given 4-8 hours 
prior to elective PCI. This demonstrated safety and significantly reduced periprocedural MI in 
patients pre-treated with 600mg of clopidogrel (107). There was no significant difference in 
30-day incidence of cardiac death, MI or unplanned target vessel revascularisation or bleeding 
in patients given 600mg of clopidogrel 4 to 8 hour or immediately prior to PCI (108).   
A loading dose of 600mg of clopidogrel produces a maximal antiplatelet effect within 90-120 
minutes and maintains a sustained effect with a daily 75mg dose.  Similar antiplatelet effects 
are observed with ingestion of 75mg of clopidogrel for at least three consecutive days (106).  
At the University Hospital of Wales, we typically prescribe a loading dose 600mg of clopidogrel 
in clopidogrel naïve patients undergoing PCI with coronary stenting. No additional loading 
dose of clopidogrel is administered prior to procedure for the patients who are already 
receiving long term clopidogrel therapy.  
Clopidogrel non-responsiveness 
Adverse cardiovascular events still occur despite patients being on a recommended dual 
antiplatelet therapy (aspirin and clopidogrel).  Clopidogrel has its limitations, in terms of 
delayed onset of action, modest antiplatelet action, and significant variation in responsiveness 
in patients.  
It has been estimated that about 15-50% of patients have high platelet reactivity while on 
clopidogrel therapy; this is termed as “high on treatment platelet” reactivity (HPR) (or equally 
“Resistant” or “non-responsive” with some variation in their definitions) (109). Several 
observational studies have demonstrated a strong link between HPR/resistance and recurrent 
Ischaemic events in post PCI patients(110, 111).  
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The possible causes for inter individual variation and hypo responsiveness remain largely 
unexplained but include 
a) Clopidogrel metabolism:  
• Variable absorption of drug (101, 109) 
• Genetic polymorphisms have been identified in individuals which interfere with 
the CYP2C group of enzymes required for activation.(112) 
b) Drug interactions 
• Drugs enhancing or inhibiting CYP activity or competing with Clopidogrel for 
enzyme can affect the metabolism.  
• Proton pump inhibitors, Statins, calcium channel blockers(113-116)  
c) Other conditions like diabetes mellitus, renal failure, cessation of smoking, and non-
compliance (117-119).  
 
Platelet function testing (LTA, Multiplate, PFA-100, VerifyNow) and genetic testing are 
frequently used methods of assessing responses to clopidogrel. No single method is validated 
or developed as a robust clinical tool for use. Most studies testing platelet inhibition using the 
verifyNow P2Y12 point of care test have shown an increase risk of thrombotic occlusion in 
patients who have poor response to clopidogrel treatment. It is more commonly seen in 
patients undergoing PCI. The major adverse event being acute stent thrombosis which can 
be fatal in a few cases (120, 121). The suggested approaches of managing poor responses 
are, altering the dose of clopidogrel, changing to alternate, newer, and more potent agents 
like Ticagrelor or Prasugrel, and/or stent optimization.   
However a recent large randomised trial failed to demonstrate an improved outcome in 
patients with high platelet reactivity when given high dose of clopidogrel therapy (122). There 
were several possible reasons for a lack of beneficial effect of high dose clopidogrel; there 
was only a modest reduction in platelet reactivity with high dose of clopidogrel therapy and 
possibly had no effect on carriers of CYP2C19 allele, who exhibit high on treatment reactivity. 
The frequency of high on treatment reactivity decreased in both groups over the initial 30-day 
period and beyond, which meant there were fewer patients with high on platelet reactivity in 
both arms of the trial. This in conjunction with low event rate observed in this trial could have 
had a significant effect on the outcome. Even though this trial was a large randomised study, 
it had inherent limitations such as high-risk patients were underrepresented, and a fixed high 
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dose clopidogrel was administered rather a dose adjusted for platelet reactivity, which could 
affect the outcome of this study. 
Pleiotropic effects of clopidogrel 
Recent studies have shown novel pleiotropic properties and effects of clopidogrel in addition 
to platelet P2Y12 receptor inhibition. These actions could be partly due to its effect on the non-
platelet P2Y12 receptors which can be found in several different tissues of the body including 
the vascular smooth muscle (123), macrophages, leukocytes, macrophages, microglial and 
dendritic cells (123-125).  
Clopidogrel therapy is shown to be associated with reduced leukocyte counts (PLATO trial) 
(126), CD40 ligand, CRP, P-selectin and other inflammatory markers associated with 
activated platelets, which play a significant role in the atherosclerotic process (127, 128).  
Non- P2Y12 receptor dependent mechanisms of action of these drugs are also being 
hypothesised and researched.  Clopidogrel and Ticlopidine have a proven vasomodulatary 
activity in animal models. Jakubowski et al. have demonstrated a NO-dependent vasodilation 
in the isolated guinea pig heart(129). Warnholtz et al. for the first time demonstrated in vivo, 
clopidogrel dose-dependent improvement in endothelial dysfunction (130). This effect is only 
seen with a loading dose of clopidogrel and lost with continued use of clopidogrel over 28 days 
(131). Clopidogrel has also been shown to improve endothelial NO bioavailability in patients 
with CAD (132). 
Our research (James et al) group have successfully shown in previous studies that clopidogrel 
has a potential to form RSNO compounds in the presence of nitrite at low pH. This is a potential 
novel mechanism, which is independent of endothelial mediated NO action, and is purposed 
to form a circulating store of RSNO that can donate NO-like activity (133).   
Importantly, Clopidogrel improves endothelial NO availability (132) and shows greater 
improvement of endothelial dysfunction at higher clopidogrel dose (107) with improved 
vascular reactivity (134).  Taken with the above, it is not unreasonable to suggest these effects 
could be the result of its ability to form RSNO.  
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1.4.2.1.2 Prasugrel 
Prasugrel is a newer and potent antiplatelet drug belonging to the thienopyridine group and is 
found to be more effective than clopidogrel. The TRITON-TIMI 38 trial showed a significantly 
reduced rate of ischemic events and stent thrombosis in patients treated with prasugrel in 
comparison to clopidogrel in ACS patients (135, 136). Unsurprisingly, there was an increased 
incidence of bleeding with prasugrel therapy proving its higher potency albeit with increased 
risk.  
Like clopidogrel, prasugrel is a pro-drug and requires a one-step metabolism by the 
cytochrome P450 system to form an active metabolite. Prasugrel readily undergoes nitrosation 
reactions similar to clopidogrel (Figure 1.8) (137).  
Thornhill et al have successfully shown an acute increase in the circulating RSNO and nitrite 
levels following a single loading dose of prasugrel to CAD patients(137). This rise is not 
maintained with chronic prasugrel treatment.  The RSNO formed can potentially act as a NO 
donor. 
 
Figure 1.8: Molecular structure of prasugrel and its metabolism 
 
Pleiotropic effects of Prasugrel 
In addition to its inhibitory effect on platelets, Prasugrel metabolites can also cause an 
inhibition of neutrophil activation, thereby modulating the inflammatory process. This effect is 
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believed to be independent of P2Y12 receptor influence (138).  Totani et al. demonstrated that 
treatment of mice with prasugrel resulted in inhibition of TXB2 production, inhibition of P-
selectin expression, platelet –PMN adhesion, reduction of tumour necrosis factor α synthesis 
and increased NO metabolites in endotoxin treated mice in vivo (139). Thereby limiting the 
platelet mediated inflammatory process.  
 
 Non-Thienopyridines 
1.4.2.2.1 Ticagrelor 
Ticagrelor is a novel oral antiplatelet medication licenced for use in ACS. It belongs to a new 
chemical class of drugs called cyclopentyltriazolopyrimidines. Cangrelor was the first agent to 
be developed in this class, which has a chemical structure like adenosine. Cangrelor does not 
require prior metabolism and is a short acting drug and is available only in intravenous form.  
Ticagrelor was developed by modifying the chemical structure of cangrelor (Figure 1.9). 
Ticagrelor is marketed as a more stable drug which can be administered orally, making it a 
preferred antiplatelet agent in its class. 
   
Figure 1.9: Molecular structure of Adenosine triphosphate, Cangrelor and Ticagrelor 
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Ticagrelor is a very potent direct acting P2Y12 receptor antagonist. It is an active drug, does 
not need prior metabolism, and binds reversibly and non-competitively with the P2Y12 receptor 
(140, 141). This changes the conformation of the P2Y12 receptor and inhibits ADP induced G 
protein activation (142).  
Ticagrelor is rapidly absorbed orally with bioavailability of ~36% and reaches a peak 
concentration (T max) in 1.3-2 hours (143, 144). AR-C124910XX is a main metabolite formed 
quickly via CYP3A4 metabolism. Ticagrelor and its metabolites are both highly protein bound 
(99.7%) and pharmacologically active. Ticagrelor has a rapid (30min) onset of antiplatelet 
activity. It has a moderate half-life of 6.7 to 9 hours, hence a twice per day regime is 
recommended.  
Ticagrelor therapy is typically initiated at a higher dose of 180mg (loading dose) and then 
reduced to a continued therapy at 90mg twice daily. Ticagrelor causes maximum platelet 
inhibition (80%) within 1hr and peak inhibitory platelet aggregation achieved ~ 2 hours in 
comparison to 7.8 hours with clopidogrel. (145) 
Ticagrelor blocks adenosine diphosphate (ADP) receptors of the P2Y12 subtype like the 
thienopyridines (clopidogrel and prasugrel). It has a different binding site from ADP, hence an 
allosteric antagonist (146). Unlike the thienopyridines, which irreversibly inhibit platelet 
aggregation by selectively decreasing binding of adenosine diphosphate (ADP) to its platelet 
receptor, it acts directly by changing the conformation of the P2Y12 receptor. This results in 
reversible, concentration dependent inhibition of the receptor (147).  
The Platelet inhibition and patient outcome (PLATO) trial evaluated the efficacy of ticagrelor 
(180mg loading/90mg BD) against clopidogrel (600/300mg loading and 75mg OD) in 
prevention of cardiovascular events in patients with ACS. There was a significant reduction in 
cardiovascular death and MI at 30 days and 12 months with ticagrelor compared to 
clopidogrel. There were no differences in major bleeding in both groups. The benefit was noted 
across all groups of patients in this study, irrespective of patient’s age, type of ACS, type of 
therapy (conservative or invasive therapy) (148, 149). 
Finally, the PEGASUS-TIMI 54 trial was a randomised placebo-controlled study which tested 
the feasibility of long-term usage of ticagrelor with aspirin in patients who had previous MI. 
There was significant reduction in risk of CV death, MI and stroke with ticagrelor therapy at 3 
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years. The bleeding rates were higher in ticagrelor treated patients compared to placebo. 
There is no clear consensus for use of long-term ticagrelor use in high risk ACS patients at 
this moment (150). 
Pleiotropic effects of ticagrelor  
There was a significant reduction in all-cause mortality with ticagrelor therapy compared to 
clopidogrel in the PLATO trial (148) and in a sub group analysis of CABG patients in PLATO 
ticagrelor therapy had a reduction in vascular and infection related death (151), which was an 
unexpected finding. This finding fuels the possibility that ticagrelor does have pleiotropic 
effects independent of receptor blockage and this may have contributed to mortality benefit. 
Patients on ticagrelor in PLATO had fewer incidences of chest infection, sepsis and infection 
related deaths. It has been hypothesised that ticagrelor could potentiate the effect of 
adenosine on neutrophil chemotaxis and phagocytosis. Alsharif et al showed an inhibition of 
cellular adenosine reuptake by ticagrelor potentiates the adenosine mediated effect on 
neutrophil chemotaxis and phagocytosis, with a potential influence on host defence against 
bacterial infections (152). However, the PEGASUS trial did not show a reduction in infection 
related death in the ticagrelor group compared to placebo, which could be due to the different 
populations studied.  
Clopidogrel and ticagrelor reduce the release of pro-inflammatory cytokines TNF-α but 
ticagrelor also reduces interleukin 6 (IL-6) in a human sepsis model (128).   
 
1.5 Nitric oxide  
Nitric oxide (NO) is a key mediator in a variety of physiological processes (153). NO was first 
identified in 1777 by Joseph Priestly.  Until late 1970’s it was considered an atmospheric 
pollutant. Dr Furchgott in 1980, identified a molecule which caused smooth muscle to relax. 
He called the molecule endothelium derived relaxing factor (EDRF)(154).  Dr Murad in 
separate research found that nitro-glycerine, a drug that contains nitrate groups and known to 
be an effective anti-anginal, works by releasing NO and subsequently relaxing vascular 
smooth muscle(155). In 1986 Dr Ignarro demonstrated by biochemical analysis that EDRF 
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was identical to NO.  After more than a decade later(1992) NO was fully recognised and 
named the molecule of the year, and the three US scientists who discovered it received the 
Nobel prize for physiology and medicine in 1998.(156) 
NO is a diatomic colourless odourless gaseous molecule consisting of oxygen and nitrogen 
bound together by covalent bonds. NO is a free radical with a free unpaired electron between 
the two atoms. It is highly reactive and has a short life (milliseconds)(153). Due to these 
features its radius of effect is limited only up to 100 µm or less from its source of origin. Overall, 
NO concentration is a balance between its rate of formation and its rate of 
reaction/decomposition.  
In humans, NO is formed via endogenous synthesis and through exogenous oral nitrate 
intake(157). 
Endogenous NO is synthesised from the amino acid L- arginine by the enzyme nitric oxide 
synthase (NOS). There are three main isoforms of NOS:  
a) Neuronal type (nNOS, NOS1) primarily regulates neurotransmission and neurotoxicity, 
with some evidence of vasomotor regulation. 
b) Macrophage or cytokine inducible type (iNOS, NOS2) which regulates immune 
responses.   
c) Endothelial type (eNOS, NOS3) involved in vasomotor regulation.(158) 
 
Mitochondrial NOS (mtNOS) is a subtype of NOS found in mitochondria, generating NO, which 
is a crucial biochemical regulator of mitochondrial function (159).  
Endothelial NOS (eNOS) is present predominately on the vascular endothelium. eNOS is a 
calcium/calmodulin dependent oxidoreductase dimer. Shear stress as a result of blood flow 
activates NFĸB and promotes eNOS expression by serine phosphorylation (160). eNOS 
catalyses generation of NO in vascular endothelium from L-Arginine. It is a two-step reaction 
that starts with hydroxylation of L Arginine using two electrons from nicotinamide adenine 
dinucleotide phosphate (NADPH) and one molecule of oxygen (O2) to form N-hydroxy-L-
Arginine. N-hydroxy-L-Arginine forms NO and L-Citruline by utilising a second oxygen 
molecule and one electron from NADPH. Flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN) and tetrahydro-l-biopterin (BH4) are essential cofactors. The cyclic 
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conversion of cofactor BH4 to trihydrobiopterin radical (BH3-) is essential for eNOS activity 
(Figure 1.10) (161, 162). 
 
Figure 1.10: Endogenous synthesis of NO via eNOS 
NO has a short half-life (milliseconds), it instantaneously reacts with reactive oxygen radicals 
(ROS) like superoxide (O2*-) in cells and in blood at almost diffusion limited rates. NO in 
aqueous solution reacts more slowly with oxygen and water to form a series of nitric oxides 
which are stable endocrine molecules (Equation 1.1). Nitrogen dioxide (NO2) is hydrolysed to 
equimolar amounts of nitrite (NO2-) and nitrate (NO3-). In human blood the half-life of NO2- and 
NO3- is 110 seconds and 5-8 hours, respectively (163).  
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Equation 1.1: NO is auto-oxidised with oxygen in aqueous solution to nitrogen dioxide(NO2),(1)  which further 
reacts with NO to form nitrogen trioxide (N2O3)(2) . These oxides are further hydrolysed to nitrite and nitrate. 
NO reacts extremely quickly with ROS, produced by xanthine oxidase and NADPH oxidase 
present on the vessel wall. ROS are formed from oxygen metabolism, they are potentially 
harmful to cellular proteins, lipid, and DNA (164).  ROS are highly reactive due to the presence 
of unpaired electrons.   NO reacts with ROS to form damaging peroxynitrate (ONOO-) which 
can under certain conditions act as an alternative source of nitrite. ROS and ONOO- are 
elevated in disease conditions, thus contributing to reduce NO effectiveness.  
In blood, NO reacts with both oxygenated and deoxygenated haemoglobin forming 
methaemoglobin and nitrosylhaemoglobin respectively.  This process is believed to be the 
main mode of degradation of NO.  Under physiological conditions nitrosyl-haemoglobin 
(HbNO) has limited significance as an NO donor due to its high affinity (1500 times higher than 
CO in hypoxia) and slow disassociation rate.  NO can bind to a cysteine thiol group of 
haemoglobin, forming an S-nitroso haemoglobin (HbSNO), which is more stable and can travel 
to more distal part of circulation and release NO to regulate microvascular blood flow in 
deoxygenated tissues (165). Myoglobin has a similar nitrite bio-activation role in low oxygen 
conditions, especially in myocardial ischaemia/reperfusion injury (166).   
NO forms s-nitrosothiol (RSNO) through reacting with reduced thiols on protein (mainly 
cysteine residues) and other molecules (Equation 1.2). 
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Equation 1.2; Nitrogen trioxide reacts with molecules containing a thiol group to form nitrosothiols and nitrites, 
RSNO are more stable bi products of NO metabolism with a half-life of 1-40min.  
It is currently not possible to measure the amount of NO directly in humans due to its high 
reactivity and very short half-life. Nitrite, nitrate and RSNO are relatively stable metabolites of 
NO with half-life of 110 seconds,  8 hours and 1-40 minutes respectively, hence these 
metabolites are measurable (163, 167, 168).  
NO is eventually metabolised to nitrate and excreted in urine. NO metabolites including nitrite, 
nitrate and RSNO are now considered not only as a direct measure of physiological activity of 
NO, but also as a biologically active NO reservoir.  These intermediate molecules act as 
storage pools of NO in plasma and tissues (mitochondrial, endothelium)(157, 163).This can 
be recycled back to NO under appropriate physiological and pathological conditions. 
1.5.1 Nitric oxide in the cardiovascular system  
NO readily penetrates the membranes of neighbouring cells and through binding with soluble 
guanylate cyclase converts guanosine monophosphate (GMP) to cyclic GMP (cGMP). cGMP 
along with cAMP acts as an important second messenger in the smooth muscle 
relaxation(169) and subsequent vasodilation. The physiological effects of cGMP are 
predominantly mediated through activation of cGMP-dependent protein kinases, cyclic 
nucleotide-gated (CNG) ion channels and the activation or inhibition of phosphodiesterase 
(PDEs). NO can also exert its effects via cGMP-independent signalling, such as S-nitrosylation 
of target proteins, activation of sarco/endoplasmic reticulum calcium ATPase and production 
of cyclic inosine monophosphate (cIMP)(170). 
NO within the vascular lumen exerts a potent inhibitor effect on platelet aggregation and 
adhesion via both cGMP dependent and cGMP independent mechanisms (162). It also 
promotes angiogenesis, inhibits endothelial cell apoptosis (133, 171-173), and several other 
critical roles in maintaining normal vascular homeostasis.  
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Figure 1.11: Physiological actions of NO on the vasculature and its crucial role in cardiovascular physiology 
 
1.5.2  Nitrosothiols 
Nitrosothiols (RSNO) are endogenous metabolites of NO, exhibiting similar biological 
functions as NO in vivo as well as in vitro.  RSNO are ubiquitous molecules formed by 
nitrosation of nitrosonium cation (NO+) and thiol anion (RS-). Plasma contains ~600 µM thiol 
groups, majority of which are albumin, GSH, and cysteine. The electrophilic interaction of 
these thiols with oxides of nitrogen generates RSNO (Equation 1.2).  
They have the general formula of RSNO, R representing the protein side chain of a peptide 
containing cysteine.  The type of protein and R group determines the RSNO formation kinetics 
and chemical properties.  RSNO can be formed by endogenous NO produced by eNOS, from 
dietary sources, or from exogenous sources like S-nitrosoglutathionine (GSNO) (170, 174). 
Freely available RSNOs include S-nitrosocysteine, S-nitrosoglutathione and S-
nitrosoalbumin.  Plasma S-nitrosoalbumin levels are positively correlated with NOS activity 
(170). Typically large protein RSNO is more stable than low molecular weight RSNO(175).  
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RSNO have longer half-life than NO and are considered to be NO donors, and  transfer of 
NO+ across the plasma membrane via protein disulphide isomerases(176). RSNO are stable 
at 370 C and pH of 7.4 in the presence of transition metal ion chelators (177).  NO release 
from RSNO is facilitated by numerous factors such as light, heat, superoxide, transition metals, 
and enzymes like xanthine oxidase (178), superoxide dismutase and various dehydrogenases 
(179, 180).  NO can be transferred from a donor S-nitrosylated protein to an acceptor S-
nitrosylation substrate and this is referred as transnitrosation (equation below). 
Transnitrosation of thiol represents a potential mechanism of modification of protein and 
enzyme activity.  
 
RSNO can react with thiolate anion forming a disulfide and nitroxyl anion at intracellular level 
in response to oxidative stress. This process of S-thiolation is more stable than S –nitrosation. 
The fate and effect of by-products in vivo is unknown(181). 
 
RSNO activate soluble guanylyl cyclase (sGC) by being converted to dinitrosyl ion complexes 
which give NO+ to the sGC haem moiety. Thiol groups on haemoglobin does bind to NO+ to 
form nitrosohaemoglobin (HbSNO).  S-nitrosation of haemoglobin increases oxygen affinity at 
low oxygen concentrations (182, 183).  S-nitroso-N-acetyl penicillamine can directly stimulate 
guanylyl cyclase via interacting with the enzyme haem (184). GSNO can act as a substrate 
for several enzymes that utilize glutathione (185). 
RSNO exhibits potent vasodilatory (186-188) and platelet inhibitory effects (189).  These 
effects are largely attributed to NO release and direct binding to sGC (177, 187).  HbSNO in 
the presence of glutathione facilitates hypoxia mediated vasodilation (182).The platelet 
inhibition effect is achieved at lower concentrations than those required for vasodilation (190, 
191).   RSNO also exhibits cytoprotective effects against cellular toxicity associated with 
oxidative stress (192) and immunosuppressive effects.  
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The role of endogenous RSNO in normal cellular function and physiology is not well known. 
There are many potential clinical uses of RSNO which are yet to be fully elucidated and 
exogenous RSNO compounds have been extensively researched for their therapeutic 
potential. Exogenously administered nitrosylated bovine serum albumin has shown a coronary 
vasodilatory and antiplatelet effect in animal studies (193, 194). In humans, GSNO can inhibit 
platelet aggregation without affecting vascular tone. The platelet specificity is related to a 
mechanism by which platelets metabolize GSNO and this effect can be significantly decreased 
by use of copper specific chelators. Platelets have cell surface copper containing proteins that 
promote the release of NO from GSNO, and platelets can also concentrate GSNO and release 
upon activation by neutrophils. Human studies with GSNO administration as an antiplatelet 
agent showed a marked reduction in thrombotic embolization after carotid endarterectomy 
surgery (195), reduced clot formation in coronary artery bypass grafts (196) and normalised 
platelet function in an aggressive form of preeclampsia (197). RSNO have shown to improve 
ischaemia/reperfusion injury in the heart (198) and liver (199), relax bronchial smooth muscles 
and has antimicrobial effects in animal model studies.                                                           
RSNO have great potential as therapeutic agent. They are a useful alternative to organic 
nitrate due to their lack of development of tolerance. RSNO is available only in intravenous 
form and currently only used in a small number of animal and human studies(168, 200-204). 
Antiplatelet medications belonging to the thienopyridine class of drugs (Clopidogrel and 
Prasugrel) exhibit a critical thiol group. These active metabolites bind to the P2Y12 receptors 
on the platelet surface, inhibiting platelet activation and clot formation in vivo.  Our research 
group successfully demonstrated an in vitro formation of thienopyridine-SNO with 
pharmaceutical grade preparations of clopidogrel (133) and prasugrel (137). 
1.5.3 Nitric oxide and endothelial dysfunction 
As described above, NO plays a central role in the regulation of vascular tone and the 
maintenance of vascular haemostasis. Impaired production of endogenous NO is a hallmark 
of endothelial dysfunction. Cardiovascular risk factors like smoking, age, hypertension, 
hypercholesterolemia, diabetes and family history of Ischemic heart disease are associated 
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with endothelial dysfunction (50, 51, 205). Endothelial dysfunction is a vital step in 
atherosclerosis, leading to development of coronary artery disease. 
Endothelial dysfunction occurs as a consequence of progressive oxidative stress and 
inflammation, causing an abnormality of G protein signalling, elevated asymmetric dimethyl 
arginine, decrease in tetrahydrobiopterin and a deficiency in L-arginine. In this sense 
decreased NO is the result of either decreased NO production or increased NO denaturation. 
In CVD there is parallel enhancement of NADPH oxidases and eNOS. O2− derived from 
NADPH oxidases and/or xanthine oxidases may combine with NO· and increase the formation 
of peroxynitrite (ONOO−). ONOO- oxidises BH4 to biologically inactive products such as BH3· 
radical or qBH2. ONOO- also causes oxidative damage to eNOS resulting in destabilization of 
the dimer interface. As a consequence of this, eNOS is uncoupled, becomes dysfunctional 
and is converted into a superoxide-generating enzyme (206, 207) adding to a vicious cycle of 
oxidative insult (Figure 1.12). 
Lack of endogenous NO synthesis is a critical component in CVD. Recently there has been a 
great interest in improving the NO bioavailability in patients with endothelial dysfunction 
through exogenous (dietary) sources. 
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Figure 1.12: Diagrammatic description of the effect of endothelial dysfunction and oxidative stress on the 
functioning of eNOS system 
 
1.5.4 NO resistance and platelet function 
NO is an important down regulator of platelet function, largely through activation of soluble 
guanylyl cyclase and subsequent cGMP formation as described above. There are some 
reports of intrinsic expression of eNOS in platelets(208, 209), thereby generating their own 
NO. However this remains a contentious issue(210).   
NO resistance has been well described in CAD patients, but the exact mechanism is not 
known(211, 212). NO resistance is likely due to NO scavenging in oxidative conditions or 
impaired NO-sGC activity. It has been considered as an independent predictor of mortality 
and morbidity in CVD patients. Borgognone et al showed platelet NO resistance is an intrinsic 
phenomenon, which was successfully circumvented by nitrite causing a direct activation of 
sGC and phosphorylating VASP serine 239 independent of NO in patients with heart failure 
with preserved ejection fraction (HFpEF)(213). This study proves that inorganic nitrite 
substitution through diet could overcome the impairment in the NO-cGMP pathway (NO 
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resistance) in CVD and could improve outcomes. It is well established that nitrite forms RSNO 
as described above, and RSNO has a dual role of being a potent NO donor and a direct 
stimulator of sGC. It could be postulated that the ability of nitrite to circumvent NO resistances 
could also be due to its role in RSNO formation.  
 
1.6 Dietary Nitrate (inorganic nitrate) supplementation. 
Nitrate in humans originates from two sources, first via oxidation of endogenous eNOS derived 
NO and second through diet.   
Dietary nitrate is an important exogenous source of nitrate; nitrates are normal constituents of 
our daily diet and vegetables provide 60-80% of daily nitrate intake in the typical western diet 
(214, 215).  A vegetarian diet contains about 4.3 mM nitrate whereas a normal diet has 
approximately 1.2mM of nitrate. The cardiovascular benefits of a Mediterranean and Japanese 
diet is mainly attributed to high fruit and vegetable intake which are high in dietary nitrate(216-
218). 
Vegetables can generally be grouped into 5 groups based on their nitrate content as shown in 
Table 1.1. Examples of high nitrate vegetables includes, beetroot, spinach, swiss chard, 
rhubarb, lettuce. 
Nitrate (mg/100g weight) Vegetables 
Very Low (<20mg/100g) Asparagus, broad bean, eggplant, garlic, onion, green bean, 
mushroom, pepper, potato, pea, sweet potato, tomato, 
watermelon 
Low (20-49mg/100g) Broccoli, cauliflower, cucumber, carrot, chicory, pumpkin 
Medium (50-99mg/100g) Cabbage, turnip, dill 
High (100-249mg/100g) Chinese cabbage, fennel, celeriac, endive, fennel, leek, parsley 
Very high (>250mg/100g) Cress, chervil, lettuce, red beetroot, Swiss chard, rhubarb 
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Table 1.1 :  Classification of fruits and vegetables based on their nitrate content. 
Inorganic nitrates have a long history in the treatment of CAD, its value was earliest recognized 
by the Chinese in 700 AD (219)  Inorganic nitrates and nitrites were prescribed indiscriminately 
to treat CVD and other conditions such as lung disease, epilepsy, and edema. There was an 
increase in reports of nitrite toxicity in the 1950’s causing it to fall out of favor. There were 
concerns of carcinogenesis, teratogenesis, and infantile methemoglobinemia. Stringent 
regulations were introduced for the last 50 years by governments and by WHO to maintain 
lower nitrate concentration in food and drinking water. However recent epidemiological studies 
have failed to prove this association and in fact have been shown to have positive beneficial 
effect in CVD (220). Indeed, in large scale prospective studies the association with 
carcinogenesis could also be associated with pre-existing medical conditions (for example 
gastric ulcer or infection). 
1.6.1 Nitrate-Nitrite-NO cycle 
Lundeberg et al, Zweier et al, and Benjamin et al, in the mid-90’s demonstrated NOS- 
independent formation of NO in biological tissue from inorganic nitrate and nitrates (221, 222) 
These discoveries lead to enormous interest in this area and in particular research into the 
mechanism and its possible benefits in CVD.  Dietary in-organic nitrate and nitrites are 
explored as a viable and safe source of NO augmentation in humans especially in patients 
with endothelial dysfunction. 
The current focus is on fruits, green-leafy vegetables like lettuce, cabbage, and spinach and 
in super-foods like beetroot and garlic as a means of improving cardiovascular health.  
The nitrate components in these foods is believed to exert cardio-protective effects by 
augmenting the nitrate-nitrite-NO axis in health and CVD. 
 Dietary nitrate metabolism 
1.6.1.1.1 Nitrate to Nitrite conversion 
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Nitrate on its own has relatively few direct effects in vivo, and first needs to be metabolised to 
nitrite, which is the biologically active product. Orally ingested nitrate is rapidly absorbed in the 
proximal gastrointestinal tracts into the blood stream, mixing with endogenously produced 
nitrate. The nitrate concentration in plasma peaks within 60 minutes of ingestion and the half-
life is approximately 5 hours (215, 223).  
The majority (~75%) of nitrate is excreted via the urine, and the rest is excreted mainly in the 
saliva and sweat. Active salivary concentration of nitrate is 10 times (200-1000 µM) higher 
than plasma (224-226). The commensal bacteria (facultative anaerobes) present in the GI 
tract (highest concentration in the oral cavity), effectively reduce nitrate to nitrite (Equation 
1.3). Human cells intrinsically lack this nitrate reductase. Bacterial presence is therefore 
essential in this process. Gram negative bacteria Veillonella Spp present on the dorsum of the 
tongue accounts for >50% of nitrate reductase activity (215). Gram positive bacteria 
Actinomyces is the second most abundant bacteria causing nitrate reduction (157). This 
process of reduction of nitrate to nitrite was found to be reduced in healthy volunteers given 
antibacterial mouthwash (215, 227). 
 
Equation 1.3: Equation depicting the conversion of nitrate(NO-3) to nitrite(NO-2) via bacterial nitrate reductase 
present in the oral cavity. 
The nitrite produced in the oral cavity from salivary nitrate is then swallowed and enters the 
stomach, in acidic conditions some of the nitrite is converted to NO and other N-Oxides, the 
rest gets absorbed into the systemic circulation as nitrite.  
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Figure 1.13: Enterosalivary circulation of orally ingested nitrate source. The graphs on the left and right side of 
the diagram shows the rise in the plasma nitrate and nitrite levels respectively with time upon ingestion of dietary 
bolus in the form of Swiss chard containing gel (SIS® ltd)  
Our group investigated the rise in plasma nitrate and nitrite levels in 10 healthy volunteers after 
ingestion of a dietary nitrate supplement (a single bolus of SIS® gel containing 4.8mmol nitrate) 
which showed similar pharmacokinetic pattern (Figure 1.13) as demonstrated by Kapil et al 
(227).  
Plasma nitrate levels rise to a significant level at 60-90 minutes and reaches a peak in 2 to 2.5 
hrs of ingestion of dietary nitrate. There is a slight delay in the rise of plasma nitrite level 
compared with nitrate due to the requirement for entero-salivary reduction of nitrate to nitrite. 
It reaches a peak in 2.5 to 3 hours. 
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1.6.1.1.2 Nitrite to NO reduction 
There are numerous eNOS independent pathways that generate NO from the reduction of 
nitrite. In biological systems this is largely an enzymatic reduction process through allosteric 
reactions catalysed by nitrite reductase. Examples include xanthine oxidase (XOR), the Heme 
moiety of haemoglobin/myoglobin, polyphenols, cytochrome P450 and protons(228-230). In 
physiological conditions, globin acts as primary nitrite reductase source. In pathological 
conditions like acidosis and hypoxia, xanthine oxidase dominates as a nitrite reductase and 
generates NO (231, 232). In strong acidic environments, nitrite chemically disproportionated 
to NO – a factor that we utilise to good effect during the measurement technique (see Methods 
section). 
CVD like hypertension, atherosclerosis, and CVA are associated with endothelial dysfunction 
and reduced NO production. Under hypoxic and ischaemic conditions, nitrite conversion to NO 
via chemical acidification or by enzymatic conversion can facilitate vasodilatory, platelet 
inhibition, angiogenesis, and endothelial cell proliferation.(133, 171)  NO also provides 
protection against ischaemia/reperfusion injury in myocardial and cerebral vasculature (233, 
234). 
 
Figure 1.14: Endogenous NO generation via eNOS dependent and eNOS independent mechanisms under different 
conditions, adapted from O Lundberg et al., 2008. (32).  
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It is now well established that there are primarily two pathways to generate bioactive NO.  The 
Classical pathway of conversion of L- Arginine and oxygen through NO synthases (NOS). This 
is oxygen dependent and NO generation becomes limited as oxygen levels fall. Under 
conditions of reduced oxygen, the NOS-independent pathway for NO generation is enhanced.  
This pathway is also known as the nitrate-nitrite-NO pathway (Figure 1.14) 
The Nitrate-nitrite-NO axis complements the conventional endogenous generation of NO by 
NO synthases (NOS) (235, 236).  Parallel actions of both pathways can ensure a sufficient 
amount of NO within the tissues. 
 
1.6.1.1.3 Clinical application of in-organic nitrate therapy 
Supplementation of diet with inorganic nitrate is being studied extensively as a cost-effective 
therapeutic intervention to augment intravascular NO level in patients with endothelial 
dysfunction and healthy individuals participating in competitive sports. 
A clinically relevant blood pressure lowering effect of orally ingested dietary nitrate supplement 
is well established in trials conducted both in healthy volunteers and hypertensive patients 
(226, 227, 237). 
Larsen et al first demonstrated an enhance exercise performance in well trained male cyclist 
upon ingestion of dietary nitrate supplements.  There was significant lower oxygen 
consumption (VO2peak) with no increase in blood lactate concentration(238). Several studies 
thereafter showed a variable effect on exercise performance. A recent meta-analysis of 76 
eligible trials concluded a positive outcome on endurance exercise capacity with less likely 
effect on time-trial performance (239). 
Oral administration and intravenous infusion of nitrite in mice showed a protection against 
myocardial and hepatic ischaemia reperfusion injury and improved cardiac performance in the 
setting of heart failure (233). A recent clinical study in patients with ST elevation MI 
demonstrated a reduction in infarct size in patients who had intracoronary infusion of sodium 
nitrite (240). Interestingly, there was no change in infarct size in patients who were given 
intravenous sodium nitrite(241).  Nitrate rich beetroot juice supplementation in patients with 
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heart failure demonstrated improved exercise capacity and endurance, likely due to improved 
skeletal muscle activity (242-244).The role of NO in cerebrovascular disease has also been 
well studied, with several studies suggesting a prospect of attenuation of ischaemic and 
reperfusion brain injury after stroke with nitrate or nitrite administration (245-247). 
Dietary nitrate supplementation has been shown to reduce platelet reactivity in healthy human 
volunteers (248).  However, there is a lack of published data on the effects of nitrate 
supplementation on platelet reactivity in patients with known coronary artery disease.  Hence 
it is clear there is a need to understand the role of naturally occurring supplements in diseased 
states. This thesis addresses this directly and aims to establish the influence of nitrate 
supplement on platelet inhibition and nitrate metabolism in CAD patients.  
1.6.1.1.4 Commercially available dietary nitrate products 
Nitrates are fast gaining a reputation as a health and performance enhancing nutritional 
supplement.  Beetroot juice is the most commonly used nitrate supplement across the 
published studies and is well-known for its high nitrate content (>250mg/100g fresh 
vegetable). Dietary nitrate products from natural sources are commercially available for 
general population use. These products are very popular among individuals participating in 
sports. Some of the more commonly available dietary nitrate products include, Holland & 
Barrett beetroot capsules, bio-synergy power beet-beetroot capsules, Raspberry extract, Beet 
it, and Science in sport (SIS®) Go plus gel (SIS® Go+). 
SIS® Go+ nitrate gel (SIS® Limited, UK), is a natural inorganic nitrate supplement gel, based 
on Swiss chard, manufactured and marketed in UK by SIS® limited. It is available as a 60 ml 
sachet in all leading superstores as an over the counter product. The cardio-beneficial effects 
are well studied in the field of sports science. SIS® Go+ nitrate gel is a widely available sports 
gel with inorganic nitrate extracted from natural resources. This form of nitrate supplement is 
very popular amongst cyclists and other endurance athletes. Celebrated sports personalities 
like Sir Chris Hoy, Helen Jenkins and Team GB rowing athletes have endorsed and used this 
product to help them achieve improved muscular effort during performance (249).  
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”Beet- it” is another popular product readily available in most supermarkets across UK. 
Beetroot products have been shown to enhance physical stamina and recovery in trained 
athletes (0.5l/day for 6days) (250). The constituents of SIS® Go+ Nitrate and Beet-it are 
described in Table 1.2 for comparison. 
The plasma nitrate and nitrite levels are enhanced upon ingestion of these dietary nitrate 
supplements, and our group studied the pharmacokinetics of SIS® Go+ Sports gel in healthy 
human volunteers.  10 healthy volunteers were given 2 sachets of SIS® Go+ nitrate Gel. Blood 
samples were collected for up to 24 hours after ingestion of the gel. Isolated plasma samples 
were analysed for nitrite and nitrate levels and were plotted against time. (Figure 1.15). The 
peak concentration of nitrite and nitrate occurred at 90 minutes and 120 minutes respectively. 
 
Figure 1.15: Plasma levels of nitrite and nitrate with time upon ingestion of 120ml of SIS® Go+ nitrate supplement. 
Plasma nitrate levels and plasma nitrite levels measured in micromolar and nanomolar respectively.  
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Commercial product-Ingredients 
SIS® Go+ nitrate gel (60ml/Sachet) 
Swiss chard juice concentrate (15%)  
Maltodextrin (from maize) (5.5%) 
Rhubarb juice concentrate (4%) 
Acidity regulator (citric acid, sodium citrate) 
Preservatives (potassium sorbate, sodium 
benzoate 
Sweeteners (acesulfame K, sucralose) 
Flavoring 
Folic acid 
Gelling agents (xanthan gum, gellan gum) 
Water 
Beet It® ( 500  ml) 
Pressed organic beetroot juice (90%) 
 
 
 
Pressed organic apple juice (10%) 
 
Table 1.2: Ingredients and constituents of the leading commercially available nitrate supplements 
Luke et al. demonstrated a similar extent of increase in plasma nitrate, nitrite levels upon 
ingestion of beetroot juice and chard gel (SIS® Go+) in their study on healthy human 
volunteers, intriguingly there was a greater increase in RSNO with ingestion of beetroot juice 
in comparison to chard gel, which was believed to due to higher content of phenols in the 
chard gel (251). 
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1.7 Antiplatelet therapy and Nitric oxide 
1.7.1 Clopidogrel and nitric oxide metabolism 
It is considered that the clinical benefit of clopidogrel is due largely to its antithrombotic and 
antiplatelet activity. Recently, off target effects have emerged including improvement in  
endothelial dysfunction in stable CAD patients via a mechanism independent of platelet 
function (107, 130, 132, 252) , and improvement in brachial artery vasodilation independent 
of endothelial NO production with higher clopidogrel doses (107, 132, 252).  
In vivo, the active metabolite of clopidogrel (as with all Theinopyridines) exhibits a critical thiol 
group that governs its interaction with platelets. This prompted investigation at the WHRI into 
whether active clopidogrel might form nitrosothiol (-SNO) derivatives. Indeed, the James 
group have shown direct nitrosothiol formation from clopidogrel, prasugrel, and ticlodipine 
formulations when under acidic conditions and in the presence of background nitrite. The 
RSNO formed exhibits direct anti-platelet and vasodilator activity (133).   This occurs without 
the need for prior metabolism. The group has since demonstrated increased NO metabolites 
in CAD patients following an acute or chronic dose of clopidogrel (253). Clopidogrel-SNO also 
causes an endothelium independent vasodilatory effect. Clopidogrel SNO also participate in 
transnitrosation reaction with other thiol groups (133). Taken together, this implies clopidogrel 
induced RSNO formation might represent an important and yet unstudied pathway in CAD 
patients. 
Clopidogrel-SNO can exert its antiplatelet activity potentially via three mechanisms. Firstly, it 
activates the cGC via NO+ causing an inhibition of intracellular calcium influx, thereby 
dampening the P2Y12 mediated activation(254). Secondly, it can directly inhibit the activation 
of P12K pathway by TRAP (255). Finally, by nitrosation of proteins like tyrosine residue of 
COX1 enzyme within the platelets, which inhibits the conversion of arachidonic acid to TXA 
(256).  
It is noteworthy that ideal conditions exist in humans for formation of thienopyridine RSNO.  
Orally ingested clopidogrel enters the acidic environment of a fasting stomach, and encounters 
nitrite present in saliva and the stomach (<20µM) favouring expression of thiol groups on the 
parent drug and formation of clopidogrel RSNO (Figure 1.16).  In vitro studies have showed 
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that formation of SNO is dependent on nitrite concentration, the dependence is linear up to 
the point of saturation of free thiols and the availability of clopidogrel substrate.  
 
 
Figure 1.16: Clopidogrel SNO formation in vivo in the stomach and its absorption into the blood vessel where it 
acts as a NO donor. 
 
1.7.2 Prasugrel and nitric oxide  
James et al have successfully shown that prasugrel can also readily form nitrosothiol. 
Prasugrel exhibits a higher number of free thiols than clopidogrel and ticlopidine, and 
consequently forms SNO more readily in vitro (133),  
In CAD patients our group have recently demonstrated an increase in circulating SNO store 
following prasugrel in the acute and chronic setting (137). More importantly, the occurrence of 
plasma SNO following prasugrel was found to depend on co-treatment with PPI (which alters 
stomach pH and thus SNO formation) which was inversely associated with the extent of 
platelet inhibition in patients.  
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1.7.3 Thienopyridine-SNO 
Clopidogrel and prasugrel readily undergo nitrosation, and form SNO in the presence of nitrite 
and in low PH without need for in vivo metabolism. Prasugrel-SNO is more stable in 
comparison with Clopidogrel-SNO (137). 
The potential for antiplatelet drugs, such as clopidogrel and prasugrel, to influence this 
circulatory NO pool and enhance ‘pleiotropic’ non-platelet effects of these drugs in the 
circulation are as yet poorly characterised. 
These findings warranted a further investigation to understand the formation and the role of 
clopidogrel-SNO in patients with stable CAD and their association with nitrate supplements.   
1.7.4 Non-thienopyridine-SNO 
Ticagrelor lacks a free thiol group with the sulphydryl group contained within the ring structure 
of the molecule (as shown in Error! Reference source not found. ), hence it was predicted 
that ticagrelor will not have the ability to form an S-nitrosothiol products.  
In vitro experiments conducted in our laboratory by Dr Thornhill as a part of his thesis showed 
ticagrelor formed RSNO efficiently as the pH dropped below 3 in the presence of background 
nitrite and to a greater degree compared with RSNO formation with the thienopyridine drugs 
clopidogrel, ticlodipine and prasugrel (133).  This was an important and unexpected finding. 
In addition to this finding, when subjected to a pH of below 3 the parent drug lost its ability to 
inhibit platelet aggregation completely in response to activation by either ADP or TRAP agonist 
in platelet rich plasma (137, 257). Commercially available ticagrelor tablets have a waxy 
coating, and there was no difference in time for the whole table to dissolve in simulated gastric 
medium at various pH levels (within 4 minutes). Extrapolated to the in vivo patient scenario, 
ticagrelor molecules would be fully exposed to the acidic environment in the human stomach 
within 5 minutes of its ingestion which would render the ticagrelor parent drug ineffective at 
inhibiting platelets. This was unexpected given the clear effectiveness of ticagrelor as a potent 
antiplatelet agent in CAD patients. 
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Furthermore, in the PLATO trial proton pump inhibitors (PPIs, which typically rise the gastric 
pH levels in patients to >5) therapy was associated with increase adverse outcomes (including 
mortality) with both clopidogrel and ticagrelor (258).  
Given the above findings of a direct effect of pH on the capacity for ticagrelor to inhibit platelet 
aggregation and adverse clinical outcome, along with a novel evidence of Ticagrelor-induced 
RSNO formation, merits further investigation. 
1.8 Overall Thesis Aims  
The benefits of antiplatelet therapy in patients with established coronary artery disease are 
well established. Dual antiplatelet therapy of aspirin with either thienopyridine or non-
thienopyridine agents is a standard treatment for patients undergoing percutaneous 
angioplasty to lower the risk of stent thrombosis and myocardial infarction. Despite this, 
adverse events still occur. 
It is well established that the beneficial effect of thienopyridine and non-thienopyridine drugs 
is due to their ability to block P2Y12 receptor mediated platelet activation. There is novel but 
limited evidence to suggest that thienopyridine agents have additional, P2Y12 independent 
effects. Clopidogrel and prasugrel exhibit vasomodulatory properties in addition to the 
established P2Y12 inhibition. Newer non-thienopyridine agents also show non- P2Y12 receptor 
mediated effects in trials but the exact mechanism is not established.  
Dietary nitrates form an important source of exogenous nitrate, thereby forming an imperative 
and alternate source of NO via nitrate-nitrite-NO cycle in humans. There is considerable 
evidence suggesting that dietary nitrate supplementation enhances platelet inhibition in 
healthy volunteers and a decline in vasomotor tone in healthy human volunteers and 
hypertensive patients. CAD patients are known to have impaired endothelial NO production. 
Yet there is no study to date that describes the effect of these supplements in patients with 
established CAD, specifically in terms of platelet inhibition, the mechanisms involved and how 
this relates to nitrate metabolism. 
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This thesis aims to further investigate the effect of dietary nitrate supplement with or without 
clopidogrel therapy on NO metabolites and platelet inhibition in patients with stable CAD.  
Newer more potent antiplatelet agents like ticagrelor have developed some of the same 
limitations of clopidogrel therapy, and they have also shown non- P2Y12 receptor mediated 
effects in trials, but the exact mechanism is not established.  This thesis will also explore 
whether ticagrelor can form RSNO compounds in patients with stable CAD and how this 
relates to platelet inhibition. 
1.8.1 Specific aims 
• To characterise and develop an in vitro model of conversion of dietary nitrate to nitrite 
upon ingestion of oral dietary nitrate. 
 
• To investigate the influence and relationship between NO metabolite formation with 
ingestion of dietary nitrate in CAD patients. 
 
• To investigate the effect of dietary nitrate ingestion on the ADP and TRAP mediated 
platelet inhibition in stable CAD patients on and off clopidogrel treatment. 
 
• To investigate the ability of non-thienopyridines (ticagrelor) to form nitrosothiol under 
laboratory condition and in stable CAD patients. 
 
1.8.2 Hypothesis 
• Commercially available dietary nitrates undergo enterosalivary metabolism and 
participate in the Nitrate-Nitrite-NO cycle. 
 
• Concurrent ingestion of clopidogrel and dietary nitrate augments the level of circulating 
nitrite, nitrate and RSNO in stable CAD patients. 
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• Elevated RSNO levels secondary to clopidogrel therapy with dietary nitrate will 
augment platelet inhibition. 
 
• Ticagrelor has no ability to from RSNO due to the lack of a critical thiol group in its 
chemical structure.  
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2 General methods: 
2.1 Patient Recruitment 
Patients for this study were recruited from the cardiology outpatient clinics and cardiac day-
case unit at the University Hospital of Wales (UHW).  
The cardiac day unit at UHW is a 15-bed unit, with the specific remit of delivery and support 
of elective cardiac procedures. Patients typically undergo a pre-procedural assessment and 
evaluation a week prior to their proposed procedure date.  
Patient’s participation was voluntary.  Full ethical approval for the study was sought and 
approved by the Local Research Ethics Committee (LREC) for Wales (IRAS Project ID 
102427) (appendix i), and the study was conducted with the recommendations for physicians 
involved in research on human subjects adopted by the 18th World Medical Assembly, Helsinki 
1964 (and later revisions). 
Patients with known stable CAD were identified and approached for study participation. The 
study details were discussed with the potential participants in person, and a study information 
leaflet (appendix ii) was given. After a minimum of 3 days we re-approached the participants 
and sought their informed consent for participation. 
On the day of procedure, the patients arrive at 8 am and pre-procedural checks were 
conducted by the clinical team. Patients, who are for coronary interventions, would be given a 
loading dose of antiplatelet drugs (clopidogrel 600mg or ticagrelor 180mg or prasugrel 60mg) 
as per clinical indication and preference of the Lead/Consultant clinician. 
Patients who had agreed for voluntary participation in the pre-assessment appointment were 
approached, the study details were re-discussed with emphasis on addressing the patient’s 
concerns.  An informed consent (Appendix iii) is obtained and each patient was assigned a 
research code.  
The following inclusion and exclusion criteria were applied for the recruitment. 
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 Inclusion Criteria 
i. Adults over the age of 18 years with Stable CAD admitted to the University hospital 
for planned coronary angiogram ± PCI 
ii. All patients to be taking aspirin 
iii. Patients due to be given or already on clopidogrel or ticagrelor therapy for clinically 
approved condition 
iv. Patients were fasted for >6 hours 
 Exclusion Criteria 
i. Contraindication to or patients not able to take clopidogrel/ticagrelor medication 
ii. Patients unable to provide informed consent 
iii. Patients with acute coronary syndrome (STEMI, NSTEMI, Unstable angina) 
iv. Patients on long term oral anticoagulant drugs 
v. Patients on non-steroidal anti-inflammatory drugs 
vi. Patients receiving intravenous or subcutaneous anti thrombin therapy 
 
2.1.2 Patients groups 
The patients were grouped according to the antiplatelet therapy, as follows 
 Clopidogrel and dietary nitrate study 
A) Clopidogrel naive group  
These patients were on aspirin alone and no other antiplatelet drugs.  
 
B) Acute loading group (Group A): 
These patients were on aspirin and no previous P2Y12 therapy. They were prescribed 
with a loading dose of clopidogrel 600mg as per clinical guidelines on the day prior to 
their coronary intervention. 
   
KV 
54 
 
 
C) Chronic clopidogrel (Group B):   
These patients were on dual antiplatelet therapy of aspirin and clopidogrel (75mg once 
a day) for more than 1 month and scheduled for a day case coronary intervention. 
This cohort of patients included both diabetic and non-diabetic patients. 
2.1.2.1.1 Dietary nitrate supplementation and study design 
SIS® Go+ nitrate supplements are used as the dietary nitrate source. SIS® Go+ nitrate 
supplements are available as a gel in a 60 ml sachet. An identical sachet of placebo gel was 
prepared which contained all ingredients except the nitrate (Swiss chard). These gels are 
prepared, marketed and sold by Science in Sport Ltd which is based in UK.   
A randomised double blinded placebo control design was applied for the dietary nitrate and 
clopidogrel study. Patients were randomly allocated with either active nitrate gel or placebo 
gel. The recruiter and patient were blinded regarding the form of gel being administered. 
 Clopidogrel naive study: This was a paired cross over randomised double blinded placebo-
controlled study, with cross over after a wash out period of 7 days as shown in Figure 2.1. 
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Figure 2.1: Clopidogrel Naïve patient flow chart showing patient selection, randomisation and allocation to either 
X(placebo) or F(nitrate) gel at their first visit,  and then at 2nd visit  after a 1 week wash out period the patient is 
crossed over to the other gel. Blood samples were collected at 0 hours and 2 hours post ingestion on both 
occasions. 
 
Figure 2.2 : Group A and B patients were randomly given either nitrate or placebo gel, which are coded F and X 
respectively. These patients were not paired.  
The Group A (clopidogrel 600mg) and Group B (clopidogrel 75mg) study: This was 
designed as a randomised double blinded placebo controlled, unpaired study, as shown in 
Figure 2.2. 
The nitrate gel and placebo gel sachets were coded as F or X gel. The un-blinding of the codes 
was done at the stage of writing the thesis. The F and X gels were nitrate and placebo 
supplements respectively.  Each patient was randomly administered either 2x60ml (9.6mmol 
total nitrate dose) of active supplement or placebo supplement, as shown in Figure 2.1 and 
Figure 2.2.  
A zero-hour blood sample was collected just before supplementation with dietary nitrate in all 
groups as described in section 2.2. This sample provided the baseline measurement of the 
NO metabolites and platelet function.  The second sample was collected 120 minutes post 
ingestion of dietary nitrate in the same patients in all groups. This was based on the pilot study, 
evaluating the pharmacokinetics of SIS® Go+ Sports gel in healthy human volunteers.  The 
peak concentration of nitrate and nitrite occurred at 90 minutes and 120 minutes respectively 
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(Figure 1.15). This timing was also practically applicable for patients who were waiting for their 
PCI, both samples were collected before the coronary angiogram +/- PCI, thereby limiting the 
confounding effect of drugs such as heparin used during the procedure. 
 Ticagrelor Group 
A) Acute Ticagrelor loading group 
These patients were on aspirin therapy listed for coronary intervention and they were 
prescribed with Ticagrelor 180mg (loading dose) prior to their intervention as per 
clinical guidelines. 
 
B) Chronic Ticagrelor group  
This group of patients were dual antiplatelet therapy of aspirin 75mg once a day and 
ticagrelor (90 mg twice a day) for at more than one month. 
Patients who were prescribed either with a loading dose of ticagrelor 180mg or maintained on 
a dose of ticagrelor 90mg BD were enrolled for this study. A zero hour and 2 hour blood sample 
were collected in ticagrelor (180mg) loading group as described in section 2.2. The second 
sample was collected at 2-hour to match with the median Tmax of ticagrelor in the plasma (1-
4 hours) and cause minimal interruption for the patient’s clinical management who are due for 
coronary angiogram +/- PCI. A single blood sample was collected in patients on maintenance 
ticagrelor therapy (90 mg twice a day). 
 
2.2 Blood collection 
2.2.1 Blood sampling process 
The blood sample collection was in accordance with Cardiff and Vale University Health Board 
policy and guidelines after obtaining a valid consent.   An 18-gauge intravenous (IV) cannula 
was inserted into the subjects’ antecubital fossa under strict aseptic precautions. Blood was 
directly drawn into vacutainers via the cannula. A total of 15ml of blood collected in vacutainers 
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(Vacuette Greiner Bio-OneTM).  The IV cannula was flushed with 10ml of 0.9% saline solution. 
The same cannula was used for collecting the 2nd sample after an interval of 120 minutes. 
10ml of blood is drawn in a syringe and discarded, to ensure there are no clots and no 
contamination.  A further 15ml of blood collected into the vacutainers and the cannula was re-
flushed with 10ml of normal saline solution. 
Blood samples for antiplatelet study were collected into 3ml vacutainer tubes containing 
hirudin.  For NO metabolites (nitrate, nitrite and RSNO) study the blood samples were 
collected in a 4ml K3EDTA vacutainer tube. The 4ml K3EDTA blood tubes were immediately 
placed into an airtight ice box and hirudin tubes were kept at room temperature in a well-
padded box to prevent agitation and minimise the activation of platelets during the 
transportation to the laboratory. 
2.2.2 Storage of blood samples 
In the laboratory, the 4ml K3EDTA blood tubes were centrifuged at 3000 g for 10 minutes at 
4oC. Plasma and cells are separated forming platelet poor plasma (PPP). The PPP samples 
were allocated into 500 µl aliquots and immediately snap frozen in liquid nitrogen. The frozen 
samples are stored at -800C and used for batch analysis of NO metabolite at a later date.  
Prof James’s Group at WHRI has previously shown that total plasma NO metabolites remain 
relatively stable after snap freezing (259) for 7-10 days. We were able to recruit 2-3 patients 
in one session, and it was not practically feasible to immediately analyse NO metabolites. The 
process of freezing and storage of the samples allowed us to analyse them at a later date. 
This was undertaken in batches of approximately 10-15 samples per day. 
 
2.3 Measurement of nitric oxide metabolites 
2.3.1 Ozone based chemiluminescence  
Numerous methods are described in the literature for measurement of NO metabolites in 
human biological fluids; colourimetry, spectrophotometry, fluorescence, chemiluminescence, 
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gas and liquid chromatography, electrophoresis and mass spectrometry are a few of the well 
described methods (260).  The colorimetric method using the Griess reagent is a well 
described and popular method. However, this has the limitation of not being sufficiently 
sensitive to measure physiological levels of nitrite (<1 µM) present in bodily fluids (261). The 
fluorescence assay based on Griess improves sensitivity significantly with detection of nitrate 
and upper levels of nitrite possible, but physiological levels of nitrite are hampered by 
background plasma fluorescence.  
The Ozone based chemiluminescence (OBC) method is a highly sensitive and most accurate 
technique for measuring NO metabolites at physiologically relevant concentrations 
(nanomolar – micromolar). This technique involves a chemical cleavage of the NO moiety from 
the NO metabolites to form free NO in a radical, gas form. The free NO gas is carried by 
oxygen free nitrogen gas (inert gas at a constant flow rate 100-150 cm3/min) into the Nitric 
oxide analyser (NOA) for NO measurement. 
NOA generates ozone (O3) from oxygen in its reaction cell where it reacts with the sample 
derived NO carried to an excited form of Nitrogen di-oxide (NO2*) and oxygen (O2). NO2* is an 
unstable state and it returns to its original state with release of its energy as a photon (Equation 
2.1). 
 
 
Equation 2.1: NO analyser reaction equation 
The released photon of energy is amplified into an electrical signal by the NOA photomultiplier 
tube (PMT) and it is recorded in millivolts (mV).  
The Sievers NOA 280i (GE Analytix, Durham, UK) is used in our laboratory. These are 
periodically tested and maintained by the certified GE technical team, ensuring a limitation in 
errors, variations and system failures. 
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Figure 2.3: Ozone based chemiluminescent technique of measurement of NO metabolites using NOA analyser. 
 
2.3.2 Chemical cleavage 
Chemical cleavage is an essential step in the measurement of NO and its metabolites from 
biological samples. In our laboratory we use (i) tri-iodide in glacial acetic acid, (ii) vanadium 
chloride in HCl, and (iii) cuprous chloride/cysteine (2c’s), as reagents for chemical cleavage 
of NO from nitrite, nitrate and RSNO, respectively (Figure 2.4). The systems are custom 
designed and have been validated in the James laboratory and are detailed in multiple 
manuscripts(133, 253, 262-264). The limitations are well understood, and we have established 
intra- and inter-assay coefficients of variation.  
A pre-specified volume (shown below) of reagent is placed in a glass purge chamber which 
has a side port covered with rubber septum for injection of samples. Typically, 200 µl of test 
sample are drawn into a glass Hamilton syringe (Fisher Scientific, UK) and injected into the 
purge chamber. The sample interacts with the cleavage reagent generating NO.  
The reaction chambers are connected to the NO analyzer via a NaOH (40ml) trap to filter 
impurities and contaminants. The NOA create a recordable millivolt signal and construct a 
trace on the computer. 
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Figure 2.4: Chemical cleavage reagents, Tri-iodide, vanadium chloride, and cuprous chloride/cysteine (2C’s) 
reagents are used to cleave NO molecule from nitrite, nitrate and nitrosothiols as above. The NO moiety is 
detected through OBC. 
2.3.3 Measurement of nitrate level 
Vanadium chloride (VCl3) reagent was prepared by adding 785 mg of vanadium chloride into 
a mixture of 20 ml of HPLC grade water with 80 ml of hydrochloric acid (HCL). The cloudy 
turquoise blue reagent formed was stirred for 10 minutes and then filtered through a millipore 
filter; giving a clear mixture. 
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Figure 2.5: Schematic diagram of setup of Nitrate measurement using Vanadium chloride reagent and OBC. The 
purge vessel contains 30 ml of vanadium chloride reagent kept at 85° C via a thermostatically controlled water 
bath. The test sample is injected into the purge cell through a rubber septum injection port.  The cleaved NO is 
carried by inert N2 gas into NO-Analyzer where reacts with ozone (O3) to form an electrical signal detected by the 
photomultiplier tube for the measurement of NO. 
 
 
Equation 2.2: Chemical reaction depicting the reduction of nitrate using Vanadium trichloride (VCL3) and 
Hydrochloric acid (HCL). The end products are Vanadium pentachloride (VCL5), water (H2O) and Nitric oxide (NO) 
Vanadium chloride is a strong reducing agent, it predominantly reduces nitrates, but has ability 
to reduce nitrite and some RSNO (Equation 2.2). Hence the amount measured by this method 
is a total of nitrate+nitrite+RSNO released form the sample.  
 Calibration of the NOA using sodium nitrate 
Sodium nitrate standards of 100.00, 50.00, 25.00, 12.50 and 6.25 μM concentrations are 
prepared and used for NOA calibration using vanadium chloride to cleave nitrate (Figure 2.6 
& Figure 2.7).  
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Figure 2.6: Computer recorded trace obtained from injection of serial dilutions of nitrate in HPCL graded water, 
the area under curve (AUC) is calculated. The AUC of water is subtracted from each of the serial nitrate 
measurements, thereby eliminating the water background signal. 
  
 
Figure 2.7: The corrected AUC values are plotted against the known concentration of nitrate and a straight-line 
correlation  is plotted. An R value of more than 0.95 is considered acceptable for the experiment. 
2.3.4 Measurement of plasma nitrite and nitrosothiols 
Tri-iodide (I3) reagent was prepared by mixing 1g of potassium iodide in 10 ml of HPLC grade 
water with 650mg of iodine in 70ml of glacial acetic acid. The prepared solution was kept at 
room temperature with constant stirring for 30 minutes (Figure 2.8) 
The acidic iodine solution readily cleaves both nitrite and nitrosothiols present in plasma.  
Nitrite was converted to nitrous acid and NO in the presence of excess acid (Equation 2.3). 
 
Equation 2.3: Chemical reaction of nitrite in triiodide solution 
The free iodine in the presence of potassium iodide reduces nitrosothiols to NO and water 
(Equation 2.4). This reaction gives a total of plasma nitrite and nitrosothiols. 
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Equation 2.4: Chemical reactions of free iodine and RSNO in the triiodide solution. 
 
 
Figure 2.8: Schematic diagram showing the practical setup for nitrite and nitrosothiol measurement using Tri-
iodide reagent and OBC. The purge vessel contains 5ml of reagent kept at 500 C in a thermostatically controlled 
water bath. The test sample is injected into the purge cell through a rubber septum injection port.  The cleaved 
NO is carried by inert N2 gas into NO-Analyzer where reacts with ozone (O3) to form an electrical signal detected 
by the photomultiplier tube for the measurement of NO. 
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2.3.4.1.1 Selective measurement of plasma nitrosothiols 
Acidified sulphanilamide pre-treatment of the sample renders the plasma nitrite undetectable 
by the above tri-iodide method. This technique would allow a selective measurement of the 
remaining nitrosothiol in the plasma. Acidified sulphailamide is prepared by dissolving 500mg 
of sulphanilamide in 10ml of 1M Hydrochloric acid. 
Typically, 540µl of plasma sample was mixed with 60µl of acidified sulphanilamide and the 
mixture kept in the dark for a period of 15 minutes to reduce all the nitrite. 400µl of this mixture 
was injected into the tri-iodide purge chamber and the cleaved NO detected via OBC, thereby 
quantifying the amount of nitrosothiol in the sample. The RSNO signals are ~40 times smaller 
compared with nitrite signals, hence double the volume injections are typically used to 
enhance the signal amplitude (typically 400 ul). The final results are divided by 2 to get a 
corrected value.  
 Calibration of the NOA using sodium nitrite 
Sodium nitrite standards of 1000.0, 500.0, 250.0, 125.0 and 62.5 nM concentrations are 
prepared and tested for NOA calibration using tri-iodide to cleave nitrite on each day of the 
experiment (Figure 2.9 & Figure 2.10).  
 
Figure 2.9: Computer recorded trace obtained from injection of serial dilutions of nitrite and HPCL graded water, 
the area under curve (AUC) is calculated. The AUC of water is subtracted from each of the serial nitrate 
measurement, thereby eliminating the water contaminants 
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Figure 2.10: The corrected AUC values are plotted against the known concentration of nitrite and a straight-line 
plotted. An R value of more than 0.95 is considered acceptable for the experiment.  
 
2.3.5 Measurement of laboratory synthesized R-nitrosothiols 
Cuprous (I) chloride/cysteine (CuCl/CSH) reagent (2C reagent) was prepared by adding 47.25 
mg of cysteine into 390 ml of HPLC grade water. 39.59 mg of cuprous chloride was then added 
into 10 ml of high-pressure liquid chromatographic (HPLC) grade water, which creates a 
solution of 40 mM concentration. This is then diluted further by 1/10 (4 mM concentration). 10 
ml of the latter solution was added to 390 ml solution containing cysteine 
The 2C reagent is highly sensitive and specific for RSNO detection. The selectivity is pH 
dependent; nitrates and nitrates are undetected at pH >6. Maintaining pH is crucial in this 
method. Cysteine can readily undergo auto-oxidation to cystine leaving the assay ineffective 
therefore care must be taken to ensure this chemical’s viability.(265, 266). The Cu+ ions 
selectively cleave the RS-NO bond and cysteine enhances the NO formation (259). 
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Figure 2.11: Diagram showing the set up for the measurement of nitrosothiols using OBC. The purge vessel 
contains 5 ml of 2C’s cleavage reagent kept at 500 C via thermostatically controlled water bath. The test sample 
is injected into the purge cell through a rubber septum injection port.  The cleaved NO is carried by inert N2 gas 
into NO-Analyzer where reacts with ozone (O3) to form an electrical signal detected by the photomultiplier tube.  
 
 Calibration of the NOA using acetyl-cysteine-SNO 
N-Acetyl-cysteine-SNO (NACSNO) was prepared by mixing 1.63 g of N-acetyl cysteine (1 M 
NAC) in 10 ml of hydrochloric acid (1 M). 759 mg of sodium nitrite (1.1 M) and was then mixed 
in 10 ml HPLC grade water. 500 μl of NAC was pipetted into a brown bottle with an injection 
port covered with a rubber septum top. 500 μl of sodium nitrite was then injected through the 
rubber septum. The mixture bubbles and turns red. NACSNO was subject to thermal and 
photochemical decomposition so is kept in the dark, on ice (267). 
NACSNO was calibrated by dilution (1/200) using HPLC grade water and analysed by light 
spectrophotometry using a single cell holder spectrophotometer (6705 UV/Vis. 
Spectrophotometer, Jenway, UK), using HPLC grade water as a blank.  
Maximal light absorbance was read at a 334 nm wavelength (expected result is ~1.5-2). The 
concentration of NACSNO (mM) was calculated using the equation [Light absorbance/ 
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Absorption coefficient (ε = 727)] x 200 (expected result is ~0.4-0.5 mM) (Figure 2.12). 
 
Figure 2.12: Representative spectrophotometric reading of NACSNO. The peak absorbance is read at 334nm (blue 
line) giving a value of 1.69 in this case.  
Acetyl-cysteine-SNO (NACSNO) standards of 4.3, 2.15, 1.07, 0.53, 0.26 μM and HPLC 
graded water are used for calibration using 2 C’s to cleave RSNO (Figure 2.13 and Figure 
2.14).        
 
Figure 2.13: Computer recorded trace obtained from injection of standards dose of NACSNO to generate a 
calibration curve with OBC, The area under the curve is calculated by the NOA analysis Liquid version 3.2.1 
software. 
 
0
10
20
30
40
50
60
70
80
90
100
NO
A 
sig
na
l (
m
V)
Time(seconds)
Standard Curve: 2 C's
4.3 2.15 1.07 0.53 0.26 Water
   
KV 
68 
 
 
Figure 2.14: The area under curve of the standards is plotted against the actual NACSNO concentrations. A 
Pearson correlation is calculated to ensure linear relationship. R value of > 0.95 is considered acceptable for 
experimental purposes.  
 
2.3.6 Standardisation of measurements 
All reagents are prepared fresh on the day of experiments. These were stored as per specified 
laboratory guidelines.  
Standard curve calibrations were performed prior to measurement of nitrate, nitrite and 
nitrosothiols on each day as described in the above sections. There is variation in the detection 
of NO by NOA on a daily basis that is well established. In our laboratory we have noticed a 
day to day variation in the area under curve of the standard curve and the actual NO metabolite 
strength.  The coefficient of variation of measuring the same NO metabolite in our lab from 
experience is in the order of 4% for nitrates, 7% for nitrites and 7% for nitrosothiols. These 
variations are due to changes in the cooling temperature of the photomultiplier tube, supply 
pressure of oxygen, and room temperature.   
Daily standard curve measurement is essential to limit these variations. The room temperature 
and the oxygen flow pressures are closely monitored through the day and stable laboratory 
conditions (air conditioning etc) are maintained.  
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Based on previous plasma analysis performed in the laboratory at our institution, typical nitrite, 
RSNO and nitrate levels measured by ozone based chemiluminescence (OBC) are 160 nM, 
25nM and 30 µM respectively. OBC has been shown to be highly sensitive for the 
determination of nanomolar quantities of NO and NO-related species in biological fluids. 
Nagababu measured fasting plasma nitrite levels in the range 56-210 nM (mean 110± 36 nM) 
with high sensitivity and an accuracy of 97%(261).  Marley et al measured, the mean 
concentration of plasma nitrosothiol levels  in venous sample of healthy humans was 21-35nM 
with high sensitivity, an ability to detect levels down to 5nM using the above method(268). 
 
2.4 Measurement of platelet aggregation  
A variety of platelet function tests are available to detect platelet dysfunction and monitoring 
of antiplatelet therapy. Platelets are influenced by several agonists which act on various 
receptors present on the platelet surface making it practically difficult to develop one test which 
measures all platelet functions.  Evaluating platelet function has a clinical relevance in patients 
who are taking anti platelet drugs because there is considerable variation in the extent of 
response to antiplatelet therapy in patients. Impaired response or resistance to antiplatelet 
therapy is known to be associated with further adverse cardiovascular events (269). In the last 
decade, there is an increase in number of coronary interventions worldwide, in UK has risen 
from 800 per million population in 2002 to 1488 per million in 2014(270). Most of these patients 
received drug eluting stents (DES) which require long term dual antiplatelet therapy. 
Decreased platelet inhibition or resistance has shown to be associated with increased risk of 
stent thrombosis and high mortality (271-273). Approximately 10% of cardiovascular deaths 
after stent implantation are attributed to stent thrombosis (ST) (274). Newer antiplatelet drugs 
such as prasugrel (135) and Ticagrelor (148) have a lower incidence of ST compared to 
clopidogrel.  Thus, it is imperative that a method be developed for routine analysis of platelet 
activity. Platelet aggregation tests have been established to test the ability of platelets to 
aggregate in response to an external agonists such as arachidonic acid (AA), collagen, 
epinephrine (EPI) adenosine diphosphate (ADP) and Thrombin activating protein 
(TRAP)(275).  
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2.4.1 Classical aggregometry 
Light transmission aggregometry (LTA) of platelet rich plasma was first described by Born in 
the year 1960(276). It is the most widely used and has been a gold standard method for the 
assessment of platelet aggregation.  Platelet rich plasma is an optically dense solution. 
Addition of an agonist to PRP triggers platelets aggregation and results in a less turbid 
solution. The LTA technique measures the rate and maximum percentage of increase in light 
transmission through the PRP sample upon addition of an agonist (increase in light 
transmission=decrease in turbidity). The signals are converted automatically into a graph and 
are readily quantified. Different platelet activation pathways could be tested with this method 
using various agonists. This method has been used in clinical trials in monitoring antiplatelet 
therapy and prediction of major adverse cardiovascular events in patients at high risk of 
thrombotic events (277, 278). This technique has its own challenges and limitations. It is highly 
dependent on pre-procedural and procedural factors like platelet counts, plasma lipids, 
anticoagulants used, preparation techniques of PRP. It also does require a high degree of skill 
and expertise among staff performing and applying this test. Its major drawback is that it 
cannot be applied to whole blood samples. 
2.4.2 Impedance aggregometry 
Impedance aggregometry is a whole blood aggregometry technique assessing platelet 
function in an anticoagulated whole blood sample. This is based on the principle that activated 
platelets adhere to the surface of two electrodes immersed in the whole blood. The platelet 
adherence onto the electrodes changes their impedance with time (279). Platelet aggregation 
is measured by detecting the increase in the impedance and recorded in Ohms (280, 281).  
This a well-established method for diagnosis of platelet dysfunction and monitoring of 
antiplatelet therapy. A specific agonist is added to stimulate the platelets and assess 
respective platelet receptor function. Arachidonic acid (AA) and Adenine di-phosphate (ADP) 
agonist are typically used for testing efficacy of aspirin and clopidogrel respectively. 
The whole blood aggregometry technique does not require pre-preparation of samples limiting 
artificial platelet activation. The platelet function is assessed under more physiological 
conditions allowing the contribution of other blood substances such as ADP derived from 
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RBC’s which may affect platelet aggregation. This is a rapid and simple method of analysis of 
platelet function (282). 
Single electrode aggregometry consisting a pair of reusable electrodes was first invented by 
Cardinal and Flower in the 1980s. Multiple electrode impedance aggregometry with two pairs 
of disposable electrodes was developed in 2006(283).  
 Multiple electrode aggregometry (MEA) 
Multiple electrode aggregometry (multiplate platelet function analyser-Dynabyte-Roche 
Diagnostic, Mannheim Germany) (Figure 2.15) is the latest device for whole blood impedance 
aggregometry available across the world. This device is used as a point of care device for 
evaluation of platelet function and monitoring of antiplatelet drug therapy. It is a five-channel 
computerised device with an automated pipetting unit and disposable cuvettes each with two 
independent sensor units and magnetic stirrer. Platelet aggregation is measured 
simultaneously by each of the units independently and calculated as area under curve (AUC).  
This device could test different agonists induced platelet response, similar to LTA. 
Comparative studies of MEA with classical aggregometry (LTA) showed similar results in 
evaluating platelet dysfunction and outperformed when monitoring anti-platelet therapy (284-
286).  Impedance whole blood aggregation is more sensitive in detecting the effect of 
clopidogrel on platelet inhibition when compared to LTA (287).  MEA testing has been used to 
identify patients who are not responding or hyper-responsive to antiplatelet drugs, thereby 
identifying those patients who are at risk of thrombotic events or bleeding (288, 289).  This 
Multiplate analyser device allows rapid, reliable assessment of platelet function at the point of 
care. The machine features an automated work pattern and step by step method with clear 
instruction needing minimum technical knowledge and training. It does not require a 
specialised laboratory setup and can be easily used in a general laboratory or in clinical areas 
(282, 290). 
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Figure 2.15: Multiplate® analyser from Roche, Germany. It has 5 channels for simultaneous measurement of 
different sample/agonist with an electronic pipette with predefined pipette programs for tests. 
 
 
Figure 2.16: Disposable cuvettate with two pairs of electrodes and a magnetic stirrer (A). The principle of platelet 
aggregation relies upon activation with an agonist and increase in impedance detected over time. 
(B) 
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Figure 2.17: Screenshot image of the computer-generated data sheet showing typical platelet aggregation in 
response to ADP and TRAP, the value is expressed as area under curve.  
The Multiplate analyser is auto calibrated every day prior to blood sample analysis. Disposable 
cuvettes are inserted into the wells and connected to the respective channels. Sample ID and 
the agonist are entered into specified fields on the data sheet for each channel. An auto 
pipetting program is activated and provides on screen step wise prompts. 
300µl of normal saline is added into each test cuvette and, left to incubate for 2 minutes. Then 
300µl of whole blood sample is pipetted into the test cuvette and incubated for a further 2 
minutes, 20 µl of ADP or TRAP reagent is then added to the above mixture and left for 6 
minutes. The increase in the impedance of electrodes due to platelet adhesion and 
aggregation (Figure 2.16) is recorded in real time by the computer software. At the end of 6 
minutes an automatic calculation of the area under curve is done and the value is displayed 
as platelet reactive units (PRUs) (Figure 2.17). The impedance of each pair of electrodes are 
measured and displayed separately as blue and red curves. A variation of <25% between two 
pairs of electrodes is acceptable.   
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2.5 In vitro dietary nitrate and clopidogrel study:  materials and methods 
2.5.1 Materials  
 
Material Source Concentration 
NADPH Beta-Nicotinamide adenine dinucleotide2’-phosphate reduced 
tetrasodium salt hydrate 
Sigma-Aldrich, UK 25 mg 
G6PD Glucose-6-phosphate Dehydrogenase from baker’s yeast (S.cervisiae) Sigma-Aldrich, UK 250 units 
G6P D-Glucose 6-phosphate sodium salt Sigma-Aldrich, UK 500 mg 
Iodine Iodine, 99.8%, A.C.S. reagent Sigma-Aldrich, UK 500 g 
Vanadium Chloride Vanadium (III) Chloride 97% Sigma-Aldrich, UK 100 g 
Potassium Iodide Potassium Iodide, 99.8% 
A.C.S. reagent 
Sigma-Aldrich, UK 100 g 
Acetic Acid glacial Acetic Acid glacial 
Analytic reagent grade 
Fisher Scientific, UK 2.5 L 
Hydrochloric Acid Hydrochloric acid 1M, Stabilised Fisher Scientific, UK 2.5 L 
Nitrate Reductase Nitrate Reductase (NAD[P]H) from Aspergillus Niger Sigma-Aldrich, UK 10 units 
Sodium Nitrate (NaNO3) Sodium nitrate 99.99+% metals basis Sigma-Aldrich, UK 10 g 
Sodium Hydroxide (NaOH) Sodium Hydroxide Trap, Volumetric solution Fisher Scientific, UK 1 M 
Peptone Casein, from bovine milk Sigma-Aldrich, UK 500 g 
D-Glucose D-Glucose anhydrous Analytic reagent grade Fisher Scientific, UK 2 kg 
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Sodium Chloride (NaCl) Sodium chloride (Laboratory reagent grade) Fisher Scientific, UK 3 kg 
Potassium dihydrogen 
orthophosphate (KH2PO4) 
Potassium dihydrogen orthophosphate (Analytic reagent grade) 
 
Fisher Scientific, UK 500 g 
Calcium Chloride (CaCl2) Calcium chloride dihydrate (Analytic reagent grade) Fisher Scientific, UK 500 g 
Potassium Chloride (KCl) Potassium chloride Laboratory reagent grade Fisher Scientific, UK 500 g 
Porcine Bile Bile extract, porcine Sigma-Aldrich, UK 100 g 
Lysozyme Lysozyme from chicken egg white Sigma-Aldrich, UK 5 g 
Pepsin Pepsin from porcine gastric mucosa powder, > or = 250g units/mg solid Sigma-Aldrich, UK 25 g 
Resazurin Resazurin sodium salt Sigma-Aldrich, UK 1 g 
N-Acetyl-L-cysetine N-Acetyl-L-cysetine Sigma-Aldrich, UK 50 g 
Copper Chloride Copper(I) chloride Sigma-Aldrich, UK 10 g 
L-Cysteine Hydrochloride L-Cysteine hydrochloride anhydrous, minimum 98% TLC Sigma-Aldrich, UK 10 g 
High-performance liquid 
chromatography (HPLC) grade water 
ELGA Lab-Water Elga-veolia. UK Reservoir 25 L 
Clopidogrel (ActavisTM)  28 tablets Clopidogrel hydrogen sulphate Bristol-Myers Squibb, UK 75 mg per tablet 
Beet It® BEET IT® James White Farm, UK 100 mg/100 ml 
SIS® Go+ nitrate gel Science-in-Sport® GO Plus Nitrate Gel Science-in-Sport (SIS®) 
Limited, UK 
250 mg/60 ml 
 
Table 2.1 : Materials are reagent-grade quality and used without further purification. 
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2.5.2 Methods 
 Enzymatic conversion of nitrate to nitrite 
A technique described and applied in a PhD project by Alexandra B Milsom in Prof James’s 
laboratory at the Wales Heart Research Institute was used as a starting point (291). A well-
known assay for the measurement of nitrate and nitrite in solution involves the initial reduction 
of all nitrate to nitrite prior to measurement. This procedure (using a bacterial nitrate reductase 
source) was adapted enabling in-vitro conversion of nitrate to nitrite.  Laboratory grade sodium 
nitrate, Beet it and SIS® Go+ nitrate gel was used as the nitrate substrates for catalytic 
conversion of nitrate to nitrite by bacterial nitrate reductase. Nitrate reductase was derived 
from Aspergillus niger (A. Niger) 
 
Figure 2.18 : Enzymatic conversion of nitrate to nitrite in the presence of co-factors 
 Nitrate reductase (NR) 
Nitrate reductases (NRs) are molybdenum dependent ubiquitous enzymes. Anaerobic 
denitrifying microflora from the posterior aspect of the tongue and gut are the principle source 
of nitrate reductase in humans. A. niger is a fungus that produces NR that catalyzes the 
reduction of nitrate in vitro and is available in commercial form.  
 Stock preparations 
All working solutions were prepared fresh on the day of the experiment. Dilutions are made 
using HPLC grade water. 
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Table 2.2: Source of nitrate used in the experiments with their concentration and stability features 
 
Table 2.3: Nitrate reductase and cofactor stock preparations 
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Table 2.4 : Contents of enzyme mixture for working solution 
 
Table 2.5:  Composition of enzyme mixture 
200 µl of known concentration of nitrate solution is mixed with 40µl of 10 µM NADPH. Equal 
quantities of G6PD (1.6 U/ml), G6P (5 mM) and NR (6 U/ml) were mixed and made up to 160 
µl. The above two mixtures were mixed together to create a total sample volume of 400 µl in 
a 1.5 ml Eppendorf.  
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 Artificial stomach media 
In order to replicate physiological conditions as closely as possible, simulated human gastric 
fluid (SGF) was prepared according to a formula reported by Beumer et al(292) . 
 
  
Table 2.6: Constituents of artificial gastric juice 
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Gastric juice is prepared fresh on the day of experiment. All materials are weighed using 
Mettler Toledo AE 50 Analytical Balance, UK. It is kept at 37±1℃ using a thermostatically 
controlled hotplate (Stuart® US152, UK). The final mixture is acidified to pH≤2 using 
hydrochloric acid; a colour change from purple to pink is noted with change in pH.  
 Clopidogrel dissolved in gastric medium 
One 75 mg tablet is dissolved in 25 ml of gastric juice (8.75mM of clopidogrel) and eight 75 
mg tablets in a separate 25 ml of gastric juice (70mM of clopidogrel). Both mixtures are 
prepared fresh and continuously mixed on the day of experiment. They are maintained at 
37±1℃ using a thermostatically controlled hotplate (Stuart® US152, UK). This model is 
adopted to mimic the patient status where 75mg of clopidogrel (typical maintenance dose) or 
600mg of clopidogrel (a typical loading dose) is ingested into a fasting stomach (25-30mL).   
The average volume of gastric volume is estimated about 25-30 ml and the typical pH of gastric 
fluid is ≤ 2 in healthy, pre-operative and fasting patients (293). A pH ≤2 is optimal for 
clopidogrel-SNO generation; pH of each mixture was checked prior to use (133). 
200 µl of this “reduced nitrite” (from SIS® Go+ nitrate gel or beet it) was added to 200 µl of 
the gastric medium, and another 200 µl of reduced nitrite stock added to 200µl of gastric 
medium and clopidogrel mixture, separately.  
200 µl samples of the above mixtures were drawn into a glass Hamilton syringe and injected 
into the purge vessel containing the 2C’s reagent to measure RSNO generation. Samples 
were test immediately and following an incubation period of 20 minutes at 37 ± 1 ℃. This time 
point was previously established as optimum for RSNO production from nitrite in aqueous 
solutions (133, 253). 
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2.6 In vitro experiments with ticagrelor  
2.6.1 Materials and methods 
 Preparation of ticagrelor solutions 
Ticagrelor (BriliqueTM, Astra-Zeneca, London, UK) film-coated tablets containing 90mg 
ticagrelor were crushed individually and mixed with 30 ml HPLC/double distilled water to 
create a stock 5.74 mM/L milky solution. Pure ticagrelor was unavailable hence crushed 
BriliqueTM tablets were used.   
 
Table 2.7: Ingredients of commercially available ticagrelor tablet (Developed and marketed by Astra-Zeneca, 
London, UK). 
Whilst the effects of BriligueTM excipients (Table 2.7) on platelet function were not specifically 
assessed, the whole tablet was used for the purposes of this study in an attempt to more 
closely replicate in vivo use.  Dr Thornhill and Prof James tested the purified Ticagrelor (made 
available via Multiplate supplier) in their experiments that confirmed the effect of pH and 
potential to form RSNO in the presence of nitrite (137).  
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 Simulated gastric fluid with ticagrelor mixture. 
SGF was freshly prepared on each day of experimentation, and two beakers were filled with 
30ml of SGF and labelled as solution G and solution TG. Whole tablets (90mg) of ticagrelor 
were mixed in 30ml of simulated gastric fluid with adjusted pH of 2, mimicking the physiological 
state of a patients who is fasted overnight, prior to a coronary angiography procedure.  The 
solution was kept at 37ºC (± 1ºC) on a thermostatically controlled hotplate with constant 
stirring. 
Varying concentrations of nitrite were mixed with the above solutions and incubated for 10 
minutes at 37ºC in a hot water bath. Samples were withdrawn and neutralised with 1 M NaOH. 
The neutralised sample was immediately injected into the purge vessel containing 2Cs reagent 
and the baseline RSNO level was measured using OBC techniques. 
It is well established that proteins containing free thiol groups readily form RSNO with nitrite. 
Casein, pepsin and lysozymes are main protein components of the SGF.   
To test the contribution of individual SGF components in the formation of RSNO, a baseline 
solution with all ingredients except resorium, lysozyme, pepsin and casein was prepared.  To 
this mixture resorium, lysozyme, pepsin and casein were added in a step wise fashion. Each 
sample was mixed with 500µmol/L of nitrite and incubated as in previous experiments.  
2.7 Data collection and integration 
The NOA signals are recorded digitally by the Liquid software on a computer and the area 
under the curve (AUC) was measured. This value was divided by the gradient of the line of 
transection from the standard curve performed on the day of the experiment.  Nitrate, nitrite 
and RSNO were measured in Molar concentration and percentage of conversion was 
determined by comparing to the original known concentration. 
The RSNO trace typically displayed a prolonged tail, often did not return completely to baseline 
(compared with nitrate and nitrite traces), which impairs accurate measurement of results. 
Hence the signal recording was stopped after 20 minutes for each sample analysed to 
maintain signal time-point comparison of the AUC. Mean values were used to minimise bias. 
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2.8 Data analysis and statistics 
2.8.1 Power calculation: 
The change in the RSNO levels with antiplatelet therapy and dietary nitrate has been used as 
primary outcome measure.  
A power calculation based on prior results from CAD patients from our laboratory showed that 
for studies of dietary nitrate supplement in CAD, 13 subjects would provide 80% power for 
detecting a 50% difference in RSNO between placebo and NO3- supplementation, assuming 
10% variation, with α=0.05.  A lower number were needed in this group as the patient were 
their own controls as it is a paired study. 
For studies of dietary nitrate supplementation and clopidogrel therapy in CAD, 25 subjects in 
each placebo and active arm would provide 80% power for detecting a 50% difference in 
RSNO between placebo and NO3- supplementation, assuming 10% variation, with α=0.05. 
The ticagrelor study would require recruiting 25 subjects that would provide 80% power for 
detecting a 50% difference in RSNO between pre and post ticagrelor therapy, assuming 10% 
variation, with α=0.05.   
GraphPad Prism Version 6.0 software was utilized for statistical analyses. Data are expressed 
as mean ± standard error of mean; error bars represent the standard error of the mean and 
n= x represents the number of repeated experiments. Two tailed student’s T test or analysis 
of variance (ANOVA) test was used to analyze the differences between means of experimental 
groups. A one-way or two-way ANOVA as appropriate was applied for comparison of three or 
more groups. Differences were considered statistically significant where P ≤ 0.05. 
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3 Results 
3.1 Results 1: In vitro model of conversion of physiological in-
organic nitrate from dietary source to nitrite and nitrosothiols. 
3.1.1 Background and relevance 
The role of the nitrate-nitrite- NO cycle upon ingestion of commercially available dietary nitrate 
supplements is not fully understood in humans. There is a need and relevance for 
understanding the processes involved in enzymatic conversion of the dietary supplements 
upon ingestion and its potential conversion to NO and RSNO.  An in-vitro model would be 
ideal for studying the kinetics and factors that may affect the production of NO and other 
metabolites with these supplements in vivo. 
A double blinded randomised placebo-controlled study was designed (which is a part of this 
current thesis (Chapter 4 to 5)), to study the effect of dietary nitrate on NO metabolites and 
platelet aggregation in patients with CAD. SIS® Go+ nitrate gel was used as the dietary nitrate 
supplement to enhance plasma levels of nitrate in patients with CAD who were on or would 
receive clopidogrel therapy. 
This sub-project was designed to establish an in vitro model under physiological conditions to 
investigate the conditions affecting nitrate-nitrite-NO (RSNO) formation. This model would 
allow us to study possible RSNO formation under in vivo conditions, and the potential influence 
of introducing clopidogrel under controlled conditions. This was aimed at mimicking the 
supplementation of dietary nitrate to CAD patients. 
Elements of this study were undertaken with the assistance of Dr Genna Logue (5th year 
medical study, joined our group for her intercalated BSc project) 
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3.1.2 Aims and hypothesis 
 Hypothesis 
An in-vitro model which facilitates the enzymatic reduction of nitrate to nitrite (hence RSNO 
and NO) from a dietary source will be successfully established and it would be in line with the 
in vivo process of Nitrate-Nitrite-NO (RSNO) cycle. 
 Aims 
a) Develop an in vitro model for enzymatic reduction of nitrate (salt) to nitrite. 
Test and optimise the reaction catalyzed by nitrate reductase from Aspergillus 
niger (Sigma Aldrich, UK) 
b) Convert nitrate present in SIS® Go+ nitrate gel and Beet It® to nitrite, using the above 
model. 
c) Test the ability of nitrite formed from the SIS® Go+ nitrate gel to form RSNO with 
gastric proteins. 
d)  Test the ability of nitrite formed from the SIS® Go+ nitrate gel to form RSNO with anti-
platelet (clopidogrel) treatment when added in gastric stomach medium.
3.1.3 Results 
 Conversion of sodium nitrate salt to nitrite  
3.1.3.1.1 Nitrate to nitrite conversion using E coli Nitrate reductase 
Initial experiments were conducted with nitrate reductase from E.Coli (Sigma Aldrich, UK), An 
enzyme mix of 0.6 U/ml of NR, 5 mM of G6P, 16 µM of G6PD and 100 µM of NADPH was 
used as described in Alexandra B Milsom’s technique (294), results are shown in Figure 3.1 
and Figure 3.2. 
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Figure 3.1: Graphical demonstration of the amount of nitrate salt reduced to nitrite with NR derived from E Coli, 
x axis represent the amount of nitrate salt added to the mixture, Y axis represent the amount of nitrite reduced. 
An ANOVA test showed a significant concentration dependent increase in nitrite formed from nitrate salt (*** 
represents p<0.0001).   
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Figure 3.2: Graphical demonstration of the percentage of nitrate salt reduced to nitrate with NR derived from E 
Coli, x axis represent the amount of nitrate salt added to the mixture, Y axis represent the percentage of nitrite 
reduced. An ANOVA test showed no significant change in extent of conversion  
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The conversion of nitrate to nitrite was consistent, the conversion rate was above 80% and 
increased to >90 % at lower starting nitrate concentrations. We were satisfied with the model 
of nitrate reductase mediated conversion of nitrate to nitrite. 
However, NR from E. Coli (Sigma Aldrich, UK), was commercially discontinued and was no 
longer available for further experiments. Nitrate reductase from other sources were explored 
and NR from Aspergillus Niger (Sigma Aldrich, UK) was tested. 
3.1.3.1.2 Nitrate to nitrite conversion using NR from Aspergillus niger 
An enzyme mix (0.6 U/ml of NR, 5 mM of G6P, 16 µM of G6PD and 100 µM of NADPH) that 
was used in initial experiment was tested with NR from Aspergillus niger.  25 µM of sodium 
nitrate was added to the enzyme mix. Samples were left at +17 ± 1 °C for 45 minutes. Results 
are shown in Figure 3.3 and Table 3.1  
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Figure 3.3 : Reduction efficacy of NR from E Coli and A Niger on nitrite production, an Unpaired t test performed 
showed a P value of < 0.0001(****). 
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Table 3.1: Data presented as mean and standard error of mean 
A total of 6 experiments (n=6) were performed on separate days. Nitrite production was tested 
with NR derived from E-Coli and A Niger.  
Nitrite production was significantly reduced using NR from A. niger (10.33%) compared to 
nitrite produced from preliminary work on E. Coli (86.83%) in the presence of similar enzyme 
mixes containing 0.6 U/ml of NR, 5 mM of G6P, 16 µM of G6PD and 100 µM of NADPH. 
3.1.3.1.3 Optimisation of enzymatic cofactors 
Experiments on reduction efficacy of NR from A. niger were then undertaken with modification 
to co-factors in the enzyme mix. Varied concentrations of G6PD and NADPH were evaluated 
in a new enzyme mix and added to 25 µM of sodium nitrate. A maximum yield of 75.11 ± 
4.34% achieved with a combination of 1000 µM of NADPH and 160 µM of G6PD and was 
therefore used in future experiments. Results are shown in Figure 3.4. 
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Figure 3.4: Optimal Enzymatic Cofactor Concentrations for Nitrate Reductase activity. 
Each group represents 3 experiments performed on separate days (n=3). Two-way ANOVA 
with Tukey’s multiple comparisons test was used, *P<0.05. (100:16 μM vs. 100:160 μM of 
NADPH: G6PD) (Table 3.2). There was no significant difference in nitrite production between 
16 and 160 μM of G6PD in the presence of 100 μM of NADPH (P=0.7824) (100:16 μM vs. 
   
KV 
89 
 
1000:160 μM of NADPH: G6PD). A significant increase in nitrite production was observed 
between 100 and 1000 μM of NADPH in the presence of 160 μM of G6PD, **** (P<0.0001).  
3.1.3.1.4 Conversion of sodium nitrate to nitrite in molar concentrations 
A total of 3 experiments were performed on separate days (n=3).  The concentration of starting 
nitrate was now increased. A control of 100 µM of sodium nitrate in water without NR in the 
enzyme mix and a second control of enzyme mix in HPLC-grade water without nitrate was 
tested, these produced negligible nitrite.  
Test samples contained sodium nitrate concentrations of 10, 25, 50, 100 and 1000 µM. there 
was linear positive correlation between the Molar concentrations of nitrite produced and molar 
concentrations of sodium nitrate in the test sample when NR was added. Results are shown 
in Figure 3.5  and Table 3.2.. 
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Figure 3.5: Graph depicting the Influence of increasing the molar concentration of sodium nitrate (µM) against 
the molar concentration of nitrite (µM) produced. 
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Sodium Nitrate (NaNO3) Tested Converted NO2 (µM) 
10 8.17±1.61 
25 16.14±1.14 
50 25.44±2.05 
100 41.16±1.89 
1000 170.61±2.33 
Table 3.2: Nitrate conversion data presented as mean ± SEM, ↑↓ represents the direction of change 
 
3.1.3.1.5 Effect of increasing concentration of nitrate on reduction efficacy of nitrate 
reductase 
To test the reduction efficacy of NR with increasing concentration of initial nitrate, the same 
test samples of sodium nitrate concentration were utilised and the percentage yield of nitrite 
produced calculated.  The results are shown Figure 3.6 and Table 2.3 
There is a linear relationship between 10 µM and 1000 µM of sodium nitrate creating a 
negative correlation against efficiency of nitrite produced. 
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Figure 3.6: Effect of increasing the molar concentration of sodium nitrate (µM) against nitrite produced (%). 
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Sodium Nitrate (NaNO3) Tested Converted NO2 (%) 
10 81.70% 
25 64.56% 
50 50.88% 
100 41.16% 
1000 17.06% 
Table 3.3: Nitrate conversion data presented as mean ± SEM, ↑↓ represents the direction of change 
 
3.1.3.1.6 Time course of sodium nitrate conversion to nitrite by nitrate reductase 
A fixed concentration of nitrate was mixed with the enzyme mix and kept at room temperature; 
the sample mix was injected at regular intervals of 15 minutes for a total investigation period 
of 1 hour 45 minutes. Mean values of sodium nitrate conversion to nitrite at each time point 
were recorded. Minimal and maximal nitrite production occurred at 0 and 45 minutes ± 30 
seconds, respectively. Results are shown in  Figure 3.7 and Table 3.4. 
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Figure 3.7: Percentage of nitrite converted from fixed amount of nitrate with time 
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Table 3.4: Nitrate conversion efficiency rate with change in time 
A total of 3 experiments performed on separate days (n=3). There was a significant increase 
in nitrite production between 0 and 15 minutes (*P<0.05) and between 0 and 45 minutes, ** 
(P=0.0050). There was no further significant increase in nitrite production after 45 minutes 
(P=0.9952). 
The above experiments successfully established an in-vitro model of enzymatic conversion of 
laboratory grade sodium nitrate to nitrite (>95%) at 17± 1 0C to serve as a standard method 
for future experiments with dietary nitrate supplements. 
Samples were left at 17± 1 0C for 45 minutes thereafter before testing (unless time was the 
dependent variable under investigation).  
Additionally, nitrate salt conversion to nitrite was measured on each day of future 
experimentation to ensure the enzyme model was functioning efficiently prior to testing the 
commercial products. This served as a control and standardized the experiments. 
3.1.3.1.7 Pilot study to convert nitrate within SIS® Go+ nitrate gel and Beet It® using 
the above model 
The typical NOA signal from 25 µM sodium nitrate following reduction to nitrite showed a peak 
of ~840 mV and the AUC representing the quantity of nitrite generated as shown in Figure 3.8. 
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Figure 3.8: Nitrite production from sodium nitrate (25 µM) in relation to time 
The experiment was then conducted to reduce nitrate contained within SIS® Go+ nitrate gel 
sachets in its commercially available original form using the successful model developed. A 
typical trace from reduction of the gel (containing 4.8M of starting nitrate) showed a peak of  
~50 mV and the AUC represented the quantity of nitrite present and or generated (Figure 3.9). 
 
Figure 3.9: NOA signal from SIS® Go+ nitrate gel and beet it, following incubation with the nitrate reductase 
enzyme mixture for 45 minutes 
Similar experiments reducing nitrate contained within ‘Beet it’ were also undertaken using the 
successful model developed for sodium nitrate. The typical NOA trace showed a peak of 120 
mV and the area under the curve is measured to quantify the nitrite generated (Figure 3.9) 
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Table 3.5; Data presented in mean and percentage of the nitrite converted from the test sample of nitrate. The 
nitrate concentrations of commercial products are specified at the manufacturer’s labeled value (4.8 mM for SIS® 
Go+ and 6.5mM for Beet it).    
There is minimal nitrite generated from the nitrate present in the commercial products, in their 
commercially available original form, in contrast with nitrate salt when using the model of 
nitrate reduction (Table 3.4) 
 Optimisation of conversion of nitrate in commercial products 
3.1.3.2.1 Conversion of nitrate in diluted SIS® Go+ nitrate gel to nitrite  
The SIS® Go+ nitrate gel was a thick concentrate. It was diluted by factors of x4, x8, x40, x80, 
x400 and x800, and applied to the successful NR enzyme model. The resulting amount of 
nitrite generated was measured. Results are displayed in tabular form (Table 3.6) and graph 
(Figure 3.10)  
A total of 7 experiments were performed on separate days.  There was no significant difference 
in nitrite produced between 1/4 and 1/40 dilution, (P>0.9999). There was a significant increase 
in nitrite produced between 1/40 and 1/80 dilutions of the gel, *(P=0.0168).  A prominent 
increase occurs between 1/80 and 1/400 dilutions and a further marked increase between 
1/400 and 1/800 dilutions, **** (P<0.0001) (Table 3.6). 
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Figure 3.10: Nitrite production from diluted concentrations of SIS® Go+ nitrate gel. A one-way ANOVA and Tukey’s 
multiple comparison test was employed. * denotes p ≤ 0.05, *** denotes p < 0.0001. 
 
 
Table 3.6: Statistical comparison of data presented as mean ± SEM, ↑↓ represents the direction of change 
 
3.1.3.2.2 Conversion of nitrate in diluted Beet It® to nitrite  
Beet it is supplied as a semi-concentrated juice. The juice was diluted by factors x2, x10, x20, 
x100, and x200 and the nitrite formed was measured. Results are presented in and Table 3.7. 
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Figure 3.11: Effect of dilution of Beet it on nitrite production catalysed by NR. One-way ANOVA test with tukey 
post test showed (1 vs. 1/200) ** denotes P<0.05. **** denotes P<0.0001.   
 
Table 3.7; Data presented as mean ± SEM, ↑↓ represents the direction of change 
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Table 3.8: Statistical comparison of data presented as mean ± SEM, ↑↓ represents the direction of change 
 
3.1.3.2.3 Measurements of nitrate and converted nitrite  
A total measure of nitrate, nitrite and RSNO in a SIS® Go+ nitrate gel and Beet it samples 
were measured using the VCl3 assay. The sample was then added to an enzyme mix and 
incubated for 45 minutes at 170 C. Total nitrites produced was measured using the l3 assay. 
Nitrite recovered from the nitrate sample was then calculated. Results are shown in Table 3.2.  
 
Table 3.9: SIS® Go+ nitrate gel and Beet it samples Nitrate and nitrite levels 
 
3.1.3.2.4 A Time course of SIS® Go+ nitrate gel conversion to nitrite  
A fixed concentration of 200 µl of the sample containing SIS® Go+ nitrate gel (1/800 dilution) 
and Beet it (1/100 dilution) was mixed with the enzyme mix as separate experiments and kept 
at room temperature, the sample mix was injected at regular intervals of 15 minutes for a total 
investigation period of  1 hour 45 minutes (Figure 3.12).  
A total of 4 experiments were performed on separate days.  There was a significant increase 
in nitrite production between 0 and 15 minutes (P=0.0003) and between 0 and 45 minutes 
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(P<0.0001)). There was a non-significant increase in nitrite production after 45 minutes 
(P=0.2727). 
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Figure 3.12: Time effect on nitrite produced from of SIS® Go+ nitrate gel and Beet it. One-way ANOVA and Tukey’s 
multiple comparison test was used. *** denotes p<0.001, ****denotes P<0.0001. 
 
 Effect of ingredients in the gel on nitrate conversion to nitrite  
The SIS® Go+ placebo gel contains identical ingredients to SIS® Go+ nitrate gel, except a 
negligible nitrate content. To test the influence of ingredients in the gel on nitrate to nitrite 
conversion with the NR model developed, varied dilutions of the placebo gel were also 
prepared similar to SIS® Go+ nitrate dilutions). Sodium nitrate salt was introduced into 1/4, 
1/40 and 1/400 dilutions of placebo gel, so as to achieve final concentrations of 500, 50 and 5 
µM. 200 µl of an enzyme mix was added to 200 µl of placebo gel and sodium nitrate mixtures. 
The standard procedure developed was followed and nitrite production was measured. 
Conversion of sodium nitrate mixed within placebo gel to nitrite 
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Figure 3.13: Effect on nitrite production from known concentrations of sodium nitrate (5, 50, 500 µM) contained 
in diluted concentrations of placebo gel. Two-way ANOVA and Tukey’s multiple comparison test was applied, 
*P<0.05. (1/4 vs. 1/40 and 1/400 placebo). * denotes P<0.05. 
A total of 3 experiments were performed on separate days. There was a significant difference 
in nitrite production between 1/4 vs. 1/40 and 1/400 dilutions of the placebo gel mixed with 500 
μM of sodium nitrate, ****(P<0.0001). There was no significant difference in nitrite production 
between 1/40 and 1/400 dilutions of the placebo gel mixed with 500 μM of sodium nitrate, 
(P=0.6210). There was no significant difference in nitrite production between 1/40, 1/40 and 
1/400 dilutions of the placebo gel mixed with 5 or 50 μM of sodium nitrate. Control experiments 
using each dilution of the placebo gel and NR show negligible nitrite production. HPLC-grade 
water and NR also show negligible nitrite production. 
In summary, 1/4 dilution of the gel has an inhibitory effect on sodium nitrate reduction and 
consequently minimal nitrite yield. With increasing dilution there was an increase in 
percentage of nitrite produced. Results are shown in Figure 3.13. 
50 µM of sodium nitrate was tested against placebo gel. Nitrite yield was 91.28 ± 6.44% in the 
absence of placebo gel. In the presence of 1/40 and 1/400 dilutions of the placebo gel nitrite 
production significantly decreased, as shown in Table 3.10. 
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Table 3.10: Percentage of nitrite conversion with diluted placebo and 50μM nitrate mix 
 
 RSNO generation from Nitrite in gastric medium 
 Conversion of nitrite formed from sodium nitrate reduction to RSNO 
Using the model described above, the formation of RSNO in simulated gastric fluid from nitrite 
(produced by NR catalysis of 50 µM sodium nitrate) was investigated. The yield was 4.41 ± 
3.05% of RSNO as shown in Figure 3.14 
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Figure 3.14 : Nitrite produced from sodium nitrate (catalyzed by NR) and subsequent RSNO formation in gastric 
medium.  
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A total of 3 experiments was performed on separate days. 104.49 ± 4.48% of nitrite was 
produced from 50 µM of sodium nitrate. Of the nitrite produced, 4.41 ± 3.05% formed RSNO 
in the presence of gastric proteins. Control experiments using 50 µM sodium nitrate plus 
Gastric juice (GJ) and GJ alone showed negligible RSNO production. 
 Conversion of nitrite formed from SIS® Go+ nitrate gel to RSNO 
Using the model described above, the formation of RSNO in simulated gastric fluid from nitrite 
produced from NR catalysis of a 1/400 dilution of SIS® Go+ nitrate gel was investigated. An 
yield of 36.71 ± 13.01% of RSNO was measured (Figure 3.15). 
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Figure 3.15: Nitrite produced from SIS® Go+ nitrate gel (catalyzed by NR) and subsequent RSNO in gastric 
medium. 
A total of 3 experiments were performed on separate days. 72.11 ± 13.48% of nitrite was 
produced from 1/400 dilution of SIS® Go+ nitrate gel. Of the nitrite produced, 36.71 ± 13.01% 
formed RSNO in the presence of gastric proteins. Control experiments using 1/400 dilution of 
SIS® Go+ nitrate gel plus GJ and GJ alone show negligible conversion to RSNO. 
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 RSNO formation from nitrite formed from SIS® Go+ nitrate gel in the 
presence of thienopyridine 
 An experiment similar to the above was performed to investigate the influence of clopidogrel 
on the formation of RSNO in the gastric juice mixed with nitrite reduced from SIS® Go+ nitrate 
gel, from the NR activity.  
Clopidogrel 75mg and 600mg added separate samples of artificial gastric juice and nitrite 
converted from 1/800 diluted of SIS® Go+ nitrate gel 
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Figure 3.16 : RSNO formation from nitrite that is produced from 1/800 dilution of SIS® Go+ nitrate gel in gastric 
juice proteins and clopidogrel. One-way ANOVA and Tukey’s multiple comparison tests, (0 mg vs. 75mg vs. 600 
mg clopidogrel). 
A total of 3 experiments were performed on separate days. There is no significant difference 
in RSNO formation between the 3 groups. Summary (P=0.9731). Control experiments using 
GJ in the absence or presence of 75 mg or 600 mg of clopidogrel are shown as black symbols 
and indicate RSNO production. 
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Table 3.11: Data presented as mean ± SEM 
There is no significant difference in RSNO production in the absence or presence of 
clopidogrel (75 or 600 mg) in the gastric medium with similar starting nitrite concentrations as 
shown in Figure 3.16, and Table 3.11.   
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3.1.4 Summary of principal findings 
 An enzyme mix composition of 0.6 U/ml of NR from A. niger, 5 mM of G6P, 1000 
µM of NADPH and 160 µM of G6PD resulted in optimum conversion of nitrate to 
nitrite. 
 
 A positive relationship occurs between increasing the starting molar 
concentrations of laboratory grade sodium nitrate and the nitrite produced. 
 
 Nitrate present within the commercial products, SIS® Go+ nitrate gel and Beet It 
® (in their original commercially available forms) produced limited nitrite, when 
using the above model. 
 
 Dilution of the SIS® Go+ nitrate gel concentration by 400 and Beet It® 
concentration by 100 enhanced the nitrate to nitrate conversion. 
 
 Optimally 45 minutes was required to improve nitrite production from nitrate within 
SIS® Go+ nitrate gel and Beet It®. 
 
 The placebo gel (in its commercially available form) inhibited nitrite production 
from sodium nitrate, under standard conditions. 
 
 RSNO was produced in gastric medium which was converted from sodium nitrate 
and SIS® Go+ nitrate gel. 
 
 A greater amount of RSNO was formed from the nitrite converted within the SIS® 
Go+ nitrate gel, compared to that converted from sodium nitrate.  
 
 There was no significant difference in RSNO produced in the absence or 
presence of 75 mg and 600 mg of clopidogrel within gastric medium.  
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3.2 Results 2: Dietary Nitrate supplement in Stable CAD Patients 
3.2.1 Background 
Dietary nitrate administration among healthy volunteers has shown a considerable reduction 
in platelet reactivity and increase in NO metabolites in the circulation. Endogenous sources of 
NO and its metabolites are impaired in patients with CAD, and exogenous sources through 
diet may present a promising and feasible alternative to maintaining NO biology in humans, 
thereby regulating vasomotor function and haemostasis.  There is no study published to date, 
which has tested the effect of dietary nitrate supplements in patients with established CAD, 
other than the work of our own research group, where a portion of this data,  along with other 
parallel work was published recently (263). This section presents the results of dietary nitrate 
supplementation on platelet function and NO metabolites in patients with stable angina. 
3.2.2 Hypothesis 
We hypothesised that administration of dietary nitrate supplement in patients with stable CAD 
would 
• Enhance the circulatory NO metabolites, hence increase NO bioavailability. 
• Reduce platelet activation via ADP and TRAP stimulation. 
• Result in an inverse correlation between the NO metabolite levels and platelet 
reactivity. 
3.2.3 Results 
Fifteen patients with established CAD consented to take part in this study. Patients attended 
the cardiology day care unit, as part of their normal clinical care. All patients were randomised 
to receive either 2x60ml placebo coded nitrate supplement, followed by a wash out period 
then the active nitrate supplement or vice versa.  A seven-day wash out period was adopted 
in line with several other studies (295). The study design is illustrated in Figure 2.1. 
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 Patient characteristics 
Of the 15 patients recruited to this study, 13 were male. The mean age of the group was 62.7 
± 3.2 years, 4 had previous MI and undergone percutaneous intervention, 4 were diabetic, 12 
had hypertension and majority of them had hypercholesterolemia.  There was a mixture of 
cardiovascular risk factors in the group, depicting the general presentation of the population 
of CAD patients (Table 3.12). 
Participant Characteristics Naïve group (n=15) 
Age(mean) 62.7 ± 3.19 
BMI (kg/m2) 29.9 ± 1.49 
Male 13(87%) 
Cardiovascular Risk Factors  
Diabetes Mellitus 1 (7%) 
Past/Current Smoking 7 (46%) 
Hypertension 12 (80%) 
Dyslipidaemia 15 (100%) 
Stroke/TIA 1 (7%) 
Peripheral Vascular Disease 1 (7%) 
History of MI 4 (27%) 
Previous Revascularisation  
PCI 4 (27%) 
CABG 2 (14%) 
Medications  
Aspirin 13 (86%) 
Clopidogrel 0 (0%) 
Proton Pump Inhibitor 9 (60%) 
Beta Blockers 7 (46%) 
ACE inhibitors/ARB 10 (66%) 
Statins 15(100%) 
Thyroxin 1 (10%) 
NSAIDs 0 (0%) 
Table 3.12: Baseline characteristics of patients, summary sheet including age, cardiovascular risk factors and 
medications. 
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 Effect of nitrate and placebo gel supplementation on NO metabolites  
3.2.3.2.1 Nitrate levels 
The mean plasma concentration of nitrate rose significantly from a baseline of 30.92 µM (± 
10.9) to 266.1 µM (± 90) following intake of nitrate gel (Figure 3.17A), whereas there was no 
rise in mean nitrate concentration with a baseline of 29.20 µM (±12.6) to 31.71 µM (±13.8) 
following intake of placebo gel (Figure 3.17B). There was a statistically significant (P<0.0001) 
increase in the nitrate level 2hrs following ingestion of nitrate gel in comparison to placebo gel. 
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Figure 3.17: Mean plasma concentration of nitrate at baseline and 2 hours post nitrate gel ingestion and placebo 
gel respectively. *** represents p<0.001 and ns represents no significance. 
The mean difference in the rise of nitrate levels from baseline to 2-hour post ingestion was 
235.2µM (±89) and 2.5 µM/L (±6) after ingestion of active and placebo gel respectively. There 
was a statistically significant (P<0.0001) increase in the nitrate level upon ingestion of nitrate 
gel in comparison to placebo gel (Figure 3.18). 
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Figure 3.18: The mean difference derived from nitrate levels before and after ingestion of nitrate and placebo 
gel. *** represents p<0.001 
 
3.2.3.2.2 Nitrite levels 
The mean plasma concentration of nitrite rose significantly (P<0.0001) from a baseline of 
115.9nM (± 68) to 330nM (±193) following intake of nitrate gel (Figure 3.19A), whereas there 
was a small non-significant rise in mean nitrite concentration with a baseline of 137nM (±159) 
to 167nM (±198) following intake of placebo Gel (Figure 3.19B). 
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Figure 3.19: Effect of the dietary supplement of nitrate gel (A) and placebo gel (B) on plasma nitrite at 0 hour and 
two-hour post ingestion. Data are expressed as mean ± standard error of mean. Student paired T-test is applied 
for test of significance.  
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The mean difference in the rise of nitrite levels from baseline to 2-hour post ingestion was 
214.6nM (±144) with 95% confidence interval of 134.8 to 294.4 for nitrate gel. For the placebo 
gel the mean difference was 29.8nM with 95% confidence interval of -6.9 to 66.4. A paired T 
test showed a statistically significant (P=0.0002) change in the nitrite levels with ingestion of 
nitrate gel in comparison to placebo gel (Figure 3.20) 
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Figure 3.20:  A comparison of the change (Δ) in the nitrite levels from baseline to 2 hours post ingestion nitrate 
gel and placebo gel measured in nmol/L. Data are expressed as mean (difference) ±SEM. 
 
3.2.3.2.3 RSNO levels 
The mean plasma concentration of RSNO rose significantly from a baseline of 8.3 nM (± 4.5) 
to 18.6 nM (±14.6) following intake of nitrate gel (Figure 3.21A), whereas there was no rise in 
mean RSNO concentration with a baseline of 10.89nM (±7.4) to 10.95nM (±7.4) following 
intake of placebo gel (Figure 3.21B). A paired student T test showed a statistically significant 
(P=0.049) increase in the RSNO levels measured two hours post ingestion of nitrate gel 
(Figure 3.21A). 
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Figure 3.21:  Mean plasma concentration of RSNO at baseline and 2 hours post nitrate gel ingestion (graph A) 
and placebo gel (graph B) respectively. 
The mean difference in the rise of RSNO levels from baseline to 2-hour post ingestion was 
10.38 nM at 95% confidence interval of 3.8 to 17 after ingestion of nitrate gel and with placebo 
gel ingestion the mean difference in from baseline to 2 hours was 0.05 nM with 95% 
confidence interval of -1.9 to 2. A paired t test confirmed a statistically significant (P=0.014) 
increase in the RSNO levels following ingestion of nitrate gel (Figure 3.22). 
∆ RSNO
Active Placebo
0
5
10
15
N=15 (Paired Samples)
*
Pla
sm
a S
NO
 (n
M)
 
Figure 3.22: Mean difference in RSNO levels before and after ingestion of active and placebo gel. * represents 
P<0.05 
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 Effect of nitrate and placebo gel supplementation on platelet reactivity  
3.2.3.3.1 ADP induced platelet reactivity 
The mean platelet response to ADP was measured using multiple electrode aggregometry 
(Multiplate®). Applying a Kolmogorov-Smirnov test and D’Agostino & Pearson omnibus 
normality testing confirmed Gaussian normal distribution of the data. A paired t-test was used 
for analysis of significance. The platelet reactivity was 527.7 (±156.8) AU/min at baseline and 
574.6 (± 239) AU/min at 2 hours following the intake of nitrate gel (Figure 3.23A), with a P 
value of 0.32. With the intake of placebo gel the platelet reactivity was 530.4(±223) AU/min at 
baseline and 635.8 (± 239) AU/min at 2 hours (Figure 3.23B)with a P value of 0.06115.  
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Figure 3.23: Platelet reactivity upon stimulation with ADP agonist, Measure at baseline (0 ADP) and two-hour 
post ingestion of F (graph A) and placebo gel (graph B), measured in AU*min. ns represents statistical no 
significance. 
The mean difference in the platelet reactivity from baseline to 2-hour post ingestion was -48.87 
(±176.1) AU/min and -105.4 (±200) after ingestion of active and placebo gel respectively. 
There was an apparent decrease in the platelet reactivity with nitrate gel compared to placebo 
gel, however there was no statistical difference (P=0.29) (Figure 3.24). 
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Figure 3.24 : Mean difference in measured Platelet reactivity from baseline to 2 hours upon stimulation with ADP 
agonist 
3.2.3.3.2 TRAP induced platelet reactivity 
The platelet reactivity to TRAP was 917.7 (±214) AU/min at baseline and 1065 (± 264) AU/min 
at 2 hours following the intake of nitrate gel (Figure 3.25A), with a P value of 0.02.  With the 
intake of placebo gel the platelet reactivity was 917.8(±276) AU/min at baseline and 981.5 (± 
286.5) AU/min at 2 hours (Figure 3.25B), with a P value of 0.354. A student paired t test 
showed a statistically significant increase in platelet reactivity at 2 hours with ingestion of 
nitrate gel. 
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Figure 3.25: Platelet reactivity upon stimulation with TRAP agonist, Measure at baseline (0  TRAP) and two hour( 
2-TRAP) post ingestion of nitrate (graph A) and placebo gel(graph B), measured in AU*min. * represents p<0.05 
and ns represents no significance 
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The mean difference in the platelet reactivity from baseline to 2-hour post ingestion was 147.5 
(±225.7) AU/min and 63.67 (±210) after ingestion of active and placebo gel respectively. There 
was no statistically significant variation (0.42) in the platelet reactivity to TRAP with nitrate gel 
or placebo gel intake (Figure 3.26). 
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Figure 3.26: Mean difference in measured Platelet reactivity from baseline to 2 hours upon stimulation with TRAP 
agonist,  
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3.2.5 Summary of principle findings 
 Ingestion of active SIS® Go+ nitrate supplement is associated with a significant rise in the 
plasma nitrate levels in CAD patients 
 
 CAD patients have lower level of plasma nitrite at baseline compared with healthy 
volunteers 
 
 Ingestion of active SIS® Go+ nitrate supplement is associated with a significant rise in the 
plasma nitrite levels within two hours in CAD patients 
 
 There was also a significant rise in the plasma RSNO levels in patients after ingestion of 
SIS® Go+ nitrate supplement. 
 
 The finding of generation of nitrite and RSNO following intake of nitrate supplement is 
consistent with in vitro experiments described earlier in chapter 3. 
 
 There was no effect on ADP mediated platelet aggregation with SIS® Go+ nitrate 
supplement in CAD patients. 
 
 There is a significant change in the TRAP mediated platelet aggregation from baseline to 
2 hours, with SIS® Go+ nitrate supplement in CAD, however this effect becomes non-
significant when compared with placebo supplementation. 
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3.3 Results 3: Dietary nitrate supplementation with clopidogrel 
therapy in stable CAD patients  
3.3.1 Background:  
Clopidogrel therapy is commonly prescribed in patients with ACS and or in patients undergoing 
PCI. This section reports the results of a double-blinded, randomised placebo-controlled study 
of concomitant intake of dietary nitrate supplementation and clopidogrel in patients with stable 
CAD. This is the first known study to explore a combined effect of clopidogrel and nitrate 
therapy. 
3.3.2 Hypothesis 
In this chapter, we hypothesised that administration of dietary nitrate supplement along with 
clopidogrel therapy in patients with stable CAD would 
• Enhance the circulatory NO metabolites, hence increase NO bioavailability. 
• Promote Clopidogrel reaction with exogenous derived nitrite in vivo and form 
clopidogrel-SNO. 
• Cause additional platelet inhibition independent of P2Y12 receptor blockage. 
• Influence RSNO formation and platelet aggregation in patients on concomitant proton 
pump inhibitor therapy (PPI).  
 Subgroups: 
1.  Acute Clopidogrel Loading group (clopidogrel 600mg): Group A 
These patients are on aspirin alone and no other antiplatelet therapy. They are 
prescribed with a loading dose of clopidogrel 600mg as per clinical guidelines on the 
day of their coronary intervention procedure. 
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2. Chronic clopidogrel (clopidogrel 75mg):  Group B 
These patients are on aspirin and Clopidogrel therapy (75mg) for more than 1 month 
and listed for a day case coronary intervention. 
Dietary nitrate or placebo supplementation was given in randomised fashion as shown in 
Figure 2.2 of Materials and Methods (Chapter 2).  
 
3.3.3 Results  
A total of 104 patients were recruited for this study.  They were divided into Group A 
(clopidogrel 600mg) (n=50) and Group B (n=54) based on the clopidogrel treatment regime 
as explained in the Methods.  
 Patient characteristics 
Group A: SCAD patients with acute clopidogrel loading 
Patients in this group were diagnosed to have stable angina and were scheduled for elective 
coronary angiogram and PCI. As a part of established evidence based clinical practice, these 
patients received a loading dose of 600 mg of clopidogrel prior to their procedure.  
A total of 50 patients met the inclusion criteria and gave voluntary consent for participation. 
Three patients were excluded; 1 because of inability to collect the 2-hour sample, 2 due to 
analysis issue. The final number of patients was 47, with 24 patients were randomly assigned 
to nitrate gel Group A (clopidogrel 600mg) and 23 patients to placebo gel group. 3 Baseline 
blood samples were collected. Patients were given 2 sachets of study gel (active or placebo) 
for ingestion, along with 600 mg of clopidogrel.  A second blood sample was collected 2 hours 
later, as described in the Methods.  
There was no significant difference in the age, gender, clinical presentation, past medical 
history (e.g. hypertension, diabetes, cigarette smoking, cardiac procedures) or other medical 
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conditions and prescribed medications comparing patients receiving nitrate gel versus placebo 
gel (Table 3.13). 
Demography Nitrate gel 
(n=24) 
placebo gel 
(n=23) 
P value 
Age 67 (± 29) 63(±20) ns 
Male 16 15 ns 
chest pain 26 24 ns 
SOB 17 16 ns 
Myocardial infarction 7 6 ns 
Previous PCI 10 5 ns 
Cardiac surgery 2 1 ns 
Diabetes 8 5 ns 
Hypertension 20 19 ns 
Hyperlipidaemia 17 19 ns 
Smoker 16 17 ns 
Thyroid 1 0 ns 
Respiratory problem 6 3 ns 
CVA/TIA 3 1 ns 
Renal history 2 0 ns 
Medications 
Aspirin 26 24 ns 
Beta blockers 20 15 ns 
ACE inhibitors 13 9 ns 
Statins 22 20 ns 
Diabetic drugs 9 5 ns 
CCB 5 5 ns 
Thyroxin 1 0 ns 
NSAID 13 10 ns 
PPI 13 10 ns 
Table 3.13: Demographic and clinical characteristics of Group A patients, including list of current medication. 
Aspirin was prescribed in all patients 
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Group B:  SCAD Patients with chronic clopidogrel treatment 
Patients in this group were diagnosed to have stable angina and are on long-term aspirin and 
clopidogrel therapy. They are scheduled for elective coronary angiogram and PCI on the day 
of recruitment.  
A total of 53 patients met the inclusion criteria and gave a voluntary consent for participation. 
28 patients were randomly assigned to nitrate gel and 25 patients to the placebo gel group.  
Baseline blood samples were collected. Patients were given 2 sachets of study gel for 
ingestion (active or placebo).  A second blood sample was collected 2 hours later. 
Demography Nitrate 
gel(n=28) 
placebo gel 
(n=25) 
P value 
Age 66 (± 29) 65(±20) ns 
Male 23 21 ns 
chest pain 23 15 ns 
SOB 12 9 ns 
Myocardial infarction 22 16 ns 
Previous PCI 18 17 ns 
Cardiac surgery 6 5 ns 
Diabetes 4 2 ns 
Hypertension 24 19 ns 
Hyperlipidaemia 25 19 ns 
Smoker 18 17 ns 
Thyroid 2 2 ns 
Respiratory problem 5 3 ns 
CVA/TIA 3 2 ns 
Renal history 0 0 ns 
Medications 
Beta blockers 17 14 ns 
ACE inhibitors 13 14 ns 
Statins 23 20 ns 
CCB 6 5 ns 
Thyroxin 1 2 ns 
NSAID 2 2 ns 
PPI 15 13 ns 
 
Table 3.14: Summary of patient’s characteristic, collected at the time of recruitment of group B. There is no 
statistically significant variation between two groups. 
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 Effect of nitrate and placebo gel supplementation on NO metabolites  
Nitrate levels 
There was no significant difference in the baseline levels of plasma nitrate between nitrate 
supplement and placebo therapy in either groups  [Group A : Nitrate:-28.7(±9) vs 33.98(±17),  
P>0.05 and [Group B: Nitrate:- 28.7(±9) vs 33.98(±17), P>0.05] as shown in Figure 3.27.  
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Figure 3.27: Baseline Nitrate measured in Group A (clopidogrel 600mg) and Group B (clopidogrel 75mg) 
The mean plasma concentration of nitrate rose significantly (P<0.0001) from a baseline of 
28.77 µM (± 9) to 288.9 µM (± 85.64) in Group A (clopidogrel 600mg) (Figure 3.28A) and from 
a baseline of 30.40 µM (± 13) to 307.3 µM (± 100) in Group B (clopidogrel 75mg) following 
intake of nitrate gel (Figure 3.29A)  
 There was a non-significant small rise in mean nitrate concentration from the baseline of 
33.98 µM (±17.27) to 36.04 µM/L (±20.62) (Figure 3.28B)  in Group A (clopidogrel 600mg) and 
from a baseline of 30.03 µM (±16.54) to 31.25 µM (±49) (Figure 3.29B). Group B respectively 
following intake of placebo gel   
D’Agostino & Pearson omnibus normality test of data showed a non-Gaussian distribution, a 
Wilcoxon matched pairs test of significance showed a statistically significant (P<0.0001) rise 
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in nitrate levels with nitrate gel and a non-significant rise (P>0.5) with placebo gel in these 
groups, respectively. 
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Figure 3.28: Mean plasma concentration of Nitrate at baseline and 2 hours post Active and placebo respectively 
in Group A (clopidogrel 600mg). *** represent p <0.001 and ns represent no significance 
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Figure 3.29 : Mean plasma concentration of Nitrate at baseline and 2 hours post Nitrate gel and placebo 
respectively in Group B (clopidogrel 75mg). *** represent p <0.001 and ns represent no significance 
In Group A (clopidogrel 600mg), the mean difference in the rise of nitrate levels from baseline 
to 2-hour post ingestion was 260.1 µM (with 95% confidence interval of 225 to 295.2) and 2.05 
µM (with 95% confidence interval of -7.25 to 11.37) for nitrate gel and placebo gel, respectively 
(Figure 3.28).    
In Group B (clopidogrel 75mg), the mean difference in the rise of nitrate levels from baseline 
to 2 hour post ingestion was 276.9µM (with 95% confidence interval of 239.6 to 314.2) and 
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1.213 µM (with 95% confidence interval of -3.431 to 11.25) for nitrate gel and placebo gel 
respectively  (Figure 3.29).   
A statistically significant (P<0.0001) change in the plasma nitrate level following ingestion of 
nitrate gel in comparison to placebo gel in both groups was observed (Figure 3.30). 
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Figure 3.30: Mean difference in nitrate levels between baseline and 2 hour following ingestion of dietary nitrate 
supplement and placebo gel in Group A and Group B. A Mann-Whitney t test showed a statically significant 
change in both groups (*** Denotes a p ≤ 0.001, data presented as mean with error bars representing standard 
of error).  
 
There was an identical rise in the level of nitrate following the ingestion of active nitrate 
supplement in both groups (Figure 3.31 ). 
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Figure 3.31: A comparative graph of the rise in nitrate levels at two hours post ingestion of dietary nitrate 
supplementation gel in Group A (clopidogrel 600mg) and Group B (Clopidogrel 75mg) patients.( ns represent no 
significance Data presented as mean with error bars representing standard of error).  
  
Nitrite levels 
There was no significant difference in the baseline level of plasma nitrite between nitrate gel 
and placebo gel in either groups [Group A (clopidogrel 600mg): Nitrite: - 220.1nM (±145) vs 
246.6(±146), P>0.05] [Group B: Nitrite:- 220.1nM (±145) vs 246.6(±146), P>0.05] as showed 
in Figure 3.32. 
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Figure 3.32 : Baseline nitrite measured in Group A (clopidogrel 600mg) and Group B (clopidogrel 75mg), Data 
presented as mean with error bars representing standard of error.  
The mean plasma concentration of nitrite rose significantly (p=0.0001) from a baseline of 
220.1nM (± 145) to 455.1nM (±266) (Figure 3.33a) in Group A (clopidogrel 600mg) and from 
a baseline of 168.7nM (± 88) to 368.8nM (±238) (Figure 3.34A) in Group B following intake of 
nitrate gel. 
There was a non-significant small rise in mean nitrite concentration from a baseline of 248.6nM 
(±146) to 294.1nM (±282) in Group A (clopidogrel 600mg) [P<0.0001] (Figure 3.33B) and a 
small non-significant drop in mean nitrite concentration with a baseline of 235nM (±303) to 
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173.1nM (±127) [P>0.05] following intake of placebo gel in Group B (clopidogrel 75mg) (Figure 
3.34B).  
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Figure 3.33: Mean plasma concentration at baseline and 2 hours post nitrate gel (Graph A) and placebo gel 
(graph B) respectively in Group A (Acute clopidogrel 600mg). A Wilcoxon matched pair test showed a statistically 
significance (P<0.0001) rise with dietary nitrate supplement and a non-significance (P>0.05) with placebo gel 
ingestion 
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Figure 3.34 : Mean plasma nitrite concentration at baseline and 2 hours post nitrate gel ingestion (graph A) and 
placebo gel (graph B) respectively in Group B (Chronic Clopidogrel 75mg). A Wilcoxon matched pair test showed 
a statistically significance (P<0.0001) rise with dietary nitrate supplement and a non-significance (P>0.05) with 
placebo gel ingestion 
The mean difference in the rise of nitrite level from baseline to 2-hour post ingestion was 235.0 
nM (with 95% confidence interval of 142.6 to 327.5) for dietary nitrate gel and for the placebo 
gel the mean difference was 46.13nM (95% CI of -55.34 to -144.6) in Group A (clopidogrel 
600mg) patients.  
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The mean difference in the rise of nitrite level from baseline to 2-hour post ingestion was 
200.0nM (with 95% confidence interval of 107.3 to 292.7) for dietary nitrate gel and with the 
placebo gel the mean difference was -69.53nM (with 95% confidence interval of -178.1 to 
39.03) in Group B (clopidogrel 75mg) patients 
There is a statistically significant (P<0.01) change in the nitrite level following ingestion of 
dietary nitrate gel in comparison to placebo gel in both groups (Figure 3.35) 
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Figure 3.35: Mean difference in nitrite levels following ingestion of dietary nitrate and placebo gel in Group A 
(clopidogrel 600mg) and Group B, A Mann-Whitney t test showed a statistically significant (P<0.01) change in 
the nitrite levels in upon ingestion of dietary nitrate gel in comparison to placebo gel in both groups (Data 
presented in mean with standard of error of mean, ** denotes p=0.001, *** denotes P<0.001) 
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Figure 3.36: A comparative graph of the rise in nitrite level at two hours post ingestion of dietary nitrate 
supplementation gel in Group A (clopidogrel 600mg) (Clopidogrel 600mg) and Group B (Clopidogrel 75mg) 
patients. (Data presented in mean with standard of error of mean) 
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There was a numerically higher nitrite measured at 2 hours in Group A (clopidogrel 600mg) 
patients in comparison with and Group B (Clopidogrel 75mg) patients, but this was not 
statistically significant (Figure 3.36).  
 
RSNO levels 
There was no significant difference in the baseline levels of plasma RSNO between nitrate 
supplement and placebo therapy in either groups [Group A (clopidogrel 600mg):  RSNO-: 
15.8nM (±13) vs 26.2(±23), P>0.05] and [Group B: RSNO-: 36.38nM (±42) vs 23.8(±32)] as 
shown in Figure 3.37 
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Figure 3.37: Baseline RSNO levels in Group A and Group B patients, Unpaired t test showed a non-significance. 
Data represented as mean with SEM as error bars.  
The mean plasma concentration of RSNO rose significantly (P= 0.0001) from a baseline of 
15.79 nM (± 13) to 32.83 nM (±30.) at 2 hours following intake of dietary nitrate gel (Figure 
3.38A) whereas there was no significant change in the mean RSNO concentration from a 
baseline of 26.24nM (±23) to 21.18nM (±13) at 2 hours following intake of placebo gel in Group 
A (clopidogrel 600mg) patients (Figure 3.38B) 
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The mean plasma concentration of RSNO rose significantly from a baseline of 36.38 nM (± 
42) to 50.04 nM (±45) at 2 hours following intake of nitrate gel (Figure 3.39A) and There was 
a no change in the mean RSNO concentration from a baseline of 23.8nM (±32.3) to 23.25nM 
(±31.4) at 2 hours following intake of placebo gel (Figure 3.39B) in group B (Clopidogrel 75mg) 
patients.  
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Figure 3.38: Mean plasma concentration of RSNO at baseline and 2 hours post Dietary nitrate gel ingestion and 
placebo gel respectively in Group A (clopidogrel 600mg), D’Agostino & Pearson omnibus normality test of data 
showed a non-Gaussian distribution,   and the applied Wilcoxon matched pair test showed a statistically 
significant *** (P=0.0001) increase in the RSNO levels in upon ingestion of nitrate gel (A) and no significant 
change (0.14) with ingestion of placebo gel(B). 
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Figure 3.39: Mean plasma concentration of RSNO at baseline and 2 hours post Dietary nitrate gel ingestion and 
placebo gel respectively in group B (Clopidogrel 75mg), D’Agostino & Pearson omnibus normality test of data 
showed a non-Gaussian distribution,   and the applied Wilcoxon matched pair test showed a statistically 
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significant *** (P=0.0001) increase in the RSNO levels in following ingestion of nitrate gel (A) and no significant 
change  (0.14) with ingestion of placebo gel (B) 
In Group A (clopidogrel 600mg), the mean difference in the rise of RSNO levels from baseline 
to 2 hours post ingestion of the nitrate gel was by 17.05nM (95% CI: 8.25-25.84nM). Following 
the placebo gel, RSNO levels decreased by 5.05nM (95% CI: –12.94-2.83nM) (Figure 3.40A). 
In Group B (clopidogrel 75mg), the mean difference in the rise of RSNO levels from baseline 
to 2 hour post ingestion was 13.67 nM (95% CI; 7.423 to 19.91) following nitrate gel and 
following  the placebo gel the mean difference was –1.51nM (95% CI; –12.19 to 9.17) as 
showed in Figure 3.40B. 
There is a statistically significant (P=0.001) change in the RSNO levels in upon ingestion of 
nitrate gel in comparison to placebo gel in both groups (Figure 3.40) 
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Figure 3.40: Mean difference (delta) in change in RSNO levels following ingestion of dietary nitrate and placebo 
in Group A (clopidogrel 600mg and Group B (Clopidogrel 75mg), A Mann-Whitney t test showed a statistically 
significant (P=0.001) change in the RSNO levels in upon ingestion of nitrate gel in comparison to placebo gel in 
both groups (Data presented in mean with standard of error, ** denotes p=0.001, *** denotes P<0.001) 
There was a numerically higher change in RSNO level (17nM vs 14nM) formed 2 hours post 
dietary nitrate ingestion in Group A (clopidogrel 600mg) compared to Group B (Clopidogrel 
75mg), but this was not statistically significant (Figure 3.41). 
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Figure 3.41: A comparative graph of the rise in RSNO levels at two hours post ingestion of dietary nitrate 
supplementation gel in Group A (clopidogrel 600mg)) and Group B (Clopidogrel 75mg) patients. 
 
 Effect of nitrate and placebo gel supplementation on platelet reactivity 
 ADP induced platelet reactivity 
3.3.3.4.1 Group A (clopidogrel 600mg) 
The mean platelet response to ADP was measured using Multiplate® electrode aggregometry. 
The platelet reactivity was 636.2 (±239.9) AU/min at baseline and 368.8 (± 213.7) AU/min at 
2 hours following the intake of dietary nitrate gel and clopidogrel 600mg (Figure 3.42A), with 
a paired t test, P value = <0.0001. The mean platelet aggregator response to ADP with the 
intake of placebo gel and clopidogrel 600mgs was 578.4(±191) AU/min at baseline and 345.2 
(± 185) AU/min at 2 hours (Figure), with a P value of <0.0001 in Group A (clopidogrel 600mg) 
(Figure 3.42B) 
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Figure 3.42: Platelet reactivity upon stimulation with ADP agonist, measured at baseline (0  ADP) and two hour 
post ingestion of dietary nitrate gel and placebo gel, measured in AU*min. *** Denotes a p ≤ 0.0001 
 
3.3.3.4.2 Group B (clopidogrel 75mg) 
The platelet reactivity was 411.5 (±221) AU/min at baseline and 356.2 (± 158) AU/min at 2 
hours following the intake of nitrate gel (Figure 3.43A), with a P value of <0.0795. With the 
intake of placebo gel the platelet reactivity was 338.4(±146) AU/min at baseline and 344.4 (± 
194) AU/min at 2 hours (Figure), with a P value =0.882(Figure 3.43B) 
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Figure 3.43: Platelet reactivity upon stimulation with ADP agonist, measure at baseline and two hour post 
ingestion of nitrate (A)  and placebo (B) gel, measured in AU*min. A paired T test as applied for testing the 
significance 
The mean difference in the platelet reactivity from baseline to 2-hour post ingestion was -267.4 
AU/min (with 95% confidence interval of -351.5 to -183.3) and -233.3 AU/min (with 95% 
confidence interval of -327.1 to -183.3) for dietary nitrate gel and placebo gel administered to 
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Group A (clopidogrel 600mg), respectively.  There was a minor increase in platelet inhibition 
with nitrate gel compared to placebo gel but this did not reach statistical significance (P=0.57) 
using unpaired t test (Figure 3.44A).  
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Figure 3.44: Mean difference in measured platelet reactivity from baseline to 2 hours upon stimulation with ADP 
agonist Data presented as mean with standard of error of mean. 
The mean difference in the platelet reactivity from baseline to 2-hour post ingestion was -55.36 
AU/min (with 95% confidence interval of -118.6 to 7.86) and 5.96 AU/min (with 95% confidence 
interval of -49.06 to 60.98) for nitrate gel and placebo gel in Group B, respectively.  There was 
a minor increase in platelet inhibition with nitrate gel compared to placebo gel, but this did not 
reach statistical significance (P=0.20) (Figure 3.44B above).  
 TRAP induced platelet reactivity 
3.3.3.5.1 Group A (clopidogrel 600mg) 
The platelet reactivity was 1050.0 (±234.1) AU/min at baseline and 927.3 (± 298) AU/min at 2 
hours following the intake of nitrate gel and clopidogrel 600mg, this was statistically significant 
(P = 0.019) as showed in Figure 3.45A. With the intake of placebo gel and clopidogrel 600mg 
the platelet reactivity was 1048(±267) AU/min at baseline and 943 (± 226) AU/min at 2 hours, 
which was not significant (P= 0.056) (Figure 3.45B). 
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Figure 3.45 : Platelet reactivity upon stimulation with TRAP agonist, measured at baseline (0  TRAP) and two 
hours ( 2-TRAP) post ingestion of nitrate and placebo gel, measured in AU*min. A paired T test as applied for 
testing the significance. (* denotes P<0.01 and ns denotes non-significance)  
 
3.3.3.5.2 Group B (clopidogrel 75mg)   
The platelet reactivity was 924.4 (±304) AU/min at baseline and 887.4 (± 286) AU/min at 2 
hours following the intake of dietary nitrate gel (Figure 3.46A) with a paired test P value of 
0.39. With the intake of placebo gel the platelet reactivity was 930.1(±287) AU/min at baseline 
and 893.5 (± 279) AU/min at 2 hours, with a P value of 0.52. (Figure 3.46B) 
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Figure 3.46 : Platelet reactivity upon stimulation with TRAP agonist, measured at baseline (0  TRAP) and two 
hours ( 2-TRAP) post ingestion of dietary nitrate and placebo gel, expressed in AU*min. (ns denotes non-
significance) 
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The mean difference in the TRAP induced platelet reactivity from baseline to 2 hour post 
ingestion was -122.5 AU/min (with 95% confidence interval of –224.4 to -20) and -105.1 
AU/min (with 95% confidence interval of –213.3 to 3.165) for nitrate gel and placebo gel in 
Group A (clopidogrel 600mg), respectively (Figure 3.47A). 
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Figure 3.47: Mean difference in measured platelet reactivity from baseline to 2 hours upon stimulation with TRAP 
agonist in Group A (clopidogrel 600mg) and group B (clopidogrel 75mg) patients expressed in AU*min. (ns 
denotes non-significance) 
The mean difference in the platelet reactivity from baseline to 2-hour post ingestion was -37.07 
(±226) AU/min and 36.56 (±280) AU/min after ingestion of active and placebo gel, respectively. 
There was no increase in platelet inhibition with nitrate gel compared to placebo gel, P value 
=0.65 (Figure 3.47B). 
3.3.4 Combined results  
 Overall effect of nitrate supplement on NO metabolites in patients with 
stable CAD 
This section is a comparison of results of the mean change in values (from baseline to 2 hours) 
comparing ingestion of nitrate supplement in the three patient groups (studied in Chapter 4 
and in the current chapter): CAD patients naive to clopidogrel, group A (Acute clopidogrel 
600mg), and group B (Chronic clopidogrel 75mg). A one-way ANOVA (non-parametric) 
statistical analysis method was applied while comparing the 3 groups.  
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Nitrate 
The mean change in plasma concentration of nitrate following nitrate gel was 235.2(±88) µM, 
276.9 (±96) µM and 264.9 (±84) µM in clopidogrel naïve (CAD only), Group A (clopidogrel 
600mg) and Group B (clopidogrel 75mg). respectively.  There was no statistically significant 
difference (P=0.56) noted between these three groups. (Figure 3.48A) 
Nitrite 
The mean change in plasma concentration of nitrite following nitrate gel was 214.6(±144) nM, 
235 (±219) and 207.4 (±240) nM in clopidogrel naïve (CAD only), Group A (clopidogrel 600mg) 
and Group B (clopidogrel 75mg), respectively.  There was no statistically significant difference 
(P=0.69) noted between these three groups. (Figure 3.48B) 
RSNO 
The mean change in plasma concentration of RSNO following nitrate gel was 10.4(±11) nM/L, 
17.1 (±21) nM/L and 13.7 (±16) nM/L in clopidogrel naïve (CAD only), Group A (clopidogrel 
600mg) and Group B (clopidogrel 75mg), respectively.  There was no statistically significant 
difference (P=0.58) noted between these three groups. (Figure 3.48C)  
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Figure 3.48: A Comparative chart of mean difference in the nitrate, nitrite, and RSNO levels 2 hour after ingestion 
of nitrate supplementation in stable coronary artery disease patients with and without clopidogrel therapy. These 
are unpaired samples, data represented as mean with standard error of mean. CAD only: stable CAD patients not 
on clopidogrel therapy. Group A (clopidogrel 600mg): SCAD patients on Clopidogrel loading (600mg), Group B: 
SCAD patients on Chronic clopidogrel therapy (75mg)., ** denotes p=0.001, *** denotes P<0.001. 
 
Platelet aggregation 
ADP 
The change in platelet reactivity to ADP following nitrate gel was 46.87 (±176) AU/min, -267.4 
(± 212) AU/min and -55.36 (±163) AU/min in clopidogrel naïve (CAD only), Group A 
(clopidogrel 600mg) and Group B (clopidogrel 75mg), respectively.  There was a significant 
difference (P<0.001) noted between these CAD vs Group A and Group A vs Group B (Figure 
3.49 A) 
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TRAP 
The change in platelet reactivity to TRAP following nitrate gel was 147.5 (±225) AU/min, -
122.5 (± 257) AU/min and -37.1 (±227) AU/min in clopidogrel naïve (NC), acute clopidogrel 
loading and chronic clopidogrel loading group respectively.  There was a statistically significant 
difference (P=0.01) noted between these CAD vs Group A (clopidogrel 600mg) and B. (Figure 
3.49 B) 
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Figure 3.49:A Comparative chart of mean difference in the ADP and TRAP inhibition 2 hour after ingestion of 
nitrate supplementation in stable coronary artery disease patients with and without clopidogrel therapy. These 
are unpaired samples, data represented as mean with standard error of mean. CAD only: stable CAD patients not 
on clopidogrel therapy. Group A (clopidogrel 600mg): SCAD patients on Clopidogrel loading (600mg), Group B: 
SCAD patients on Chronic clopidogrel therapy (75mg)., * denotes p<0.05, ** denotes P<0.01. and ***p<0.001. 
3.3.5 Correlations between NO metabolites and platelet inhibition.  
In this section a relationship between change in RSNO levels with change in platelet reactivity 
was investigated by collating the data of all three patient groups.  
There was a significant correlation between the change in RSNO levels and ADP/TRAP 
mediated platelet inhibition. No similar correlations were observed between the other NO 
metabolites (nitrate, nitrite) and platelet inhibition (Table 3.15)  
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Table 3.15: A correlation matrix demonstrating the relationship of Change(delta) in the NO metabolites and 
Platelet inhibition, significant correlations are highlighted in bold. 
 
There is a negative correlation between RSNO levels and platelet reactivity with ADP and 
TRAP agonist. The association was strongest with statistical significance between increase in 
RSNO and the decrease in the TRAP mediated platelet inhibition (P=0.01) as shown Figure 
3.50. 
 
Correlation Matrix 
 Delta Nitrate Delta Nitrite Delta RSNO Delta ADP Delta TRAP 
Delta Nitrate Pearson Correlation  .076 -.196 .016 -.007 
Sig. (2-tailed)  .541 .112 .900 .953 
N  67 67 67 67 
Delta Nitrite Pearson Correlation .076  .061 -.046 -.181 
Sig. (2-tailed) .541  .623 .710 .143 
N 67  67 67 67 
Delta RSNO Pearson Correlation -.196 .061  -.194 -.312* 
Sig. (2-tailed) .112 .623  .116 .010 
N 67 67  67 67 
Delta ADP Pearson Correlation .016 -.046 -.194  .595** 
Sig. (2-tailed) .900 .710 .116  .000 
N 67 67 67  67 
Delta TRAP Pearson Correlation -.007 -.181 -.312* .595**  
Sig. (2-tailed) .953 .143 .010 .000  
N 67 67 67 67  
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure 3.50: The correlation of change in the RSNO levels in relation to platelet inhibition. Graph A, demonstrates 
there is a negative association between ADP inhibition and RSNO with R value of 0.0038, Pearson correlation 
coefficient of -0.194 and p>0.05. Graph B shows a significant negative correlation between the change in RSNO 
and change in TRAP mediated platelet inhibition with a R value of 0.097, Pearson correlation coefficient of -0.312 
and a P<0.05.  
 
  
A B 
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3.3.6 Summary of principle findings 
 There was no significant difference in the baseline levels of plasma nitrate and nitrite 
between nitrate supplement and placebo therapy in both groups (Group A and Group 
B)  
 
 The baseline plasma RSNO levels were significantly lower in the nitrate receiving 
group compared to the placebo group in patients given 600mg of clopidogrel (Group 
A). No such difference seen in Group B patient with nitrate or placebo therapy. 
 
 There was a significant rise in the plasma nitrate, nitrite and RSNO levels 2 hrs post 
ingestion of the nitrate gel in both groups.  
 
 There was no significant difference in NO metabolite’s levels 2-hour post ingestion of 
placebo gel in either groups. 
 
 There was a significant drop in the platelet aggregation simulated via ADP receptors 
both in nitrate and placebo gel groups given 600mg of clopidogrel (Group A). No such 
difference was observed in Group B patients receiving nitrate or placebo therapy. 
 
 The platelet aggregation due to simulation via TRAP was significantly lower in patients 
given nitrate gel given 600mg of clopidogrel (Group A). No such difference seen in 
Group B patient with nitrate or placebo therapy. 
 
 There was a significant correlation between the change RSNO metabolite and change 
in TRAP mediated platelet aggregation. 
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3.4 Results 4: The role of newer antiplatelet drugs (ticagrelor) in 
Nitrate-nitrite-RSNO metabolism 
3.4.1 Background 
Ticagrelor is a newer potent P2Y12 receptor blocker. Its potency is primarily attributed to its 
P2Y12 receptor blocking effect. The P2Y12 independent effects are recognised but exact 
mechanism is not established.   
3.4.2 Hypothesis 
In this chapter we hypothesised that  
• Ticagrelor, would not form ticagrelor-SNO in the acidic milieu of a gastric environment 
using a simulated stomach media in presence of nitrite. 
 
• Ticagrelor therapy would not have an effect on plasma RSNO levels in patients 
undergoing PCI for CAD and thereby beneficial effects of enhanced NO metabolites. 
 
• Concomitant use of PPI with ticagrelor has an effect on RSNO formation and platelet 
inhibition in patients with CAD 
3.4.3 In vitro study -ticagrelor- RSNO formation in simulated gastric fluid. 
In this section we sought to investigate whether ticagrelor could form ticagrelor induced RSNO 
in an artificial simulated gastric medium in the presence of nitrite. We also studied the interplay 
of various gastric constituents’ and different nitrite concentration on the resulting RSNO 
formation.  
 Baseline RSNO levels  
Simulated artificial gastric fluid (SGF), ticagrelor solution, and SGF-ticagrelor mixtures were 
freshly prepared on each day of the experiments as described in the methods chapter.   
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200µL of each solution were incubated separately at 370C for 10 minutes and then neutralised 
with 1M NaOH. The neutralised sample was immediately injected into the purge vessel 
containing 2Cs reagent and the baseline RSNO level was measured.  A total of 3 experiments 
were performed on different days. Negligible amount of RSNO was detected in the SGF 
(0.21nM/L) ticagrelor only solution (0.22nM/L) and SGF-ticagrelor mixture (0.24nM/L) (Figure 
3.51).  There was no statistically significance difference in baseline RSNO levels in the three 
tested mixtures. 
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Figure 3.51: RSNO level measured in Gastric juice (GJ), Ticagrelor solution, and Ticagrelor mixed in gastric Juice 
without any added nitrite. 
 
 Ticagrelor induced RSNO formation in simulated gastric media in the 
presence of nitrite 
RSNO generation in SGF both with and without ticagrelor was measured.  A total of 5 
experiments were conducted on separate days. Adding nitrite at varying concentrations to 
gastric media alone resulted in the formation of RSNO from the endogenous proteins within 
the media (Figure 3.52). Furthermore, RSNO formation was augmented when ticagrelor was 
added to gastric media with similar amounts of added nitrite P=0.0084 at 5000 µmol/L and 
P=0.0360 at 500 µmol/L.  
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This effect was only modest at physiological levels of nitrite (Figure 3.53), and it was 
nevertheless measurable at the low doses. There was no statistically significant change at low 
does with a p value of 0.3146 (ns), 0.1982 (ns) and 0.2612 (ns) at 50 µmol/L, 25 µmol/L, and 
12.5 µmol/L respectively. 
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Figure 3.52: Drug-SNO formation in gastric medium and ticagrelor gastric medium mixture against high dose of 
nitrite, showing an augmented RSNO production with drug in gastric medium. There is a statistically significant 
change with a P=0.0084 at 5000 µmol/L and P=0.0360 at 500 µmol/L. 
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Figure 3.53: Drug-SNO formation in gastric medium and ticagrelor gastric medium mixture across a low 
physiological range of nitrite, showing an augmented RSNO production with drug in gastric medium.  
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 Effect of simulated gastric fluid contents on RSNO formation 
The above experiments clearly show RSNO formation in acidified gastric medium in the 
presence of nitrite.   
There was negligible RSNO measured in the baseline sample and a considerable stepwise 
increase in RSNO formation with stepwise addition of resorium, lysozyme, pepsin, casein and 
ticagrelor to the baseline sample (Figure 3.54 & Table 3.16).  
Solution RSNO (µmol/L) 
Solution 1= NACL, D GLUCOSE, KCL, CACL, KHPO4 0.158343 
Solution 2= Solution 1+ Resorium 1.814479 
Solution 3= Solution e 2+lysozyme 2.073342 
Solution 4 = Solution 3+ pepsin 3.200252 
Solution 5= Solution 4+ casein 4.168032 
Solution 6= Solution 5+Ticagrelor 6.054435 
Table 3.16: RSNO formation with stepwise addition of constituents of simulated gastric fluid upon addition of 
500µmol/L of nitrite. 
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Figure 3.54: RSNO formation in relationship with constituents of simulated gastric juice upon addition of 
500µmol/L of nitrite, Sample 1= NACL, D GLUCOSE, KCL, CACL, KHPO4.  Sample 2= sample 1+ Resorium. Sample 
3= Sample 2+lysozyme, Sample 4 = sample 3+ pepsin, Sample 5= sample 4+ casein Sample 6= sample 
5+Ticagrelor. There is a linear increase in the level of RSNO formation and it further enhanced with the addition 
of ticagrelor to the SGF (sample.  
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3.4.4 Effect of ticagrelor therapy on NO metabolites and platelet reactivity in 
patients with CAD undergoing PCI  
A total of 47 patients were recruited for this study from the pre-assessment unit, who were 
scheduled for coronary intervention (PCI) for stable CAD. The first group of 24 patients 
(Loading group) who were given a first dose of ticagrelor loading (180mg) and a second patient 
group of 23 patients (chronic group) who were already on a maintenance dose of ticagrelor 
(90mg daily) for over 28 days. 
 Patient groups and characteristics 
There were no significant differences in the clinical characteristics of the acute loading and 
chronic therapy patient groups including hypertension, hyperlipidaemia, cigarette smoking, 
family history of Ischemic heart disease and drug treatment, except for a prevalence of 
previous myocardial infarction and PCI in the chronic Ticagrelor group (Table 3.17).  
Characteristics Loading(N=24) Chronic(N=23) T Test 
Myocardial infarction 4 12 NS 
Previous PCI 4 23 NS 
Cardiac surgery 2 0 NS 
Diabetes 4 6 NS 
Hypertension 11 14 NS 
Hyperlipidaemia 10 13 NS 
Smoker 16 13 NS 
Thyroid 3 2 NS 
Respiratory problem 2 0 NS 
CVA/TIA 0 0 NS 
Renal history 0 0 
NS 
 
Medications 
Aspirin 13 10 NS 
Clopidogrel 2 1 NS 
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Beta blockers 7 10 NS 
ACE inhibitors 8 12 NS 
Statins 23 23 NS 
Diabetic drugs 1 16 NS 
Nitrates 3 0 NS 
CCB 0 5 NS 
Thyroxine 3 1 NS 
NSAID 0 0 NS 
PPI 9 6 NS 
 
Table 3.17: Patients demography and characteristics of patients on acute Ticagrelor loading and chronic 
Ticagrelor therapy 
 
 Influence of acute ticagrelor loading on NO metabolites   
The concentration of plasma RSNO rose significantly (p=0.0072) from a baseline of 23.6 
(±3.3) nM to 35.4 (±5.8) nmol/L following Ticagrelor loading (Figure 3.55). Two hours after a 
loading dose plasma nitrite concentration remained unchanged (p=ns) from 211.1 (±24.3) to 
217.7 (±25.4) nmol/L (Figure 3.56). Plasma nitrate concentration also remained unchanged 
from 30.4 (±1.9) to 28.8 (±1.4) µmol/L (p=ns) (Figure 3.57) 
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Figure 3.55: Mean plasma concentration of RSNO at baseline and 2 hours post 180mg of Ticagrelor ingestion, A 
paired T test was applied with values are presented as mean with SEM. 
Nitrite
Pre Post
0
100
200
300 P = 0.9907
N = 24
Ni
tri
te
 (n
m
ol
/L
)
 
Figure 3.56: Mean plasma concentration of nitrite at baseline and 2 hours post 180 mg of Ticagrelor ingestion, A 
paired T test was applied with values are presented as mean with SEM. 
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Figure 3.57: Mean plasma concentration of nitrate at baseline and 2 hours post 180 mg of Ticagrelor ingestion, 
A paired T test was applied with values are presented as mean with SEM. 
 
 Comparative effect of chronic treatment vs acute effect post loading of 
ticagrelor on NO metabolites 
In comparing patients on chronic ticagrelor therapy (90mg bid) to patients receiving an acute 
loading dose of ticagrelor (180mg) we observed the following changes in NO metabolites.  
Plasma RSNO levels (35.41 nmol/l ± 27) at 2 hours post ingestion of a loading dose of 
ticagrelor (180mg) were significantly higher (P=0.0043) compared with patients on chronic 
Ticagrelor therapy (17.07 nmol/L ± 7) (90mg BD). The RSNO levels on chronic therapy were 
not significantly different compared with the baseline levels (23.59 nmol/L ± 16) in the acute 
loading group (Figure 3.58 a).  
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Figure 3.58: Mean RSNO (a), Nitrite(b), and Nitrate (c) levels at baseline, 2 hours post ticagrelor loading of 180mg 
and chronic ticagrelor therapy (CT), which is measured at two hours after intake of regular dose of 90mg of 
Ticagrelor 
Plasma nitrite levels (268.8 nmol/L ± 63) were marginally higher in chronic Ticagrelor patients 
in comparison to levels at baseline (217.7 nmol/L ± 25)  and at 2 hours post ingestion (211.1 
nmol/L ± 24)  of an acute loading dose, however this was not statically significant (P= 0.45) 
(Figure 3.58b).   
Plasma nitrate level was unchanged in patients receiving chronic ticagrelor therapy when 
compared to patients at baseline and 2-hour post-acute loading of ticagrelor (Figure 3.58c). 
The mean nitrate levels were 30.44 µmol/L, 28.8, and 31.54 at baseline, 2hour post-acute 
ticagrelor loading and in chronic ticagrelor therapy patients, respectively, there was no 
statistical significance established between the results (p=0.20). 
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 Effect of acute ticagrelor loading on platelet aggregation 
MEA confirmed a mean platelet response to ADP of 659 (±53.6) AU*min before loading with 
Ticagrelor and a mean of 168 (± 14.9) AU*min 2 hours following administration (p<0.0001) 
(Figure 3.59). Platelet response to TRAP was 1024 (±47.2) AU*min at baseline and 874 
(±59.5) AU*min following Ticagrelor (p<0.0002) (Figure 3.60)
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Figure 3.59:  Representing individual and group data on the change in platelet reactivity to ADP comparing 0 hr 
(0-ADP) to 2 hr (2-ADP) post ingestion of ticagrelor, measured in AU*min. A paired T test was applied with values 
are presented as mean with SEM,  
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Figure 3.60: Representing individual and group data on the change in platelet reactivity to TRAP comparing 0 hr 
(0-TRAP) to 2 hr (2-TRAP) post ingestion of ticagrelor, measured in AU*min. A paired T test was applied with 
values are presented as mean with SEM. 
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 Comparative effects of acute post ticagrelor loading therapy and chronic 
ticagrelor therapy on platelet aggregation 
Mean ADP response was 168.8 (±72.92) AU*min 2 hours following a ticagrelor loading dose 
(180mg) which was not significantly changed at 212.6 (+/-99.44) AU*min) in patients after 
chronic therapy of 90mg twice daily (p=0.09) (Figure 3.61). Similarly, the mean TRAP 
response was 874.9 ± 59.53 AU*min 2 hours following a ticagrelor loading dose (180mg) 
which was higher (1024 ± 57.17 AU*min (p=0.0789)) after chronic therapy (Figure 3.62).  
ADP
0-ADP (TL) 2-ADP (TL) ADP (CT)
0
200
400
600
800 ***
ns
Ag
gr
eg
at
io
n 
re
sp
on
se
 to
 A
DP
 (A
U*
m
in
)
 
Figure 3.61: Mean platelet aggregation response to ADP at 2 hours post ticagrelor loading (TL) and Mean platelet 
aggregation response to ADP with chronic ticagrelor therapy (CT), which is measure approximately two hours 
after intake of regular dose of ticagrelor. One-way ANOVA test of significance was applied. 
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Figure 3.62:  Mean platelet aggregation response to TRAP at 2 hours post ticagrelor loading of 180mg and 
chronic ticagrelor therapy (CT), which is measure approximately two hours after intake of regular dose of 90mg 
of Ticagrelor, One way ANOVA test of significance was applied. 
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 The effect of ticagrelor therapy on platelet reactivity with or without a 
proton pump inhibitor 
3.4.4.6.1 Effect of acute ticagrelor loading on platelet reactivity with or without a proton 
pump inhibitor 
When differentiating the acute ticagrelor loading group into those taking a proton pump 
inhibitor (n=16) compared to those not (n=10), (Figure 3.63 a&b) using Mann-Whitney test, 
there was no significant impact on platelet reactivity to ADP with or without concomitant PPI 
therapy at 2 hours post ingestion (Median of 164 vs 187, Mann-Whitney U =59.50, n1 =16, n2 
=10, P=0.89) (Figure 3.63a)  
Similar outcomes were also seen in the platelet aggregation responses to TRAP with or 
without a PPI with a mean of 865.8 ±284 on a PPI and 893.1 ± 286.7 AU*min not taking a PPI 
at 2 hours. Using unpaired t test, there was a non-statically significant change (p=0.81) in 
response to TRAP-induced aggregation with mean difference of -27.5±115 with 95% 
confidence interval of -264.6-209.9 (Figure 3.63b). 
ADP
PPI No PPI
0
200
400
600
a
ns
Ticagrelor loadingA
gg
reg
atio
n r
esp
on
se 
to 
AD
P (
AU
*m
in) TRAP
PPI  NO PPI
0
50
100
150
200
250
b
ns
Ticagrelor loadingA
gg
reg
ati
on
 re
sp
on
se
 to
 TR
AP
 (A
U*
mi
n)
ADP
PPI No PPI
0
100
200
300
400
c
ns
Chronic TicagrelorA
gg
reg
ati
on
 re
sp
on
se 
to 
AD
P (
AU
*m
in) TRAP
PPI No PPI
0
500
1000
1500
d
ns
Chronic TicagrelorA
gg
reg
ati
on
 re
sp
on
se 
to 
AD
P (
AU
*m
in)
 
Figure 3.63: ADP and TRAP induced platelet aggregation with or without PPI in ticagrelor loading and chronic 
ticagrelor therapy. (a) & (b) ADP and TRAP response in acute ticagrelor loading respectively, (c) & (d) ADP and 
TRAP response in chronic ticagrelor therapy respectively. 
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3.4.4.6.2 Effect of chronic ticagrelor loading on platelet reactivity with or without a 
proton pump inhibitor 
Similarly, in the chronic ticagrelor group, upon differentiation into those taking a proton pump 
inhibitor (n=6) compared to those not (n=8), (Figure 3.63c &d) using Mann-Whitney test, there 
was no significant impact on platelet reactivity to ADP with or without concomitant PPI therapy 
(Median of 221 vs 183, Mann-Whitney U =18, n1 =6, n2 =8, P=0.49) (Figure 3.63) 
The mean of platelet aggregation responses to TRAP with or without a PPI was 1096 ±258 on 
a PPI and 910.6 ± 218.5 AU*min respectively. Using unpaired t test, there was also no 
statically significant change (p=0.17) in response to TRAP-induced aggregation with mean 
difference of 185±127 with 95% confidence interval of –91.9 to 463.3 (Figure 3.63 d). 
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Figure 3.64:  comparative graphs of Plasma RSNO levels measure at 2 hours post Ticagrelor loading between 
patients on PPI and not on PPI (a) and similar comparison in patients on chronic Ticagrelor (b). 
There was a consistent rise in plasma R-SNO in patients with or without concomitant PPI 
therapy [(∆11.37±5.2 nmol/L (p=0.0422) with a PPI vs ∆7.4±5.3 nmol/L (p=0.0197) without 
PPI (p=ns between groups)] (Figure 3.64a) in the ticagrelor loading group. There was no 
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statistical significance difference in the levels of RSNO (∆13.44±5.2 nmol/L vs ∆18.62±5.7 
nmol/L (P=ns)) with or without PPI (Figure 3.64b). 
 
3.4.5 Summary 
 Ticagrelor has an ability to form drug-SNO in an acidic environment in the presence of 
nitrite, despite the lack of a free thiol group in its original chemical structure.   
 
 There is a higher proportion of ticagrelor SNO formed with higher dose of nitrite 
compared with low dose nitrite 
 
 Ticagrelor is a potent antiplatelet drug suggested by a significant ADP and TRAP 
mediated platelet inhibition with loading dose. 
 
 There is a significant increase in plasma RSNO post ingestion of 180mg of Ticagrelor 
 
 There is no effect of concomitant PPI therapy on platelet inhibition or NO metabolites 
with acute ticagrelor loading or chronic ticagrelor therapy. 
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4 Discussion  
The focus of this thesis is on the comprehensive evaluation of the influence of dietary nitrate 
supplementation and clopidogrel therapy on NO metabolites and platelet aggregation in 
patients with known stable CAD. The initial portion of study focused on understanding the 
detailed role of nitrate reductase enzyme, and the process of nitrate-nitrite-RSNO-NO cycle 
with respect to the dietary nitrate supplement and antiplatelet drug interaction under laboratory 
settings. This part of the study complemented the second part of the thesis involving a 
placebo-controlled, cross over trial in stable CAD patients where the NO metabolites and 
platelet aggregation response were measured following intake of the same dietary nitrate 
supplement. Thirdly, this thesis for the first time explores the effects of co-administration of 
clopidogrel and dietary nitrate supplement in CAD with emphasis on the RSNO formation and 
platelet inhibition. Additionally, my studies identified the ability of ticagrelor, a non-
thienopyridine antiplatelet agent to form RSNO directly in patients. 
CVD is associated with endothelial dysfunction with impaired NO bioavailability. The 
cardiovascular role(s) of NO have been well described in numerous published articles since 
its discovery in 1980. It is a vital signalling molecule in maintaining vascular homeostasis and 
a healthy cardiovascular system. It acts as a primary substrate for the sGC enzyme mediated 
vasomodulation and inhibition of platelet aggregation with thrombus formation.  Reduced 
bioavailability of NO as seen in patients with CAD is associated with endothelial dysfunction, 
results in vasoconstriction, thrombosis, inflammation and vascular hypertrophy. A drug or 
molecule capable of delivering NO or augmenting NO levels in these patients therefore has a 
clear therapeutic benefit.  
Dietary sources of inorganic nitrate are a subject of major interest in research because of their 
potential role in promoting cardiovascular health.  Discovery of the nitrate-nitrite-NO pathway 
as an alternate and promising process to replenish NO levels in tissues has opened a new 
avenue of research in the area of using dietary nitrate supplements as NO augmenting 
therapies, and there are numerous studies published exploring their preventive and 
therapeutic potential. 
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It is now well established that the cardio protective effect of a fruit and vegetable rich diet is 
attributed largely to their nitrate content, with orally ingested nitrate now a well-established 
exogenous source of nitrite.  
 
4.1 In vitro experiment of Nitrate-Nitrite-RSNO(Clopidogrel-SNO) 
formation. 
Nitrite is formed through the reduction of nitrate present in the dietary supplement via the 
reduction by NR. Facultative anaerobes present in the oral cavity and GI tract facilitates this 
conversion via NR. The in vitro study of this process of enzymatic conversion of nitrate to 
nitrite and its subsequent NO and RSNO formation under controlled laboratory conditions 
provides a valuable model in which to gain better insight into the process of dietary nitrate 
metabolism and kinetics in patients.  
Enzyme mixes containing NR derived from E Coli facilitated a maximal (~96%) nitrate to nitrite 
conversion from laboratory grade sodium nitrate in preliminary experiments, however upon 
adopting the same mix with NR from A Niger (due to cessation of commercial availability) 
yielded only a 8.8% conversion. The initial cofactor concentration was modified and tested at 
different ratios.  At 1000 µM of NADPH and 160 µM of G6PD in the enzyme mix, a significantly 
enhanced reductive potential of NR was established (100 µM of NADPH and 16 µM of G6PD). 
NADPH acts as an essential electron donor for this reaction and G6PD acts to scavenge 
NADP+ and regenerate NADPH. Enhanced NADPH amplified the nitrate reduction process 
and simultaneously an increased NADPH in the enzyme mix requires heightened levels of 
G6PD to maintain a high NADPH/NADP+ ratio thereby facilitating the enzyme kinetics (296-
298). 
In vitro experiments showed that the nitrite generation is dependent on the sodium nitrate salt 
concentration, suggesting increasing nitrate enhances NR’s turnover of the substrate. The 
reduction efficacy of NR enhances up to >90% (NR concentration was constant in each 
sample) at high concentration. The capacity for NR to reduce nitrate eventually reaches its 
maximum and a plateau was reached. In vivo, nitrite concentration in saliva positively 
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correlates with increased dietary nitrate (299), implying the capacity of the bacterial NR system 
in humans is unlikely exceeded. 
In the oral cavity, nitrate reduction occurs on the dorsum of the tongue in an aqueous solution, 
facilitated by the colonizing bacteria. In vivo only ~20% of salivary nitrate is reduced (5% of 
ingested nitrate) to nitrite by anaerobic oral bacteria. A significant amount of nitrate remains 
unreduced(299), due to a short transit time of the ingested nitrate in the oral cavity and rapid 
transfer of the majority of nitrate through the alimentary canal. Nevertheless, significant levels 
of nitrate are accumulated in the salivary glands where NR can reduce the available nitrate to 
nitrite. The in vitro model showed a maximum nitrate accumulation occurred at 45 minutes 
and although nitrate reduction occurs within minutes, this implies nitrate reduction may be a 
relatively slow process. 
Nitrate contained within SIS® Go+ nitrate gel and Beet It® was inefficiently converted to nitrite 
when in its original form with this model. SIS® Go+ nitrate gel is a viscous gel-like solution of 
an array of ingredients (Table 3.1.4).  Beet It®, despite being a thin liquid composed of pressed 
organic beetroot and apple juice had a similar property of not being reduced to nitrite. 
Regardless of their consistencies, nitrate ion contained in the SIS® Go+ nitrate gel and Beet 
It® was not freely accessible for NR. Progressive dilution improved the conversion of nitrate 
to nitrate.  A possible explanation for this is that the nitrate molecules present within the gel 
are physically bound to an ingredient in the gel or vegetable extract in the juice such that only 
a modest component of nitrate is available to the enzyme, which potentially may also block 
the binding of nitrate and the active site of NR. Diluting the original supplements may have 
overcome this blockage, facilitating the diffusion of the nitrate through the gel or vegetable 
extract to bind to the active site of NR. There may also be a strong cross-linked pore, limiting 
the anions mobility and interaction. Dilution of the supplements possibly caused a strong 
electrostatic matrix interaction(300) and hydrodynamic forces(301) that encourage enzymes 
and substrates to move towards one another, thus potentially explaining increased reduction 
efficacy The SIS® Go+ nitrate gel and SIS® Go+ placebo gel had identical ingredients except 
for nitrate. We found insufficient nitrate to nitrite conversion by NR when known amounts of 
laboratory grade sodium nitrate was added to the placebo gel. This confirms under laboratory 
condition components of the gel either prevent or limit nitrate reduction from taking place or 
prevent the availability of nitrate present in swiss chard.  
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A further testing of the second cycle of the entero-salivary Nitrate-nitrite-NO cycle, which is 
the 2 hours after ingestion of the SIS® Go+ nitrate gel, nitrate is accumulated in the blood 
stream via absorption from the intestinal tract and there is active sequestration of nitrate by 
the salivary glands,  The commensal bacteria present in the oral cavity converts the nitrate to 
nitrite via NR and the majority of this is swallowed forming the main source of nitrite in the 
acidic gastric environment (302). This nitrite, upon entering the gastric cavity encounters thiol 
groups on gastric proteins and possibly other thiol containing molecules like thienopyridines 
(clopidogrel) allowing nitrosation to occur.  
RSNO formation occurs in acidic gastric medium in the presence of nitrite. In vitro, SGF has 
no background nitrite, hence there was no RSNO measured in the gastric medium or mixture 
of the SIS® Go+ nitrate and SGF.  The nitrite which is converted from SIS® Go+ nitrate by 
NR does form RSNO when mixed in SGF suggesting that the thiol groups on gastric proteins 
are readily subject to nitrosation and create RSNO(157, 303). 
There was a greater percentage of RSNO generated from nitrite converted within SIS® Go+ 
nitrate gel, compared to that converted from sodium nitrate.  This is an interesting finding 
which indicates that adjuvant ingredients in the swiss chard gel exhibit additional free thiol 
groups that can bind nitrite and form RSNO.  There is also a transnitrosation reaction between 
proteins in the gastric juice and/or ingredients in the gel. This is a measure of total RSNO, and 
it is not possible to categorize individual types of RSNO.  
The presence clopidogrel tablets (75mg or 600mg) did not affect the RSNO yield in gastric 
medium with nitrite derived from SIS® Go+ nitrate. The possible explanation for this is that the 
amount of nitrite generated from diluted SIS® Go+ nitrate gel was minimal (43.75 μM) which 
is 20 times less than Bundhoo et al. recommended.   An estimate of more than 10mM of nitrite 
is need for detectable clopidogrel-RSNO generation, and it is dependent on the quantity of 
background nitrite (133) (79). The inability of nitrate present in the undiluted SIS® Go+ nitrate 
gel to be converted to nitrite was a major hurdle, that need to be addressed in future 
experiments. 
In vitro experiments (Chapter 3 results 1) demonstrated a need for an optimum mixture of co-
factors such as NADP, G6PD and A Niger derived nitrate reductase in order to efficiently 
convert nitrate to nitrite. The dietary nitrate supplement (SIS® Go+ nitrate gel) tested in this 
thesis required significant dilution prior to its reduction demonstrating that the supplement in 
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its original form is not able interact instantaneously with nitrate reductase (NR) enzyme derived 
from bacterial commensals under laboratory conditions. This implies that in vivo, nitrate 
present in the supplements first needs absorption into the blood stream, then is actively 
concentrated in the salivary glands and subsequently the nitrate rich saliva in the mouth 
interacts with bacterial NR for conversion of nitrate to nitrite to take place. This then 
subsequently can enter the alimentary canal, be absorbed into the circulation, or interact with 
protein and other components contained within the stomach. This is confirmed by our studies 
in CAD patients where we observed a mean rise of nitrite level of 214nM following ingestion 
of dietary nitrate gel, confirming a functioning entero-salivary cycle. Interruption of this cycle 
would prevent nitrate reduction to nitrite and subsequent NO formation, as shown in 
experiments using antibacterial mouthwash and salivary spitting techniques (304).   
A successful in vitro model was established for the enzymatic reduction of nitrate from 
laboratory grade sodium nitrate, SIS® Go+ nitrate gel and Beet It® to nitrite catalysed by 
nitrate reductase from Aspergillus niger.  RSNO formation occurred within a simulated acidic 
gastric medium and in the presence of background nitrite. The ingredients within the gel, in its 
concentrated commercial form, limit the accessibility of nitrate anions for nitrate reductase to 
catalyse a reaction. Dilution of the gel with HPCL graded water overcomes this obstacle. 
Interestingly RSNO experiments suggested proteins within the gel exhibit thiol groups that 
enhance nitrosation with nitrite.  These products can also act as NO metabolite-delivery 
vehicles. This project gives significant insights into the understanding of nitrate-nitrite-RSNO-
NO cycle and understanding the results of my clinical research trial on the study of nitrate 
supplementation in patients on clopidogrel therapy. 
4.2 Dietary nitrate supplementation in stable CAD patients 
Dietary nitrate supplementation in healthy volunteers and hypertensive subjects is known to 
exhibit a vasodilatory  effect, significant blood pressure reduction and noticeable antiplatelet 
effect (226, 236, 248, 305).  Little was known regarding their use in humans with established 
CAD who are known to have impaired endogenous NO levels associated with endothelial 
dysfunction.  
Clopidogrel is the most commonly prescribed P2Y12 receptor blocking antiplatelet drug across 
the globe. It is utilised with aspirin in patients with acute coronary syndrome and in most 
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patients undergoing PCI. Clopidogrel still remains the number one choice of antiplatelet 
therapy in this group of patients despite the availability of newer and more potent antiplatelet 
agents like ticagrelor and prasugrel. This could be explained due to an established trust and 
experience of its use by clinicians for more than 15 years, along with being a cost effective 
P2Y12 blocker.  It is also prescribed in patients with cerebrovascular and peripheral vascular 
disease and it has a proven, long-standing record of efficacy and safety in a wide variety of 
patients. Despite having universal acceptability, it has its own limitations, mainly variability in 
antiplatelet response and interaction with other commonly prescribed drugs such as PPI and 
calcium channel blockers.  
In our research group, Bundhoo et al conducted in vitro experiments leading up to this thesis 
and showed that clopidogrel has P2Y12 independent modes of action. It has an ability to 
actively form RSNOs in its original inactive prodrug form when in the presence of inorganic 
nitrite and in an acidic environment.  
However, initial in vivo studies by our group in CAD patients did not find a significant rise in 
the overall plasma RSNO with clopidogrel loading (600mg) or maintenance therapy (75mg 
daily). This could be explained by insufficient RSNO formation above baseline with 
physiological levels of nitrite (100-200nM), such that these RSNO concentrations would be 
close to the detectable limit by OBC. We therefore hypothesized in vivo RSNO formation could 
potentially be enhanced following elevation of nitrate and nitrite in the acidic stomach milieu 
when given exogenous nitrate.  Indeed, this is the first study which shows that administration 
of a single dose of dietary nitrate supplement along with clopidogrel therapy results in 
significant increase in the plasma NO metabolites, particularly RSNO, at 2 hours in patients 
with stable CAD.  
The baseline levels of plasma nitrate before the nitrate or placebo gel supplementation was 
29.93 ± 1.41 µmol/L & 31.27±2.29 µmol/L respectively. These values are similar to the plasma 
nitrate levels measured previously in healthy volunteers in our laboratory using OBC(306). 
Basal nitrate production from endogenous sources is in the range from 1.2 to 2mmol/per day 
whereas the dietary nitrate intake contributes from 75-150mmol/day. The amount of nitrate 
measured in plasma or urine is therefore significantly influenced by the diet. Patients in our 
group were fasting for > 6 hours, limiting the influence of recent dietary intake on the measured 
plasma nitrate values.  
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There was a noticeably lower level of basal plasma nitrite measured in this patient group prior 
to intake of the supplement on both occasions of the study (nitrate (175.3 ±13.94nM) and 
placebo gel  (194.1±17.8 nM)) compared with the values typically observed in healthy 
individuals (200-300 nM) which we have reported previously (28). 
Previously, Kehmeier et al., had shown similar lower levels of whole blood nitrite in patients 
with myocardial infarction(167). The findings of low levels of nitrite in CAD patients may reflect 
and supports the concept of reduced systemic NO bioavailability and prevalence of endothelial 
dysfunction in CAD patients.  
Supplementation of SIS® Go+ nitrate gel caused a 10-fold rise (29.93 µM to 291.49 µM) in 
the circulating levels of nitrate, indicating that the nitrate content within the gel is efficiently 
absorbed from the gut, entering the blood stream. The plasma nitrite level rose by 2.3-fold 
from baseline (175nM to 391nM), confirming an active conversion of a proportion of the 
ingested nitrate to nitrite via an intact entero-salivary circulation. The observed rise in nitrite 
level with SIS® Go+ nitrate gel (9.6 mmol nitrate dose) in CAD patients is marginally higher in 
comparison (3-fold vs 1.6-fold), with intake of beetroot juice (5.5mmol nitrate dose) in healthy 
volunteers.  This difference in rise in the nitrite levels is difficult to assess because this could 
be due to use of gel versus beetroot concentrate or the fact our study was in CAD patient vs 
previous studies in Healthy volunteers. It may be also be implied that CAD patients have 
efficient nitrate to nitrite conversion when compare to healthy volunteers. Nitrite can also 
mediate its effects directly (307) without need for conversion to NO, or indirectly through the 
production of SNO (308) or nitroso-fatty acids(309). Impaired platelet response to NO is a 
known characteristic of many cardiovascular disease, chircov et al in 2013 demonstrated that 
nitroxyl by its virtue of not being inactivated by ROS, does induce platelet inhibition in platelet 
NO resistance subject(310). Madhani et al group recently showed that nitrite overcomes the 
platelet resistance in patients with heart failure preserved ejection fraction and chronic AF and. 
NO scavenging agents failed to revert the platelet inhibitor effect of high concentration of 
nitrite, indicating a NO independent effect of nitrite on platelet inhibition(213). An exponential 
rise in the level of nitrite upon ingestion of the SIS® Go+ nitrate gel in this study should 
augment platelet inhibition independent of its NO donor property. It can also be postulated that 
this effects are mediated by a s-nitrosation or s-thiolation.    
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My study demonstrates a significant increase in RSNO levels in all groups (CAD only, Group 
A (clopidogrel 600mg) and Group B (Clopidogrel 75mg) following dietary nitrate 
supplementation, confirms that enhanced nitrite levels facilitates S-nitrosation and s-thiolation, 
hence enhanced formation of RSNO.  This effect is not seen in CAD patients who were on 
regular oral organic nitrate medication (ISMN, ISDN) suggesting that dietary nitrates have a 
high bioavailability, and an intrinsic potential to form RSNO (137). This is a significant positive 
feature, along with other known advantages of dietary nitrate and nitrite, compared to the 
negatives associated with organic nitrate therapies, for example, nitrate tolerance and high 
first past metabolism. 
RSNOs are more stable and exhibit longer half-life than NO. They actively undergo 
transnitrosation reactions, participating in potential post-translational mechanisms of 
modification of protein and enzyme activity. RSNO are NO donors, with an additional 
characteristic of direct binding to sGC there by facilitating antiplatelet and antithrombotic 
effects (177, 187). The ability of nitrite to overcome platelet resistance in CVD could be 
potentially due to RSNO formation via nitrate-nitrite-RSNO-NO axis. 
Parental GSNO infusion has shown a highly platelet selective effect with an inhibition of 
platelet activation with GSNO infusion 10 minutes before PCI and a resulting decrease in stent 
thrombosis (190). In a similar way, enhanced RSNO formed with dietary nitrate 
supplementation within 2 hours could potentially offer synergistic platelet inhibition along with 
antiplatelet drugs in patients undergoing PCI and therefore has clinical relevance. The patients 
in this research study are ideal as they are all listed for elective PCI and require optimum 
platelet inhibition prior to prevent thrombosis following implantation of stents. These findings 
make a strong case for future research projects that are specifically designed and adequately 
powered to address the potential longer-term benefits of dietary nitrate on clinical outcomes 
like stent thrombosis and myocardial infarction in a similar patient cohort.  
It was not possible to differentiate the sub-types of RSNO in the plasma in this study. The 
majority of RSNO are protein bound and a small portion are from non-protein thiol containing 
molecules(133).  The total amount of RSNO measured here is a composite of all RSNO 
species present in plasma at a given time. A specific quantification of the amount of 
Clopidogrel-SNO formed was not possible because of its transnitrosation reactions, platelet 
sequestration and its metabolism to several oxidative products.  Indirect evidence of possible 
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Clopidogrel-SNO formation is derived from a comparison of the amount of RSNO formed in 
patients with CAD only compared to patients with CAD on clopidogrel therapy, however only 
a marginal increase in RSNO was observed that was not statistically significant (6.7nM in 
Group A & 3.4nM in Group B). Interestingly patients who had a loading dose of Clopidogrel 
(600mg) formed numerical higher amounts of RSNO compared to those receiving 75mg daily, 
which could be explained by Clopidogrel-SNO formation. However, this study was not 
adequately powered to test this finding.  
Despite an intrinsic ability of clopidogrel prodrug to form RSNO as shown in in vitro studies, 
there was no rise in RSNO level in patients on clopidogrel only therapy (placebo group), 
suggesting further increases in nitrate/nitrite may be required for formation of noticeable 
clopidogrel-SNO. This might be explained by the relative low levels of baseline nitrite found in 
patients with CAD due to impaired NO synthesis/increased inactivation of NO. Interestingly in 
the active nitrate group, there was no significant rise in the RSNO levels in CAD patients with 
intake of either a loading dose of clopidogrel (600mg) or a long-term maintenance clopidogrel 
(75mg). This was also evidenced in my in vitro experiments described in chapter 3 where 
small amounts of converted nitrite from SIS go+ gel failed to produce significantly more 
clopidogrel-SNO and is in close agreement with the findings of Dr Bundhoo  previously (133).  
A study on prasugrel loading therapy (60mg) in a similar cohort of patients undertaken 
concomitantly by a colleague in our laboratory showed a significant rise in RSNO levels at 
physiological levels of nitrite/nitrate (i.e. without dietary nitrate supplementation), suggesting 
that prasugrel exhibits a greater capacity for formation of RSNO (109). This is certainly in line 
with in vitro studies and is an interesting observation, in that enhanced Prasugrel associated 
RSNO formation hypothetically could be one of the reasons for greater platelet inhibition with 
prasugrel therapy compared to clopidogrel therapy as observed clinically in patients - this 
warrant further investigation. 
This study demonstrates that dietary nitrate supplement actively increases circulation nitrate-
nitrite and RSNO levels, via the Nitrate-Nitrite-NO pathway and, thereby replenishes the 
depleted NO pool in CAD, which is associated with endothelial dysfunction. 
Previous studies by Ingram et al from our research group have demonstrated than an acute 
increase of nitrite levels as little as 200nM is associated with an improvement in myocardial 
ischaemia and can induce localised vasodilation under hypoxia, as observed in CAD patients 
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(311). The elevated nitrite level can protect against the ischaemia reperfusion injury, especially 
in patients have acute arterial occlusion in myocardial infarction or stroke. The findings of 
elevated nitrite and RSNO in this thesis could hypothetical minimise myocardial 
injury/ischaemia caused by transient coronary arterial occlusions during balloon dilation and 
stent implantations in SCAD patients who are undergoing complex coronary intervention. In 
this study, post procedural measurement of CK or Troponin (markers of myocardial injury) was 
not performed, limiting the evaluation of this effect.  
ADP and thrombin activate platelets by binding to the cell surface P2Y12 receptor and the 
protease activated receptor (PAR) respectively, causing an intracellular influx of calcium 
stores from the sarcoplasmic reticulum, resulting in a series of secondary reactions causing 
platelet aggregation. A key secondary reaction is the activation of the phosphoinositide 3 
kinase pathway (PI3K) which plays a crucial role in the cytoskeletal reorganisation of activated 
platelets. The PI3K pathway is directly activated via TRAP (312, 313). RSNO by virtue of being 
a NO donor, directly inhibits the activation of P13K pathway and activates sGC causing an 
inhibition of intracellular calcium influx thereby inhibiting platelet aggregation.  
Interestingly we did observe an overall increase in platelet reactivity with the ADP and TRAP 
agonists, from baseline to 2 hours measured at both intervention points in stable CAD patients 
not on clopidogrel therapy. This is potentially explained by the naturally occurring diurnal 
variation in the platelet reactivity in humans. We did not account for this in our studies which 
were largely undertaken at the beginning of the working day using a similar protocol/timeline. 
Ischemic events such as myocardial infarction and stroke tend to occur more often in the 
mornings than at other times (314-316) and this has been attributed to the increase in platelet 
aggregation, platelet count, haematocrit and catecholamine in the morning.  It is also linked 
with physical activity after waking up (317, 318). There was a non-statistically significance in 
the change in platelet reactivity to ADP or TRAP upon administration of the dietary nitrate 
supplement in this group of patients. 
The platelet aggregation to ADP following a loading dose of Clopidogrel (600mg) was 
significantly decreased following both nitrate gel and placebo, which is unsurprising due to the 
large dose of clopidogrel received, and this is consistent with other platelet function studies 
reported (319-321).  
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Importantly the platelet aggregation response to TRAP was significantly impaired with dietary 
nitrate supplementation therapy and not with placebo in patients given a loading dose of 
600mg of clopidogrel. It is well known that clopidogrel primarily acts via ADP associated P2Y12 
receptor mediated inhibition and theoretically has no effect on thrombin mediated inhibition. 
However, inhibition of TRAP mediated platelet activation by clopidogrel in patients with ACS 
was reported but the exact mechanism was not explained. 
It is worth noting that there was a significant correlation between rise in the RSNO level with 
the drop in TRAP mediated platelet reactivity found upon combining all the three patient 
groups who ingested dietary nitrate supplement.  This inverse correlation it taken to reflect a 
rise in RSNO levels dampens platelet activation. Diminishing platelet activation via a non-
ADP-receptor mediated mechanism would significantly benefit patients with CAD and 
especially those undergoing percutaneous coronary interventions.  Taking together the 
findings of this study and earlier in vitro evidence it is reasonable to hypothesize that the 
enhanced TRAP inhibition is due to RSNO formation, which in turn can be stored in platelets 
and can potentially directly inhibit the TRAP mediated aggregation (Figure 4.1) 
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Figure 4.1: Diagrammatic depiction of ADP (P2Y12) receptor and TRAP receptor (PAR) stimulation, resulting in 
increased intra cellular calcium causing a change in platelet shape and aggregation. The active Clopidogrel 
metabolite blocks the P2Y12 receptor and RSNO can inhibit platelet activation via P2Y12 independent mechanisms 
via donation of NO resulting in activation of sGC, and via a direct action on PI3K receptors. (-ve represents a 
negative effect) 
Conversely, there was no statistically significant effect of dietary nitrate therapy on overall 
platelet reactivity against ADP or TRAP in patients receiving chronic clopidogrel therapy 
(Group B). This could be due to reduced amount of RSNO formed in this group or, intra-
individual variation and underpowering of the study. 
Interestingly, there is a trend towards numerically higher platelet inhibition in both Group A 
(clopidogrel 600mg) (ADP: -352 Vs -327 & TRAP: -123 vs -105) and Group B (ADP: -119 Vs 
6 & TRAP: -37 vs -36) patients given a dietary nitrate supplement.  This does strengthen the 
hypothesis that dietary nitrate supplementation with clopidogrel therapy could facilitate 
additional platelet inhibition through augmenting NO metabolites (RSNO) which is P2Y12 
independent, and this will need to be addressed in studies with greater patient numbers in 
each patient group.  
It was anticipated that a rise in RSNO level should translate into a decrease in platelet 
responsiveness in individual groups. The lack of a statistically significant response could be 
due to several potential reasons. This may be due to a relatively small number of patients, as 
the study was not primarily powered for measuring a change in platelet reactivity.  
There were multiple independent variables in the study cohort, which could potentially impact 
on the baseline platelet reactivity and its response to dietary nitrates. The placebo control 
study design was employed to limit these confounding effects and there were no significant 
difference in the variables such as diabetes, hypertension, smoking between the active group 
and placebo group (Table 3.12, Table 3.14 & Table 3.17 ). Despite this, these factors may still 
have influenced the outcome, especially diabetes.  
There were noticeably number of diabetic patients recruited in this study, which are in line with 
the everyday clinical practice. A combined total of 13 and 8 patients with diabetes enrolled in 
nitrate supplement and placebo arms, respectively. They were all type 2 diabetics, with the 
majority on oral anti diabetic medication (Table 4.1). 
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Table 4.1: Summary of patients with diabetes enrolled in the study. The clopidogrel Naive study was a paired 
study hence had 1 patient in both arms. 
It is well known that in diabetic patients hyperglycaemia leads to oxidative stress, via 
production of advance glycation end products, enhanced polyol protein kinase C and 
hexosamine pathways, leading to aberrant NADPH oxidases (NOX) activation contributing to 
uncoupling of eNOS and endothelial dysfunction(322). NOX activity is significantly increased 
in both type 1 diabetic and type 2 diabetics(323). The excessive ROS scavenges NO, further 
reducing its bioavailability. A significant association between type 2 diabetes and eNOS gene 
polymorphisms is also known suggesting a link in NO production and insulin resistance states 
(324, 325). Type 2 diabetes has been associated with both increased and decreased level of 
circulating nitrate/nitrite  (326, 327). However, CAD patients with diabetes have typically 
shown a higher nitrate/nitrite level(328) which might be a compensatory response to elevated 
insulin and oxidative stress(329). 
Organic nitrate therapy has proven to be ineffective in patient with diabetes and metabolic 
syndrome due to its paradoxical ability of inducing endothelial dysfunction. It worsens the 
intrinsic impaired NO bioavailability and NO resistance seen in this group of patients. (330, 
331). Exogenous supplementation of dietary nitrate has great potential as a beneficial 
therapeutic intervention in type 2 diabetic patients, attributed to its ability to convert to nitric 
oxide. In vivo work on dietary nitrate conducted in animal models has shown promising results 
of improved fasting glucose levels, reduced insulin concentration, improved insulin signalling 
via restoration of NO dependent pathways(332, 333), enhanced antioxidant capacity, and 
Diabetic patient enrolled 
 
Nitrate gel Placebo gel 
 
Diet Oral Insulin Total Diet Oral Insuli
n 
Total 
Clopidogrel 
Naïve group 
(paired) 
0 1 
(7%) 
0 1 
(7%) 
0 1 
(7%) 
0 1 
(7%) 
Acute 
clopidogrel 
loading 
(unpaired) 
2 
(8%) 
5 
(19%) 
1 
(4%) 
8 
(31%) 
1 
(4%) 
4 
(17%) 
0 5 
(21%) 
Chronic 
clopidogrel 
therapy 
(unpaired) 
0 4 
(14%) 
0 4( 
14%) 
0 2 
(8%) 
0 2 
(8%) 
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protection against renal dysfunction(334). Human studies of high nitrate beetroot juice had no 
significant effect on insulin resistance, in type 2 diabetes(335) and no effect on postprandial 
plasma glucose and insulin levels in obese men(336). Dietary nitrate supplementation could 
improve vascular stiffness, and have other cardioprotective effects like anti-platelet activity, 
anti-inflammatory, hypolipidemic, improved flow in hypoxic and ischemic tissue(337-339). 
These effects are yet to be confirmed in diabetic patients(340).  
These studies were limited due to a short intervention period. The antiplatelet effect and blood 
pressure lowering effect seen in healthy volunteers would be mild in diabetic patients, due to 
the impaired metabolic pathways and NO resistance. The presence of numerically higher 
number of diabetic patients in the nitrate supplement arm might have attenuated the beneficial 
effect of dietary nitrate, though this is not definite as nitrite and theoretically RSNO could 
potentially overcome the nitrate resistance as shown in HFpEF patients. A further randomised 
study of large number of patients with and without diabetes would test this effect.  
The lack of antiplatelet effect could also be due to a relatively small effect of nitrate may be 
relatively small compared to the large inhibition found with clopidogrel itself, and this is further 
complicated by significant variation in the platelet responsiveness noted in this study. 22% (6 
out of 27) of patients in Group A (clopidogrel 600mg) were clopidogrel non-responsive 
[exhibited less than 10% inhibition of ADP mediated aggregation at 2 hours (341)] whereas 
36% (10 out of 28) had high on-treatment platelet reactivity [HPR, Multiplate ADP 
>468AUC(109)] in Group B (clopidogrel 75mg, chronic therapy) patients supplemented with 
dietary nitrate gel. This finding is consistent with the published data on clopidogrel resistance 
(342). There was a greater degree (-109 AUC vs -25 AUC) of platelet inhibition observed in 
patients who had higher platelet reactivity compared to those who were responsive which is a 
very interesting finding, which was also noticed in the GRAVITAS randomized trial (122) and 
this additional inhibition is possibly due to the clopidogrel-SNO formation and its effect as a 
NO donor. This hypothesis needs more exploration.  
Other possible explanation  could be due a  delayed platelet effect (beyond the period 
measured in this study), an augmented baseline platelet reactivity in CAD patients compared 
to healthy volunteers, or a dose effect where levels of nitrite achieved were not adequate to 
show a demonstrably significant(although we think this unlikely given that beneficial effects of 
exogenous nitrate administration have been observed using a similar dose). 
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This study demonstrates enhanced formation of NO metabolites with a noticeable trend 
towards the attenuation of platelet reactivity against ADP mediated platelet reactivity with 
supplementation of a single dose of nitrate supplement in patients with CAD. Importantly, it 
demonstrates for the first-time in vivo formation of circulating RSNO from exogenous nitrate, 
and when taking all patients, we confirm RSNO level attained is inversely associated with 
platelet reactivity. 
Exploring these pleiotropic effects of thienopyridines is where our group has focussed 
attention. This is a very novel and encouraging finding which encourages future studies to 
evaluate the option of using dietary nitrates, perhaps at elevated doses than used herein, as 
an alternative therapeutic option for attenuation of platelet reactivity and, thereby reducing 
thrombotic events in patients at high risk such as CAD and cerebrovascular disease.  
The clinical studies successfully demonstrate that in patients with established CAD, dietary 
NO3-nitrate gel (SIS® Go+) is absorbed at 2 hours into the blood stream and is reflected by a 
significant rise in the plasma nitrate levels measured 2 hours post ingestion. This clearly 
confirms an intact entero-salivary pathway, with active nitrate-nitrite-NO conversion in CAD 
patients, with clear evidence for a significant rise in plasma RSNO levels. There is no 
significant platelet inhibition observed but given the relative selectivity of RSNO for platelets, 
this might point the way forward to achieving therapeutic levels of circulating RSNO, and 
significant platelet inhibition. There was no placebo effect on the NO metabolites or ADP 
mediated platelet aggregation. 
 
4.3 Ticagrelor and NO metabolites 
Ticagrelor is a more potent antiplatelet in comparison with clopidogrel. Ticagrelor has shown 
pleiotropic effects which are independent of P2Y12 inhibition, which is not entirely explained.  
Ticagrelor’s ability to form Ticagrelor-SNO when mixed with nitrite salt, despite lacking a free 
thiol group, as demonstrated by Thornhill et.al in his in-vitro studies was a most intriguing 
finding. It can be postulated that some of the pleiotropic effects seen in early ticagrelor studies 
could be attributed to this feature.  
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In my in-vitro experiments, ticagrelor readily forms RSNO molecules in an acidic environment 
in the presence of nitrite, such as shown in artificial stomach medium, which is analogous to 
the human stomach. This appears over and above the amount of RSNO formed with proteins 
normally present in the stomach medium.  Ticagrelor-SNO formation was significantly 
augmented with increasing the nitrite level in the gastric medium. All these findings suggest 
that ticagrelor generates additional thiol substrate when dissolved in the acidic stomach milieu, 
thereby enhancing the formation of SNO with nitrite at both physiological and excess levels. 
RSNO compounds are known to be potent vasodilators and inhibitors of platelet aggregation.  
Combining these findings with earlier results of in vitro studies conducted by Thornhill et al 
raises the exciting possibility that the anticipated mode of action of ticagrelor via P2Y12 
receptor inhibition may not be as expected in vivo and is actually lost in the acidic condition 
(pH<3) of the stomach. It also follows the anti-platelet effect of ticagrelor in vivo relies upon 
the formation of Ticagrelor induced RSNO as an extremely potent antiplatelet agent. This may 
go some way to explaining the observation that proton pump inhibitors (via raising stomach 
pH) blunted the clinical effectiveness of this drug in the PLATO trial (258).  
Consistent with this hypothesis, the clinical study in this chapter interestingly showed a single 
180mg ticagrelor dose (without concomitant administration of exogenous nitrate) results in a 
significant rise in plasma RSNO at 2 hours in addition to a profound platelet inhibition in 
patients with stable CAD. There was a significant inhibition of both ADP and TRAP mediated 
platelet activation. The inhibition of TRAP mediated activation suggests a non-P2Y12 receptor 
effect, warranting further investigations and explanation.  These findings were consistent 
regardless of concomitant PPI therapy. This significant rise in plasma RSNO was however not 
maintained in patients during chronic ticagrelor use (90mg bid), and there was a modest 
accompanying rise in platelet reactivity compared with acute loading group. This may reflect 
a dose dependent change in platelet inhibition where a 180mg dose is given acutely whereas 
the chronic dose is 90mg daily. Other plasma NO metabolites (nitrite and nitrate) did not 
change with ticagrelor loading or during chronic therapy.  
Our in vitro data had shown that there was a pH dependent effect on formation of ticagrelor-
SNO (137, 257) . However in vivo clinical data appears to show no confounding effect of 
concomitant proton pump inhibitor with ticagrelor on acute RSNO formation., with a consistent 
elevation in plasma RSNO acutely in both groups (on versus off a PPI). There were however 
more subtle changes in other NO metabolites with a significant decrease of plasma nitrate 
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post loading dose in subjects not taking a PPI implying utilization (consumption) of nitrate in 
this cohort, and this aligns with the increase in RSNO levels in both groups. This data may not 
mimic the pH dependent effect of RSNO generation seen in vitro as PPI therapy in humans 
does not produce a consistent rise in stomach pH ; during any 24 hour period the stomach pH 
on PPI still varies between 2 and 6 (343) (344). Therefore although the patients are taking 
PPIs the stomach pH is likely to remain at  ~pH5, sufficient to support efficient RSNO formation 
as we  demonstrated in vitro (345).  
Our data also showed that PPI therapy had no effect on platelet inhibition after a Ticagrelor 
loading dose by either ADP or thrombin stimulation, despite recently published real life registry 
data demonstrating a tendency for higher risk of adverse events similar to that in the PLATO 
trial with concomitant use of Ticagrelor and PPI in ACS patients. However, the impact on 
clinical outcome was non-significant (346)  
The significance of acute elevation in RSNO after Ticagrelor loading doses remains unclear. 
This ability to generate RSNO is an unexpected discovery because Ticagrelor lacks a free 
thiol moiety. By implication, the formation of Ticagrelor-derived RSNO is dependent on 
liberation of the thiol group from within its structure, and although the mechanism of this 
remains unclear in vivo, it is likely that it becomes available following the breakdown of 
Ticagrelor in the acidic stomach environment. Typical gastric emptying half-life is 20-40 
minutes in patients, Ticagrelor is not protected from this harsh gastric environment by its waxy 
coating due to its rapid dissolution at all pH levels within 4 minutes(137). This is likely to be 
the case clinically and is potentially prolonged in patients with delayed gastric emptying, a 
feature seen in acute myocardial infarction(347). Conversely crushing Ticagrelor in humans 
would be expected to increase the ability of Ticagrelor to form RSNO in the acidic milieu in the 
stomach by increasing the availability of drug to proceed with chemical reaction. Indeed this 
approach has shown to increase the onset of platelet inhibition in patients (within the 1st hour) 
loaded with Ticagrelor in STEMI (348). 
The acute elevation in RSNO levels in CAD patients after Ticagrelor has many potential 
important consequences. RSNO, and therefore potentially Ticagrelor-SNO, can exhibit 
platelet anti-aggregatory properties similar to biologically occurring RSNOs like Glutathione-
SNO(133). There are 3 potential antiplatelet activity targets. Firstly, downstream dampening 
of the P2Y12 mediated activation pathway by activating soluble guanylate cyclase (sGC) 
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causing inhibition of intracellular calcium flux(254). Secondly, by acting as a source of NO, 
thrombin-induced platelet activation is decreased via direct inhibition of PI3K pathway 
activation by TRAP(255). This could be the likely mechanism for the inhibition of TRAP 
mediated activation, seen in patients loaded with ticagrelor.  The third target involves 
nitrosation reactions in platelets, specifically protein tyrosine residues of the COX1 enzyme 
which inhibit the conversion of arachidonic acid to thromboxane-A2(256). Activation of platelet 
sGC to produce cyclic guanosine monophosphate (cGMP) causes a fall in intracytoplasmic 
calcium levels, which inhibits platelet shape change and glycoprotein IIb/IIIa expression, but 
how much platelet inhibition mediated by NO donor compounds is cyclic GMP-dependent and 
how much is via cyclic GMP-independent pathways remains unclear(349).  
Nitroso-vasodilation can also occur with RSNO via NO (or more correctly, NO+) donation which 
can induce relaxation of vascular smooth muscle, mediated via classic sGC signal 
transduction. This phenomenon has been previously observed in patients as soon as 2 hours 
after a loading dose of clopidogrel with an increase in NO bioavailability and effective 
vasodilation, as reflected by higher levels of plasma nitrite and cGMP (254, 262).  
The demonstration of increased plasma RSNO with Ticagrelor loading may also be of 
relevance to some of the ‘pleiotropic’ effects shown recently in the microvascular circulation 
in patients where it augments adenosine induced microvascular vasodilation compared to 
placebo – an effect seen with the parent drug rather than the metabolite (350). 
Furthermore, in vitro studies show that Ticagrelor can inhibit P2Y12-mediated vasoconstriction 
in small human arteries (351).  
Once formed, the fate of ticagrelor induced RSNO in vivo is unclear. We have previously 
shown that clopidogrel derived nitrosothiols can participate in transnitrosation reactions with 
bovine and human albumin with the potential to shuttle around the human circulation (133). It 
has also been demonstrated that in patients following an oral dose of prasugrel, the rise in 
plasma RSNO measured is largely the result of protein based-SNO (albumin-SNO) which 
implies in vivo transfer and circulatory stability. The tissue effects of all RSNOs are largely 
determined by their ability to release NO, Localised platelet inhibition and nitro-vasodilatation 
are likely sequelae to nitrosothiols in vivo and this is the first demonstration of a freely available 
antiplatelet mediated rise in plasma levels seen in CAD patients.  
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A 180mg Ticagrelor dose results in a consistent and significant rise in plasma RSNO at 2 
hours in addition to a profound platelet inhibition in patients with stable CAD. These findings 
were consistent regardless of concomitant PPI therapy. Elevated levels of RSNO at the time 
of coronary intervention is likely to be responsible for some of the early putative pleiotropic 
effects of this medication seen in coronary and peripheral vasculature, in addition to its potent 
antiplatelet effect. However, these effects are not sustained and therefore may not contribute 
to the longer-term effects of Ticagrelor. 
4.4 Limitations to these studies 
In addition to the factors mentioned above, several important limitations and mitigating actions 
are considered. 
The measurement of NO metabolites via OBC method utilizing NOA is highly sensitive to 
atmospheric temperature and the cell pressure changes, which is subject to day-to-day 
variation. Maintenance of a steady temperature between -15 °C and -18 °C, the cell pressure 
of 102000 Pa and the supply pressure of 41000 Pa is essential. The baseline value can be 
altered with variation in these conditions, affecting the reproducibility of experiments. The 
equipment is kept in an air-conditioned laboratory at a set temperature, with regular checks of 
gas supply pressures to minimize variation. Daily calibration of the NOA was performed prior 
to experimentation and is further repeated at the end of the day.  An average of the two 
standards would more precisely account for changes in NOA sensitivity throughout the day 
(60). Importantly, change in baseline does not affect NOA sensitivity to given NO per se, and 
given that AUC is measured (as opposed peak height) these limitations can be considered 
negligible. 
There is the potential confounding effect of other additives present within the dietary gels, 
which could not be evaluated fully. There is evidence suggesting that folate improves NO-
dependent vasodilation and reverses endothelial dysfunction in vivo. Food preservatives such 
as benzoate and sorbate inhibit the growth of fungi and certain bacteria (85). Further 
biochemical tests to assess the pharmacologically active ingredients within the gel like citrate, 
folic acid, ascorbic acid and their effect on nitrite production would be very useful in future 
when considering use in patients. Nevertheless, these studies compared all results to a 
placebo control which was matched precisely.  
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The in vitro RSNO generation in presence of clopidogrel might have been enhanced if we 
could increase the amount of nitrite generated from SIS® Go+ nitrate. We were hampered by 
the lack of availability of commercial sources of NR and this limited the range of this study. 
Ours patient studies administering dietary nitrate evaluates the effect on NO metabolites and 
platelet aggregation at a single time point post ingestion (2hrs). There is a considerable intra- 
and inter-individual variation and diurnal variation in the circulating nitrate level and platelet 
reactivity(306). Despite patients being fasted more than 6 hours prior to the study, a residual 
effect of previous dietary intake might influence the measured metabolites. Therefore, a low 
nitrate diet for more than 4 days, and then applying a prolonged course of daily administration 
of nitrate might show a sustained effect on NO metabolites facilitating a greater (statistically 
significant) platelet inhibition. A strict diet and medication compliance chart would have been 
ideal for accurate evaluation of results and this was not undertaken. In previous studies we 
have shown a 12-hr nitrate free diet is sufficient to reduce plasma nitrate variation 
considerably, and we were keen in the present study not to affect the routine clinical care plan 
of the patient. Given that the baseline variation in plasma nitrate was not excessive and was 
in line with previous measures by our group following a nitrate limited diet, we believe this not 
to be a significant confounder in these studies. 
Even though there was a dampening effect of ADP and TRAP mediated aggregation in both 
groups with dietary nitrate therapy, statistical significance was not achieved. This could have 
been addressed more suitably if the patients/samples could have been paired, enhancing the 
power of the study. It was clinically and ethically not possible for achieving a paired sample 
approach in Group A, as this would mean giving a loading dose of 600mg of clopidogrel given 
on two separate occasions on two different days in the same individual. A paired sample could 
have been applied in Group B who are on a regular daily maintenance dose of 75mg of 
clopidogrel.   
A retrospective power analysis shows that in the order of 610 and 170 patients in each arm of 
Group A (clopidogrel loading) and Group B (clopidogrel 75mg) respectively would be required 
in order to demonstrate a significant difference of 5% based on the means and variance of 
ADP induced platelet aggregation we have measured. 
Numerous platelet activation markers have been described which could be measured using 
flow cytometry. A subgroup of patient (clopidogrel naive and Group B (clopidogrel 75mg)) from 
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my current study had undergone a further evaluation where blood samples were assessed for 
circulating plasma extracellular vesicles (EV) by Dr Burnley-hall as a part of his PhD work. 
Dietary nitrate supplementation in group B patients caused a significant reduction in the 
platelet derived EV, which is likely to be mediated by the concomitant increase in RSNO 
formation. This decrease in EV was associated with a reduction in platelet activation and 
platelet marker CD41. This effect was not seen in clopidogrel naïve patients(263). It was not 
practically feasible to extend these measurements to the other patient groups due to limitation 
in the time and requirement of additional assistance in running a test simultaneously to prevent 
sample degradation. This study was solely managed by me with a tight time frame. In 
retrospect, a measurement of other platelet activation markers such as P-selectin, cyclic GMP 
would have provided additional information to validate my hypothesis but due to above 
reasons was not feasible 
Although there was a consistent rise in plasma RSNO levels after a loading dose of ticagrelor 
we have not shown a direct correlation with the degree of platelet inhibition seen in each 
individual patient. This may be due to the swamping effect by the profound overall platelet 
inhibition seen with ticagrelor, where the influence of nitrate administration may have been 
masked. Furthermore, we have not undertaken detailed analysis (such as mass spectrometry) 
to 100% characterise the species of RSNO produced and whether this is ticagrelor-SNO or 
other circulating RSNO species. 
 
4.5 Future work: 
Future in vitro studies should investigate a method to increase the generation of nitrite from 
concentrated SIS® Go+ nitrate gel.  A modified experimental apparatus enabling it to hold 
larger volumes of diluted SIS® Go+ nitrate gel can be developed, thereby increasing the total 
nitrite concentration and promote clopidogrel-SNO formation. Another suggestion is to crush 
clopidogrel tablets prior to mixing with gastric medium for future work and evaluate the effect 
of coating on clopidogrel-SNO formation per se.  
The beneficial role of dietary nitrate supplementations in cardiovascular disease is well known. 
Overall, this study shows that dietary nitrate supplementation has the potential to enhance 
nitrosothiol metabolism and influence NO availability in patients with CAD.  This study 
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measured the effect of nitrate supplement on NO profile and assessed platelet reactivity at 
two hours post intervention. This study might be extended to include multiple sampling points 
following the ingestion of nitrate and clopidogrel in these patients to fully understand the exact 
kinetic interaction of these components. However, it was not practically possible to sample 
blood at multiple times in this group of patients as they were scheduled for a PCI procedure 
and would be administered with further anticoagulation as part of their routine clinical care 
which could confound the results.  Similarly, the trend towards augmented platelet inhibition 
at 2 hours post ingestion of nitrate with or without clopidogrel therapy, could be further 
explored to establish whether there would be further inhibition with time in CAD patients. 
Kapil et al had shown the antihypertensive effect of dietary nitrate supplementation upon 
administration for a prolonged period (4weeks) (237).  Expansion of these findings along with 
our results which showed a trend towards inhibition of platelet aggregation with a single intake 
of nitrate supplement suggests that long-term intake of regular nitrate supplement might 
augment platelet inhibition in CAD patients. Thus, future studies might focus on conducting a 
similar placebo-controlled study to assess the effect of these supplements and clopidogrel 
therapy in CAD patients for prolonged periods where one might also consider monitoring of 
dietary intake with specific focus on daily nitrate intake.   
This could present a feasible and acceptable therapeutic intervention especially in patients 
who are on clopidogrel therapy as it is well established that a large proportion of the patients 
are non-responders. It is crucial they are afforded optimum platelet inhibition for the prevention 
of adverse cardiac events. Regular intake of dietary nitrate along with clopidogrel could 
potentially enhance the platelet inhibitory efficacy of clopidogrel through formation of RSNO 
derivatives, thereby minimising the lack of classic response. 
The active concentration of nitrate within the salivary glands following the ingestion of these 
supplements could be quantified. A simple measure of salivary nitrate concentration and its 
correlation with the plasma nitrate would provide valuable information on the entero-salivary 
cycle and its influence on the net amount of circulatory NO metabolites.  This would be a very 
simple and useful test to apply in future studies.   
The vasomodulatory effect of dietary nitrate and clopidogrel therapy in CAD patients could be 
quantified with a quantitative controlled assessment (QCA) of coronary artery diameter using 
coronary angiographic images and a further simple test of forearm plethysmography and 
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arterial waveform (these reflecting local coronary versus systemic effects, respectively) 
Evaluation of coronary vasodilation following these supplements would be an ideal test of its 
beneficial effects, especially in patients undergoing coronary angioplasty. However, the QCA 
method of evaluation of coronary size is affected by the image quality and has an inherent 
subjective bias.  
A more comprehensive study of platelet activation to include markers such as EV, cyclic GMP, 
P-selectin and platelet macrophage aggregates would be useful in fully evaluating the 
antiplatelet effect of dietary nitrate in CAD patients.   
Prasugrel is the most potent antiplatelet of the thienopyridine class of drugs   It has shown a 
potential for RSNO formation at physiological concentration of nitrite both in-vitro and in vivo  
(137, 257).  It would very interesting to study the influence of concurrent intake of prasugrel 
and dietary nitrate supplementation on the NO metabolites and platelet inhibition. There is a 
possibility of further enhancing the pleiotropic benefits of decreased rates of MI in patients on 
prasugrel seen in the TRIOLOGY ACS-trial. However, care must be taken because inherent 
to Prasugrel treatment is the potential risk for harm due to increased risk of bleeding.  
The ability of ticagrelor to form RSNO despite lacking an available thiol is an unexpected and 
fascinating finding. In vitro experiments demonstrated an increase in ticagrelor-SNO formation 
with an increase in nitrate content. In vivo we observed a significant increase in circulating 
RSNO following nitrate administration. Therefore, it would be intriguing to study if this effect 
could be seen in patients when they were given a dietary supplement rich in nitrates.  
The laboratory studies clearly demonstrated the influence of pH on the formation of drug-SNO 
with clopidogrel, prasugrel and ticagrelor. However, in patient studies, there does not appear 
to be an effect of PPI on RSNO formation in patients given concomitant clopidogrel or 
ticagrelor. This could be due to multiple reasons as discussed in chapter 4, section 4.3. It 
would be useful if the actual gastric pH of the patients was measured and this could be 
correlated with the formation of RSNO in this group. However, it is practically very difficult to 
ascertain the gastric pH in patients. ACS patients on antiplatelet therapy, who are ventilated 
and have a nasogastric tube in-situ, could be an ideal group in whom to measure gastric pH 
and RSNO formation. This would be a very challenging study with practical and ethical issues 
to overcome.  
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5 Appendix 
5.1 Appendix I Research Ethical Approval Letter 
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5.2 Appendix II PATIENT INFORMATION LEAFLET 
 
1. Study Title 
 
Effects of Anti-platelet Drugs on Endothelial Dysfunction 
 
2. What is the purpose of the study? 
 
The overall purpose of the study is to see if the anti-platelet drugs clopidogrel, prasugrel and ticagrelor, 
drugs which are used to thin the blood of patients who are undergoing coronary stenting or those who are 
at risk of having coronary disease and heart attacks, have an additional benefit on the blood vessel wall.  
 
3. Why have I been chosen? 
 
You have been chosen because you will be undergoing a procedure called coronary stenting, where you 
will be given one of the drugs clopidogrel, prasugrel or ticagrelor before the procedure. In order to carry 
out the procedure safely, you need to have your blood thinned by taking one of the drugs clopidogrel, 
prasugrel or ticagrelor about 2 hours before the procedure. This is a standard form of treatment given to all 
patients who undergo coronary stenting. 
 
Patients undergoing coronary stenting who are already taking one of these three drugs are invited to take 
part in the study. 
 
4. Do I have to take part? 
 
Your participation in this study is entirely voluntary. You can decline to take part or withdraw at any time 
without explanation. 
 
5. What will happen to me if I take part? 
 
We will fully explain the procedure and ask you to sign a consent form. The study will take place at the 
Cardiac Day Case Unit, University Hospital of Wales, Cardiff.  You will be given sachet of dietary nitrate 
supplement product to swallow about 2 hours before you have your stenting procedure. Before giving you 
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the dietary supplement. We will take a blood sample from a vein. After 2 hours, we shall take another blood 
sample from your vein through the same drip needle. 
 
You will be invited to attend a follow up clinic. This will usually be between 1 and 12 months after your 
coronary stenting procedure. On that day we give you another sachet of supplement, one further blood 
sample from a vein taken after two hours. All that will be required at this final visit is. If needed, travel 
expenses can be provided for you for this follow-up visit. 
 
6. What do I have to do? 
 
Once you have read this form and had time to think about the study, you will be contacted by Dr James’s 
research team. If you agree to participate then you will be asked to sign a consent form. The study involves 
taking blood samples, before and after you have taken the drug, from a single drip needle (a tiny piece of 
plastic that sits in the vein) that will have already been placed into the vein of your arm for the purpose of 
your procedure. It avoids the need to puncture the vein multiple times.  
 
7. What are the drugs that are being tested? 
 
Patients who have coronary disease or diabetes are prone to have poor function of the endothelium. The 
endothelium is a lining of special cells that cover all the inner layer of all the arteries (blood vessels carrying 
oxygen). Their function is to keep the arteries healthy and allow blood to flow to all of the organs. 
Clopidogrel, prasugrel and ticagrelor are similar drugs that keep the blood thin, make the blood less sticky 
and prevent the formation of blood clots. They are widely used in patients who have had heart attacks or 
diseased coronary arteries as well as in patients who undergo coronary stenting. We are however testing 
whether the drugs have additional beneficial effects on the endothelium apart from their known function to 
keep the blood thin. 
 
8. What are the side effects of taking part? 
 
Before your doctor decides to perform the coronary stenting procedure, (s)he will check whether you would 
be suitable to take clopidogrel and dietary nitrate supplement. It is a vital requirement of your procedure 
that you take these drugs regularly; side effects from the drugs are rare. It is possible you may have some 
bruising to your forearm after the drip needle has been removed at the end of the study, or after a simple 
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blood sample is taken when you re-attend after stopping the drug. There are no direct side effects or 
consequences related to your taking part in this study. 
 
9. How much blood would be taken for the study? 
 
The total amount of blood required for each sample will be about a quarter of an eggcup full (15mls). Most 
patients will require two blood samples on the day of the procedure, unless you are already taking one of 
the drugs clopidogrel, prasugrel or ticagrelor, in which case only one blood sample is necessary. If you are 
invited to re-attend on another day once you have stopped your drug, one further blood sample will be 
needed. 
 
10. What are the possible benefits of taking part? 
 
There is no benefit to you, but by measuring any biologically active chemicals, we may be better able to 
understand people with diseased arteries. This study does not affect your treatment in any way. 
 
11. What happens when the research study stops? 
 
You may be asked to re-attend for one further blood sample once you have stopped taking the drug 
clopidogrel, prasugrel or ticagrelor. You will not be asked to attend any other additional follow up visits 
for the purpose of the study. 
 
 
12. What if something goes wrong? 
 
This study is being sponsored by the University Hospital of Wales. Therefore, if you suffer negligent harm 
as a result of participation in the study you will be covered by the NHS indemnity scheme. 
 
13. Will my taking part in this study be kept confidential? 
 
Dr James, Dr Anderson, Dr Abdul and their study personnel will collect information about you. This will 
remain confidential. This data will be kept in a secure office at the Wales Heart Research Institute. 
Anonymity will be maintained throughout the trial. 
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14. What will happen to the results of the research study? 
 
The data from this study may be used in publications. However, your name will not appear in the 
publications. 
 
15. Who is organising and funding the research? 
 
The study has been funded by the Cardiff and Vale University Health Board. It has been organised jointly 
with the Wales Heart Research Institute, Cardiff University.  
 
16. Who has reviewed the study? 
 
The study has been reviewed by the Research and Development Office at Cardiff and Vale University 
Health Board, and the Research Ethics Committee for Wales. 
 
17. Where can I obtain independent information about being involved in a research study? 
 
You can contact Dr Tim Kinnaird (Consultant Cardiologist) who is a colleague at the University Hospital 
of Wales but is not involved with this study. He is extremely experienced in-patient participation in research 
and clinical trials. 
 
Dr Tim Kinnaird, Department of Cardiology,  
Wales Heart Research Institute, Cardiff, 
CF14 4XN 
029 2074 7747 
 
 
18. Contact for further information. 
 
If you or your relatives have any questions about the study, please call Dr Fairoz Abdul 029 2074 4192, 
email fairoz@doctors.org.uk or write to: 
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Dr. Fairoz B Abdul 
Clinical Research Fellow in Cardiology 
Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN 
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5.3 Appendix III-PATIENT CONSENT FORM 
Patient Identification Number for this trial:  
The Effect of Inorganic Nitrate and Antiplatelet Drugs on NO Metabolites and Platelet 
Reactivity in Patients with Stable Coronary Artery Disease (updated) 
Name of researchers: Dr Philip James, Dr Richard Anderson, Dr Fairoz B Abdul 
 
Please initial each box 
 
1. I confirm that I have read and understood the information  
sheet dated 08/09/2013 for the above study and have had the  
Opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I  
am free to withdraw at any time without giving any reason. 
 
3. I agree to take part in the study. 
 
4.       I agree to being contacted by the research team once the 
drug treatment course has been completed (between 1 and 12  
months after procedure).  
  
 
_____________________________  ________ _____________________ 
Name of Volunteer    Date  Signature 
 
 
____________________________  ________ _____________________ 
Researcher     Date  Signature  
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5.4 Appendix IV-Patient Data Sheet 
Research code:  Hospital ID  
Date of birth  
Date of procedure  
Nitrate Gel code  
Next date of App  
Symptoms:  
Chest pain   SOB  Palpitation  
Cardiac History: 
Medical history Y/N Details 
Myocardial infarction   
Previous PCI   
Cardiac surgery   
Diabetes  Diet            Tablets                Insulin    
Hypertension   
Hyperlipidaemia   
Smoker  Non                Ex                      Current 
Thyroid   
Respiratory problem  Asthma           COAD          O2             Inhalers 
CVA/TIA   
Renal history   
Other medical history   
Medications Y/N Duration Details 
Aspirin    
Clopidogrel    
Beta blockers    
ACE inhibitors    
Statins    
Nitrates    
Thyroxin    
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NSAID    
PPI    
Anti-coagulants    
 
Pulse Pre: 2 hr. Post: 
Blood pressure Pre: 2 hr. Post: 
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5.5 Appendix V Patient Quick Reference Guide 
Study Title: The effect of inorganic nitrate and antiplatelet drugs on no metabolites and 
platelet reactivity in patients with stable coronary artery disease (updated) 
You have been chosen to participate because you will be given a medication called clopidogrel 
by your heart specialist in addition to your other medication.  
Clopidogrel will keep your blood thin and this would improve and maintain good blood flow to 
your heart, hence reducing a risk of heart attack. This a standard form of treatment given to 
majority of patients who suffered a heart attack and for all patients who undergo coronary 
stenting. 
Previous studies have shown that patient have variable blood thinning response to this 
medication.  The blood thinning effect of Clopidogrel was found to improve with food containing 
nitrates. 
In Our study we would give you two sachets of Food Product containing nitrate. We will collect 
your blood sample for measuring the blood thinning effect and additional beneficial effects on 
the blood vessel wall. We expect an improvement in the effect. 
This diagram would illustrate our study plan; 
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Your participation is entirely voluntary, you could approach the following members of team for 
any further information: 
Dr Fairoz B Abdul:      Email: fairoz@doctors.org.uk  
Ph No. 07738706675 
Dr Richard Anderson:    Email: Richard.anderson@wales.nhs.uk              
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